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Stellingen behorende bij het proefschrift 
Bone Marrow-Derived Cells in Renal Repair 
Aangezien beenmergafkomstige cellen slechts sporadisch inbouwen in het 
tubulusepitheel, is het onwaarschijnlijk dat deze cellen een structurele rol 
spelen in tu bu lair herstel na schade. (dit proefschrift) 
2 Beenmergafkomstige cellen zouden, door te differentieren tot interstitiele 
myofibroblasten, kunnen bijdragen aan het onstaan van nierfibrose. (dit 
proefschrift) 
3 De profibrotische bijwerking van ciclosporine is niet het gevolg van toegenomen 
myofibroblast differentiatie van beenmergafkomstige cellen. (dit proefschrift) 
4 De multipotente differentiatiecapaciteit van beenmergafkomstige cellen maakt 
de therapeutische toepassing van deze celten een riskante onderneming. (dit 
proefschrift) 
5 (W)eten is een primaire levensbehoefte van de mens. 
6 Het betrekkelijk lage aantal nieuwe donoren dat naar aanleiding van BNN's 
"Grote Donorshow• is geregistreerd, geeft aan dat het tekort aan donoren niet 
het gevolg is van een tekort aan publiciteit, maar eerder te wijten valt aan de 
apathie van de potentiele donorpopulatie. 
7 Wijziging van de huidige wet op de orgaandonatie door de invoering van het 
Actief Donorregistratiesysteem (ADR) is op dit moment de enige manier om het 
aantal orgaandonoren te verhogen. 
8 De wereld is een boek en zij die niet reizen, lezen slechts een bladzijde. 
(H. Augustinus van Hippo) 
9 Het leven is een feest, maar je moet wel zelf de slingers ophangen. 
1 0 Het feit dat het dankwoord van een proefschrift op de laatste pagina staat, zorgt 
ervoor dat (tot en met) de laatste pagina doorgelezen wordt. 
Martine Broekema 
14 november 2007 
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INTRODUCTION TO THE THESIS 
The kidney can recover after acute renal injury due to its highly effective endogenous 
regenerative capacity. However, under certain conditions the balance between injury 
and repair can get disturbed. This can ultimately lead to chronic renal failure, which 
is an increasing problem in the clinical setting. Therapy for renal failure has greatly 
improved over the years, especially by the introduction of kidney transplantation. 
Nevertheless, due to the shortage of donor organs and the relatively low long-term 
success rate after kidney transplantation, new therapeutic strategies are highly 
desirable. Bone marrow-derived cells (BMDC) might offer a therapeutic solution for 
renal failure. In this thesis we explored the differentiation choices of BMDC after acute 
renal injury. First, we will introduce some general aspects of renal damage, repair, and 
the possible therapeutic potential of BMDC therein and we will discuss the research 
questions addressed in this thesis. 
Acute renal failure 
Acute renal failure (ARF), which affects up to 5% of all long-term hospital patients (1), 
can be triggered by various insults, among which ischemia/reperfusion injury (IRI) 
holds a forefront role. The pathophysiology of IRI involves renal endothelial and tubular 
epithelial injury, oxidative stress, inflammation and wound healing. Post-ischemic 
endothelial damage results, due to an imbalance in the production of endothelin (2) 
and NO (3), in intra-renal vasoconstriction, which is assumed to contribute to loss of 
renal function. However, the use of renal vasodilators, which return renal blood flow 
to normal in experimental IRI, do not improve renal function, therefore the vasomotor 
component may not be the culprit. 
Studies on the mechanisms mediating IRI have been primarily focused on the renal 
tubule. The straight segment of the proximal tubule (53 segment, pars rectal is most 
susceptible to ischemic injury (4). Both the deprivation of oxygen during ischemia and 
the restoration of oxygen supply during reperfusion cause tubular damage (Figure 
1). The damage caused by renal ischemia depends largely on the duration of oxygen 
deprivation. Upon ischemia, oxygen deprivation of the tubular cell leads to depletion of 
cellular ATP, which initiates a cascade of biochemical events that lead to mitochondrial 
damage, impaired solute and ion transport, loss of cell polarity, and cytoskeletal 
disruption (5). In case of severe ischemia these events lead to cell death, shedding and 
excretion of proximal tubule brush border membranes and tubular epithelial cells into 
the urine (6). Histologically, ischemic damage is represented by patchy and focal loss 
of tubular epithelial cells, resulting in areas of denuded basement membrane, and the 
presence of intraluminal casts (7). 
Although restoration of blood flow during reperfusion is essential for survival of the 
kidney, it leads to further cellular damage. Reperfusion is therefore known as the "reflow 
paradox". The mechanism of reperfusion injury includes the generation of reactive 
oxygen species (ROS) (8). ROS have numerous deleterious effects on cells, such as lipid 
peroxidation, oxidation of cell proteins, and damage to DNA (9). Moreover, generation 
of ROS causes endothelial activation and recruitment of leukocytes through the 
upregulation of chemokines (1 O) and the proinflammatory cytokines interleukin-1 (IL-
1), IL-2, IL-8, tumor necrosis factor-alpha (TNF-a) and interferon-y (IFN-y) by affected 
cells (11-13). Adhesion molecules, such as intercellular adhesion molecule-1 (ICAM-1), 
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vascular cell adhesion molecule (VCAM) and P-selectin are upregulated during IRI 
and promote endothelial-leukocyte interactions. These adhesion molecules facilitate 
inflammation by increasing the infiltration of mainly neutrophils and macrophages in 
the renal interstitium early after ischemic injury (14), while later phases are characterized 
by infiltration of macrophages and T lymphocytes (15;16). The infiltration of leukocytes 
leads to a vicious circle of inflammation by secondary activation of leukocytes which 
release mediators, such as free oxygen radicals, proteases, and cytokines that further 
aggravate tissue damage. 
Kidney transplantation can also lead to acute renal injury and consequently, delayed 
graft function. Renal transplantation is the treatment of choice for end stage renal 
failure (17). Due to the introduction of immunosuppressive therapy (especially of 
ciclosporin (CsA) in the 1980's) and improvements in HLA matching (18), ischemic times 
and organ preservation (19), graft survival after kidney transplantation has improved 
to about 90% at 1 year post-transplantation (20). Despite major short-term graft 
survival, 30% of all renal transplant recipients experience acute rejection, which is the 
strongest risk factor for development of chronic renal transplant failure. Beside acute 
rejection, transplant injury is caused by cold and warm ischemia and nephrotoxicity 
from immunosuppressive medication. IRI augments the specific immune response 
to the allograft through the upregulation of MHC class II and adhesion molecule 
expression in the allografted kidney, thereby increasing the risk of acute rejection 
(21). In principle, IRI of the donor kidney is unavoidable, especially when a kidney of a 
deceased donor is transplanted. However, when ischemic times are short, for example 
during transplantation of a kidney of a living donor, IRI and the risk for delayed graft 
function is substantially reduced. 
Acute rejection is primarily a cell-mediated immune-response of the recipient against 
thealloantigens present in the renal graft. Histologically, acute rejection is characterized 
by interstitial inflammatory infiltrates, tubulitis and various degrees of arteritis. For 
diagnostic purposes, the abnormalities are classified in renal biopsies according to 
the Banff classification (22). Acute rejection is initiated when recipient cos+ T-cells 
recognize allogeneic MHC class I-molecules on the tubular epithelium, endothelium 
or mesangial cells of the donor kidney. Upon costimulation by professional antigen­
presenting cells (APCs) or cytokines provided by CD4+ helper T-cells, cos+ T-cells 
differentiate to cytotoxic T-cells (CTLs). These alloreactive CTLs directly lyse target cells 
of the donor kidney. Activation of CD4+ helper T-cells, by recognition of MHC class II 
molecules on APCs, results in secretion of cytokines and activation of macrophages, 
B cells and cos+ T-cells, thereby maintaining inflammation and further aggravating 
graft injury. Not only cell-mediated, but also a humoral immune response against allo­
antigens contributes to rejection. Allo-antibodies bind to endothelium, activate the 
complement system and injure graft blood vessels. 
Renal repair mechanisms after acute injury 
After acute renal injury innate mechanisms are activated that result in replacement of 
damaged tubular epithelial cells and deposition of extracellular matrix (ECM) to restore 
renal morphology and function. Better understanding of these innate mechanisms of 
repair will uncover new therapeutic targets. 
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Acute tubular injury is usually reversible. The prevailing theory is that the innate repair 
mechanisms of the kidney are dependent on surviving proximal tubular epithelial cells 
(Figure 1). After injury the surviving tubular cells have the ability to repair themselves 
by re-polarization and restoration of their cytoskeleton, mitochondria and solute and 
ion transport system. In addition, surviving tubular cells serve to replace lost tubular 
cells. In the scenario of replacement, sublethally injured tubular cells dedifferentiate to 
mesenchymal cells (23;24). Subsequently, the dedifferentiated tubular epithelial cells 
proliferate rapidly and extensively to restore original epithelial cell number (25-27). The 
dedifferentiated cells spread and migrate over the basement membrane to denuded 
areas (28;29) where they differentiate to tubular epithelial cells, leading to restoration 
of morphology and function (30). Several growth factors have been identified that may 
facilitate these regenerative responses, such as epidermal growth factor (EG F), insulin­
like growth factor-1 (IGF-1), hepatocyte growth factor (HGF), vascular endothelial 
growth factor (VEGF) and fibroblast growth factor (FGF) (31). 
Repair of the kidney after acute injury depends not only on epithelialization of the 
denuded basement membrane, but also on wound healing. Wound healing is the 
process of structural remodeling in order to maintain tissue integrity. Fibroblasts 
and myofibroblasts participate in wound healing by producing ECM components 
and by responding to and synthesizing cytokines, chemokines and other mediators 
of inflammation. When wound healing is completed, fibroblasts and myofibroblasts 
generally disappear by apoptosis (32). However, when apoptosis is lacking and 
proliferation and/or activation of fibroblasts and myofibroblasts is out of control, this 
can result in the excessive deposition ECM components. Long-term consequence of 
the disturbed balance between ECM production and degradation is interstitial fibrosis 
and chronic renal failure. 
Chronic renal failure 
If innate renal repair mechanisms are inadequately controlled, this can eventually 
lead to chronic renal failure (CRF). CRF is characterized by the progressive loss of renal 
function and can result in end-stage renal disease and the need for replacement 
therapy, i.e. dialysis or transplantation. Renal interstitial fibrosis is the hallmark of CRF 
because the extent of renal interstitial fibrosis correlates with loss of renal function 
(33). As discussed above, renal interstitial fibrosis is the result of inadequately 
controlled wound healing. Control over wound healing is lost when transforming 
growth factor-� (TGF-�), generally regarded as the inducer of fibrosis, is overexpressed 
in the kidney. TGF-� increases expression of connective tissue growth factor (CTGF) 
(34), which induces proliferation of (myo)fibroblasts (35). Similar to CTGF, TGF-� 
causes upregulation of basic fibroblast growth factor-2 (FGF-2) in renal interstitial 
(myo)fibroblasts, inducing proliferation of these cells (36). The downstream effect 
of TGF-� upregulation and subsequent (myo)fibroblast proliferation is excessive 
interstitial accumulation of ECM components, such as fibronectin, collagen I, Ill and 
proteoglycans. Formation of peptide bonds between these ECM components is 
catalyzed by transglutaminases, resulting in extensively cross linked protein polymers, 
which are resistant to degradation. Together with excessive production of ECM, this 
will lead to a disturbance in the balance between production and degradation of ECM 
13 
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components, resulting in interstitial scarring and suppression of tubular epithelial cells 
(Figure 1). 
Myofibroblasts are considered the major producers of ECM components during 
renal interstitial fibrosis (37). These cells possess phenotypical characteristics of 
both fibroblasts and smooth muscle cells. The origin of the myofibroblast remains 
subject of discussion. Several options for their origin have been reported, i.e. that 
myofibroblasts may represent an activated population of resident fibroblasts (38), 
or that myofibroblasts originate from injured tubular epithelial cells by epithelial-to­
mesenchymal transition (EMT) (39), from perivascular smooth muscle cells (40) or from 
BMDC (41) (Figure 1). 
Chronic renal injury can also occur in the renal transplant and thus lead to graft 
loss. Despite the excellent clinical perspective at 1 year post-transplantation, half of 
the transplanted kidneys are lost within 10 years after engraftment (42). The most 
important cause of graft loss is chronic allograft nephropathy (CAN); progressive 
deterioration of renal function ultimately leading to graft loss. Histopathologically, 
CAN is characterized by mononuclear cell infiltration, glomerulosclerosis, interstitial 
fibrosis, tubular atrophy, perivascular inflammation, vascular obliteration and vascular 
wall thickening. In contrast to the allo-antigen-driven event of acute rejection, CAN 
is the consequence of both immune factors, such as acute rejection episodes, and 
non-immune factors, such as donor-related factors (e.g. age, brain death), IRI during 
transplantation and immunosuppressive drug-induced toxicity (43). To date, there is 
no effective way to prevent or treat CAN. 
Currently, preventing or treating renal failure by simulating or promoting the innate 
capacity of the kidney to reverse acute tubular injury, has attracted interest as a new 
therapeutic strategy. 
Bone marrow-derived cells (BMDC) in renal repair 
The BMDC population is heterogeneous, consisting mainly of inflammatory cells, 
i.e. neutrophils, macrophages and T lymphocytes that infiltrate the kidney upon 
injury. Besides inflammatory cells, the BMDC population contains small numbers of 
stem cells and/or progenitor cells. A large body of evidence supports the idea that 
stem- and progenitor cells can infiltrate multiple organs and engraft tissue structures 
upon injury. BMD stem- and progenitor cells were reported to show the plasticity to 
differentiate towards cells from any of the three germ layers. The potential of BMDC 
subpopulations to replace damaged tissue cells by engraftment and differentiation, 
favors therapeutic cell therapy with BMDC. 
The bone marrow contains two stem cell populations that were believed to serve 
only as the blood-forming compartment of the body. However, multiple investigators 
have suggested that these stem cells mediate tissue repair by repopulation and 
differentiation in injured tissues. Firstly, hematopoietic stem cells (HSC), appeared 
capable to differentiate to multiple cell types (44). HSC are lineage-uncommitted 
(Un·) bone marrow cells that are characterized in human and mice by the expression 
of the cell surface markers CD34, Sca-1 and c-kit (45;46). Secondly, mesenchymal stem 
cells or marrow stromal cells (MSC) that are typically characterized as plastic adherent, 
non-hematopoietic bone marrow cells that can be cultured in vitro and maintained 
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Figure 1. Schematic representation of BMDC in acute and chronic renal injury. Acute renal injury will lead 
to tubular epithelial damage, loss of tubular epithelial cells and areas af denuded basement membrane. 
Acute renal injury elicits activation of endogenous renal repair, i.e. restoration of cell physiology or 
dedifferentiation, proliferation and differentiation of surviving tubular cells to replace the lost tubular cells. 
Another option for tubular repair after acute renal injury is recruitment of BMDC from the bone marrow 
upon injury and subsequent engraftment and replacement of lost tubular cells. However, a disturbed 
balance between renal injury and repair can lead to chronic renal injury. Myofibroblasts, originating from 
differentiated resident fibroblasts, BMDC, perivascular smooth muscle cells or tubular epithelium cells by 
epithelia/-to-mesenchymal transition, produce ECM components in the renal interstitium. Interstitial fibrosis, 
the hallmark of chronic reno/ injury, occurs when apoptosis of myofibrob/asts is lacking, proliferation of 
myofibrob/asts is out to control, leading to excessive deposition, cross linking and dysregulated degradation 
of ECM in the renal interstitium. Adapted from: Krause, D. and Cantley, L.G.: J Clin Invest 115: 1705-8, 2005. 
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as fibroblast-like cells. MSC have the potential to differentiate into mesenchymal 
lineages such as chondrocytes, osteocytes and adipocytes, but also into other, non­
mesenchymal cell lineages such as endothelial and muscle cells (47). Possibly, these 
bone marrow-derived (BMD) stem cell populations have the ability to mediate kidney 
repair by differentiation towards tubular epithelial cells. 
Besides stem cells, progenitor cells can be part of the BMDC population that infiltrates 
the kidney upon injury. While progenitor cells share many common features with 
stem cells, they are more restricted in terms of plasticity and self renewal. Endothelial 
progenitor cells (EPC) are BMD progenitor cells that, based on their expression of a 
restricted set of surface markers (CD34, VEGF-R2 and/or CD133), can be isolated from 
bone marrow, umbilical vein blood and peripheral blood. In vitro, EPC differentiate into 
endothelial cells and in animal models of ischemia, EPC were shown to incorporate 
into sites of active angiogenesis and mediate neovascularization (48;49). This potential 
renders the EPC an attractive candidate for therapeutic application to achieve 
endothelial repair in the injured kidney. 
In several organs BMDC or BMD stem- or progenitor cells were reported to engraft 
and differentiate towards tissue specific cell types. Since in most studies bone marrow 
transplantation was performed with whole bone marrow, the investigators were 
unable to define which BMDC subpopulation differentiated. In the infarcted heart, 
lineage-depleted, c-kit+ BMDC have been shown to differentiate into cardiomyocytes 
and vascular structures, thereby ameliorating the function of the infarcted heart (50;51). 
In the damaged liver an undefined BMDC subpopulation was shown to infiltrate and 
differentiate to hepatocytes, thereby improving liver function (52;53). Furthermore, 
undefined BMDC subpopulations have been reported to differentiate into endocrine 
� cells of the pancreas (54;55), cells of the central nervous system, such as neurons, 
oligodendrocytes and astrocytes (56-59), skeletal muscle cells (60) and intestinal 
epithelial cells (44;61). The recurrent hypothesis in all mentioned organ system is that 
upon injury, inflammation leads to the recruitment of BMDC subpopulations to the site 
of injury, where some BMDC subpopulations can repopulate the damaged structure 
by engraftment and differentiation into tissue specific cell-types. 
The hypothesis that BMDC can infiltrate and repopulate the damaged organ upon 
injury was also tested in the kidney. In experimental studies, BMDC are usually detected 
by bone marrow transplantation with labeled bone marrow cells to allow tracing 
of BMDC in an injured organ. In humans, bone marrow transplantation with sex- or 
MHC-mismatched bone marrow followed by renal injury would allow tracing BMDC 
in the injured kidney. Since this sequence of events is not likely to occur, the presence 
of recipient-derived cells after sex- or MHC- mismatched kidney transplantation 
was investigated instead. In these studies, the presence of recipient-derived cells 
was reported in vessels and tubuli of the renal transplant (62-68). Recipient-derived 
cells that engrafted the tubular epithelium adopted a tubular epithelial phenotype 
(63;65;66). Since the extent of engraftment of recipient-derived cells in donor 
epithelium or endothelium correlated with the severity of sustained graft damage 
(64;67), it was suggested that recipient-derived cells mediate graft repair by replacing 
damaged graft cells. Moreover, since the recipient-derived cells are extra-renal and 
showed plasticity to differentiate in vivo, these cells were suggested to represent a 
BMD population of stem- or progenitor cells. 
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Outline of the thesis 
In this thesis we explored the differentiation choices of BMDC after acute renal injury in 
rats. Since we performed bone marrow transplantation with whole bone marrow, we 
could not study subpopulations of BMDC but we studied the differentiation choices 
of the total BMDC population instead. Therefore, the differentiation fates of BMDC 
described in this thesis might represent differentiation of stem-, progenitor cells or 
other BMDC subpopulations. 
Acute renal damage is, when not too severe, reversible. Innate mechanisms of 
regeneration and remodeling of the kidney result in recovery of function and 
morphology of the tubular epithelium. BMD stem- or progenitor cells possibly 
mediate tubular epithelial repair by their differentiation potential and may provide 
a therapeutic solution for acute renal injury. Therefore, we investigated the capacity 
of BMDC to differentiate towards tubular epithelial cells and thereby their possible 
contribution to tubular epithelial repopulation (Figure 1). Remodeling of the kidney 
after acute renal injury may, due to an uncontrolled balance between synthesis and 
degradation of ECM proteins, result in interstitial fibrosis. Myofibroblasts contribute to 
the onset of interstitial fibrosis by producing ECM components. Therefore, we studied 
the capacity of BMDC to differentiate to renal interstitial myofibroblasts and thereby 
their possible contribution to ECM synthesis (Figure 1). 
For correct interpretation of the functional contribution of BMDC in renal repair in 
vivo tracking of BMDC is crucial. Many different tracking methods, with variable 
experimental outcomes, have been reported. In chapter 2 we provided an overview 
of the different tracking methods and discussed their advantages and drawbacks for 
use in renal injury models. Besides differences in reporter systems, differences in the 
extent of renal damage might also be a determinant for BMDC-mediated repair. In 
chapter 3 we investigated whether the severity of damage and post-ischem ic recovery 
time determines the extent of BMDC engraftment in tubular epithelium. Moreover, 
we studied the balance between endogenous and BMDC-mediated tubular cell 
replacement. Besides tubular epithelial regeneration, acute renal injury also elicits ECM 
production. In chapter4 we determined the capacity of BMDC to differentiate towards 
ECM-producing interstitial myofibroblasts. Moreover, we investigated the presence 
of BMD myofibroblasts over time and their ability to produce ECM components and 
the pro-fibrotic growth factor TGF-�. Myofibroblast differentiation is known to be 
stimulated by several pro-fibrotic stimuli. The immunosuppressive agent ciclosporin 
(CsA), widely used after kidney transplantation, is known for its pro-fibrotic potential. 
We investigated in chapter 5 whether myofibroblast differentiation of BMDC was 
stimulated by CsA. Besides the influence of pro-fibrotic stimuli on BMDC differentiation, 
transplantation injury factors, i.e. IRI and rejection-associated injury, may influence 
differentiation. Therefore, we investigated in chapter 6 the differentiation choices of 
recipient-derived cells after experimental kidney transplantation. Moreover, in chapter 
7 we studied the effects of kidney transplantation on circulating BMD progenitor cells. 
We determined the numberofEPC in the circulation of kidney transplant recipients with 
and without complications. Finally, the results described in this thesis are summarized 
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Abstract 
At this time point renal mJury, ultimately resulting in renal fai lure, can not be 
therapeutically cured by endothelial, glomerular or tubular regeneration. Over the last 
five years, several reports appeared in which the replacement of damaged renal cells 
by bone marrow-derived cells (BMDC) was shown, thereby suggesting a therapeutic 
role for BMDC in renal regeneration. For correct interpretation of the function of these 
cells in renal repair, in vivo tracking of BMDC is crucial. Since various tracking methods 
with variable experimental outcomes have been reported, we will provide an overview 
of these methods and discuss their advantages and drawbacks for experimental renal 
disease models. 
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Introduction 
At this time point renal mJury, ultimately resulting in renal failure, can not be 
therapeutically cured by endothelial, glomerular and tubular regeneration. Bone 
marrow-derived cells (BMDC) might provide a therapeutic role in renal regeneration 
by replacement of damaged cells. In various models of renal injury, BMDC have been 
shown to be recruited from the circulation to the affected kidney, where they engraft 
and can adopt epithelial, endothelial or mesangial phenotypes, which suggests 
that damaged cells are actually replaced (1-6). However, due to the low and variable 
number of BMDC that differentiated to renal-specific cell types in these models, the 
functional relevance of BMDC engraftment in renal repair is still subject of debate. 
One of the reasons for the variation in BMDC engraftment and differentiation may be 
the use of different BMDC tracking models. Moreover, there are reports suggesting 
that several BMDC tracking models are unreliable for identification of these engrafted 
cells in vivo (7;8). Since BMDC tracking models are important for investigating possible 
therapeutic applications of BMDC in renal repair, we provide an overview and review 
the advantages and drawbacks of reporter systems used for tracing BMDC in the 
kidney (Tabel 1). 
Reporter systems can generally be divided in two groups, i.e. those using genetic 
tracking devices that are present or newly introduced in the genome, and those using 
ex vivo labeling of cells. 
BMDC tracking in the kidney using bone marrow transplantation 
The most commonly used technique to track BMDC and study their role of BMDC 
after renal injury is transplantation of bone marrow from rodents that are genetically 
distinguishable from the recipient, into bone marrow-ablated recipients. After bone 
marrow transplantation, the transplanted bone marrow cells stably reconstitute the 
recipient's bone marrow compartment. In practice, the efficiency of bone marrow 
ablation and reconstitution with donor bone marrow is never 100% and a certain degree 
of underestimation of, for example the actual numberof renal infiltrated BMDC, is always 
present. Another issue to consider is that bone marrow transplantation experiments 
with newly introduced genetically modified BMDC can elicit immunological rejection .  
However, the possibility of an interfering immune response has not been studied in 
bone marrow transplantation experiments described in this article. 
Genetic "tracking devices" 
Y chromosome detection 
Male to female bone marrow transplantation offers a reliable, but laborious approach 
for tracking BMDC in the kidney. Several studies describe detection of male BMDC 
using Y-chromosome in situ hybridization (Y-ISH) to determine the bone marrow 
origin of cells engrafting the female kidney (2;4;9-12). Y-chromosome detection is also 
used to study extra-renal, host-derived cells in tissue biopsy or autopsy material after 
sex-mismatched kidney transplantation (13-15), or to study renal infiltrated BMDC in 
patients after sex-mismatched bone marrow transplantation (16). Thus, beside the 
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Tabel 1: Reporter systems and their andvantages and drawbacks 
Reporter Promoter Advantages (+) and drawbacks (-) * Circumvented by 
Y-chrom. - + Applicable in sex-mismatched patient material (13-16) 
- Unreliable in female to male combination 
- Underestimation due to thickness of sections (17) Correction factor 
- Complicated, time-consuming (9) 
- Incorrect detection due to aggregates of fluorescent 
probe (9) 
MHC/ - + Applicable in mismatched patient material (6,14) 
Blood + Simple detection techniques (14) 
group - Mismatch can cause immune rejection (6) 
�-Gal ROSA26 + Enzymatic and immunohistochemical detection 
(9,30,31) 
+ High sensitivity 
+ Quantification using soluble color substrates 
+ Ubiquitous renal expression (27) 
- Incorrect detection due to expression of mammalian- Adjust buffer pH 
and senescence-associated �-Gal (9,28,29,32,33,35,36) Use �-Gal antibody 
EGFP chicken + Direct detection by microscopy/flow cytometry (38) 
13-actin + Detection in living cells (38) 
+ Ubiquitous renal expression (38) 
+ Rat reporter model available (5,46,47) 
+ No endogenous EGFP expression (9) 
+ Spectral variants of EGFP available (37,44,45) 
- Renal autofluorescence in the green spectrum (45) Confocal micoscopy 
Spectral variants 
- EGFP in tissues often too weak for direct detection Use EGFP antibody 
hPAP ROSA26 + Enzymatic and immunohistochemical detection 
(50,51) 
+ Ubiquitous renal expression (26) 
+ Stable expression in isolated cells in culture (52) 
+ Rat reporter model available (26) 
- Endogenous alkaline phosphatase (48,49) hPAP distinguished 
by heat stability 
Firefly hCMV + In vivo, real-time, non-invasive detection (53,55-57) 
lucifer- immedi- + No animal-to-animal variation (56) 
ase ate early 
gene + Ubiquitous renal expression (53) 
+ Stable expression in isolated cells in culture (54) 
+ High sensitivity 
- Exact localization can not be determined in vivo (57) Ex vivo analysis on 
tissue samples 
Epi- Ksp-cad- + Detection of tubular epithelial cells 
thelial herin + Specific and permanent expression in mature tubular 
specific epithelium (42) 
EGFP + Additional phenotypical analysis not necessary 
- Mosaic expression pattern (42) 
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Reporter Promoter Advantages (+) and drawbacks (-) * Circumvented by 
Fibro- FSP-1 + Detection of fibroblasts 
blast- + Specific and permanent expression in FSP-1 • cells (60) specific 
EGFP + Additional phenotypical analysis not necessary 
- Specificity FSP-1 debatable 
Pro- Pro- + Detection of Pro-collagen1A2 
COL1A2 COL1A2 + Specific and permanent expression in Pro-collagen 
specific 1 -producing BMDC (35) 
lucifer- + Additional analysis for Coll I production not necessary 
ase/ 
[3-Gal 
CFDA - + Detection of ex vivo labeled cells 
+ Label retained during development, meiosis, in vivo 
tracing, cell division, fusion (64) 
+ Not transferred to adjacent cells (64) 
- Reduction of fluorescence level after cell division 
- Limited stability of the fluorescence, up to 20 days (66) 
- In vivo detection not possible (64) Expose kidney (64) 
- Exact localization can not be determined in vivo Ex vivo analysis on 
tissue samples (64) 
Iron- - + Detection of ex vivo labeled cells 
dextran + Non-invasive, in vivo, real-time detection with MRI (65) 
particles 
- MRI is laborious and requires equipment and train 
personnel 
- Possible clearance via fagocytosis 
- Exact localization can not be determined in vivo Ex vivo analysis on 
tissue samples (65) 
• References are given between brackets 
use in animals after sex-mismatched bone marrow transplantation, Y-chromosome 
detection is used for recipient-derived cell detection in humans, in which the 
introduction of transgene-expressing cells, by for example bone marrow 
transplantation, is not possible. 
The ISH method is laborious and may yield variable results, explaining the contradicting 
results of detection (2;4;9;10;12). In a study by Duffield and colleagues (9), stating that 
post-ischemic tubular epithelial restoration occurs independently of BMDC, confocal 
laser fluorescent microscopy was used to show that v+tubular cells often were artifacts. 
These artifacts were due to leukocytes overlying renal tubular structures, intratubular 
monocytes or nonspecific aggregates of fluorescent probe. This also suggests that 
the Y-chromosome positive tubular cells detected in previous studies in female mice 
following transplantation of bone marrow from male donor mice could be artifacts of 
imaging. 
A drawback of this reporter system is that ISH is necessary to detect Y chromosome­
positive cells in tissues. This technique is time consuming and requires extensive pre­
treatment of the sections, which affects tissue morphology and epitopes and therefore 
reduces the possibility to perform double-stainings for further characterization of the 
engrafted cells. Moreover, the method of Y-ISH for detection of BMDC can lead to 
an underestimation of Y-chromosome presence by distribution of the nucleus over 
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multiple thin tissue sections, and loss of the Y chromosome for detection in some of the 
sections. Because of these bottlenecks, detection of the Y-chromosome in male tissue 
sections is never 100%, as it should be. Therefore, the exact number of Y chromosome­
positive cells can only be estimated using a correction factor, as was done in a study by 
Direkze (17). In this study radiation-induced injury was shown to elicit differentiation 
of BMDC to myofibroblasts in multiple organs, including the kidney. Using Y-ISH, the 
authors showed that only 50% of all male cells were Y chromosome-positive, which 
should have been 100%. Therefore, the observed number of renal Y chromosome­
positive BMDC in the female kidney was corrected by dividing by 0.5 to estimate the 
exact number of renal BMDC. This approach is not very accurate since this is only 
an estimation and not the exact number of BMDC. Together with the fact that bone 
marrow transplantation is never 100% efficient, this estimation can lead to incorrect 
interpretation of data. Another limitation of sex-mismatched BMDC tracking, especially 
in the clinical setting, is that female to male detection is more difficult and unreliable, 
thereby excluding female to male transplantations for detection of recipient-derived 
cells. Therefore, the use of sex-mismatched bone marrow transplantation for tracking 
of BMDC can be regarded as a limited and insensitive method. 
MHC and ABO blood group antigen detection 
Although all reporter markers that are incorporated in the genome can be detected 
using in situ hybridization, other, less complicated methods for detection of recipient­
derived cells in human tissue biopsies or post-mortem tissue are possible, e.g. MHC or 
ABO blood group antigen detection by immunohistochemistry (14). Besides in patient 
studies, this strategy was also applied in rat studies, e.g. by Rookmaaker et al. (6), who 
used a rat allogenic BM transplant model in BN rats with WR rats as bone marrow 
donors to generate rat BM chimeras. In the model of anti-Thy-1.1-glomerulonephritis, 
BMDC were traced using a donor-specific major histocompatibility complex class-I 
monoclonal antibody and were found to differentiate towards glomerular endothelial 
and mesangial cells (6). Although it was not reported in this study, possible immune 
rejection of MHC mismatched bone marrow and the necessity for immunosuppressive 
therapy can be a limiting factor of this detection method. 
Transgenic reporters 
Transgenic reporters under the control of ubiquitous promoters 
Tracing of BMDC in the kidney using reporter genes relies on the expression of the 
reporter gene (i.e. the transgene) by the BMDC. Expression of the reporter gene at all 
times can only be accomplished if the gene is driven by a promoter of a ubiquitously 
expressed gene, such as mouse metallothionein (18;19), �-actin from human (20), rat 
(21) and chicken (22), ubiquitin (23), simian virus 40 (24), cytomegalovirus immediate­
early (25) or ROSA 26 (26). 
{3-Galactosidase 
Bacterial �-galactosidase-transgenic mice expressing the £.coli-derived Lacz gene 
(27), are frequently used as reporters for tracing BMDC. The presence of this reporter 
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gene can be visualized by enzymatic detection of the bacterial P-galactosidase by X­
gal staining or by immunohistochemical detection with an antibody against bacterial 
p-galactosidase. In the enzymatic detection, X-gal is converted by p-galactosidase to 
a blue reaction product which precipitates in situ. P-Galactosidase is among the most 
sensitive of reporter enzymes because only a few molecules of this enzyme readily 
convert X-gal in amounts that are detectable by light microscopy. An advantage of 
p-galactosidase is, that also soluble color substrates such as ONPG (o-nitrophenyl-P­
D-galactopyranoside) exist that are employed to determine relative or total amount of 
reporter protein in tissue extracts. 
Using this technique, previous studies have reported large numbers of X-gal+ tubular 
cells after ischemic renal injury (1;2), thereby suggesting that BMDC play an important 
role in repair of renal injury. However, many mammalian tissues, including the kidney 
(28;29), contain endogenous p-galactosidase, an enzyme important for the enzymatic 
digestion of glycolipids (30;31). This mammalian enzyme has an acidic pH optimum 
(32;33), whereas the bacterial �-galactosidase enzyme has a neutral pH optimum (34). 
In most published protocols, a weak buffer such as phosphate-buffered saline (PBS) 
was used, which may have become acidic during the exposure of fixed tissues to X-gal. 
Moreover, after ischemia the kidney becomes acidic due to disturbed pH regulation. 
At low pH, endogenous p-galactosidase is detected and, thereby, false positive cells. 
Several studies indeed showed that, using the enzymatic detection method of P­
galactosidase at low pH (6.5), endogenous P-galactosidase could not be distinguished 
from the bacterial p-galactosidase in injured kidneys (9),(35). Therefore, X-gal+ tubular 
cells reported in previous studies (1;2) may have been detected as a result of increased 
intrinsic p-galactosidase activity, rather than the presence of p-galactosidase-positive 
bone marrow cells. Another disturbance in the detection of p-galactosidase is the 
presence of senescence-associated �-galactosidase (SA-P-gal), which is defined as P­
galactosidase activity detectable at pH 6.0, in senescent cells (36). 
Despite these detection problems, p-galactosidase can still be used as a reliable 
reporter, as long as bacterial P-galactosidase is clearly distinguished from endogenous 
mammalian P-galactosidase. This can be achieved by a simple modification of the X­
gal method, raising the pH of the X-gal solution to weakly alkaline pH (29), or by using a 
commercially produced p-gal staining set which is designed to minimize staining from 
mammalian p-galactosidase (9). Another method is based on immunolabeling with 
anti-bacterial p-galactosidase antibody instead of enzymatic detection of the reporter 
by X-gal staining. The study of Duffield (9) showed that, using anti-p-galactosidase, it 
was possible to discriminate between endogenous mammalian p-galactosidaseactivity 
and that resulting from Lacz gene expression. Therefore, p-galactosidase can be 
reliably detected without interference of endogenous mammalian p-galactosidase. 
Enhanced Green Fluorescent Protein (EGFPJ 
Green fluorescent protein (GFP) is responsible for the green bioluminescence of the 
jellyfish Aequorea Victoria. Using this protein, transgenic mouse lines were generated, 
in which all tissues emitted green light under excitation. However, the first generation 
GFP transgenic mice proved to be unsuitable for use in experimental renal disease 
models, since GFP was, in the healthy animal, not expressed in all renal components 
(7;37). If, in the setting of GFP+ bone marrow transplantation, BMDC regulate GFP in a 
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similar way as kidney cells and BMDC differentiate to kidney cells, this would result in 
an underestimation of GFP expressing, bone marrow-derived, kidney cells. Therefore, 
mutants of the first generation of GFP transgenic mice were constructed that had about 
35-fold brighter fluorescence, termed 'enhanced' GFP (EGFP) (37). These mutants were 
the result of double amino acid substitutions in the wild-type GFP cDNA construct, 
placed under the control of the same chicken �-actin promoter and a cytomegalovirus 
enhancer as in the first generation of GFP transgenes. EGFP transgenic mice do 
express EGFP in all renal components, as well as in other tissues, with the exception of 
erythrocytes, hair (38) and some leukocytes (personal observation). 
Chimeric mice reconstituted with EGFP bone marrow are commonly and successfully 
used to trace BMDC in renal disease models (39-43). The advantage of EGFP as a 
reporter is that introduction of a substrate is not required, unlike other commonly used 
reporters such as �-galactosidase and alkaline phosphatase, allowing to monitor the 
presence of EGFP by sole illumination of tissue sections or living cells (38). Moreover, 
EGFP is not disturbed by expression of endogenous EGFP and because the excitation 
optimum for EGFP is close to 488 nm, the transgenic cells can also be analyzed by 
flow cytometry. A drawback of EGFP is that in tissue sections EGFP is often too weak 
for direct fluorescence microscopy, making antibody labeling necessary for detection 
(personal observation, confirmed by other researchers). Moreover, the utility of EGFP 
as a reporter in renal disease models is limited by the fact that the kidney possesses 
intensive auto-fluorescence, which complicates detection of EGFP· cells, unless 
confocal microscopy is used. This problem can also be overcome by using one of the 
spectral variants of GFP, emitting blue, cyan or yellow light (37;44;45). Moreover, these 
spectral variants of GFP can be very useful for achieving in vivo double-labeling. 
Besides EGFP transgenic mice, rats expressing EGFP ubiquitously were generated. EGFP 
transgenic rats were originally established using the same construct and technique 
described for the production of EGFP transgenic mice (38). Rats are, in comparison 
to mice, preferable in certain renal disease models, such as experimental kidney 
transplantation (easier microsurgical procedure) and anti-Thyl antibody-mediated 
glomerulonephritis model (Thyl is a well-established rat-specific mesangial marker, 
EGFP rat BM chimeras with Thyl nephritis are described in references (5;46;47)). 
Therefore, the EGFP transgenic rat is an important tool for studying BMDC in renal 
disease. 
Several characteristics of EGFP, its reliable detection, possibility of detection without 
introduction of a substrate in living cells and the availability of spectral variants of EGFP 
to avoid green autofluorescence or to simultaneously label multiple cell types, make 
this reporter an attractive option for use in BMDC tracking in renal disease models. 
human Placental Alkaline Phosphatase (hPAP) 
Alkaline phosphatase (AP) dephosphorylates many types of phosphorylated 
molecules, for example nucleotides and proteins. Besides this functional property, 
which is extensively used in molecular biology, AP is used as a label in enzyme 
immunoassays. In humans, AP is present in all tissues throughout the body, but is 
particularly concentrated in liver, bile duct, kidney, bone and placenta. The advantage 
of human placental alkaline phosphatase (hPAP) is its heat stability, which allows to 
distinguish the placental form from other forms of AP (48;49). 
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Transgenic rats have been generated in which hPAP is placed under control of the 
ubiquitously active ROSA26 gene promoter (26). The hPAP transgenic rat shows 
ubiquitous expression of hPAP in the kidney (Figure l A) and is therefore suitable for 
BM transplantation experiments and subsequent tracking of BMDC in renal disease 
models. 
We have used hPAP as a marker molecule to track BMDC in the post-ischemic rat kidney 
and showed BMDC differentiation towards tubular epithelial cells and myofibroblasts 
(50;51). To allow for renal BMDC tracking, we reconstituted lethally irradiated F344 
rats with ROSA26-hPAP transgenic bone marrow cells and subsequently studied 
infiltrating BMD (hPAP+) cells in the kidney after unilateral ischemia/reperfusion 
injury. The heat-stability of the hPAP enzyme allowed reliable detection of hPAp+ cells, 
without interference of endogenous AP, which is abundantly present in the kidney. In 
our model, we showed that heat-inactivation of endogenous AP resulted in complete 
absence of substrate conversion by this enzyme, without destroying the reactivity of 
hPAP (Figure 18} (50;51}. 
A B 
Figure 1. Renal expression of ROSA26-hPAP in transgenic rats and bone marrow chimeras. Expression of 
the ROSA26-hPAP gene was assessed by enzymatic hPAP staining on kidney sections. hPAP is ubiquitously 
expressed in the kidney of a healthy ROSA26-hPAP transgenic rat (A). ROSA26-hPAP expression can be easily 
detected on renal infiltrating hPAP' BMDC (black) in ROSA26-hPAP bone marrow chimeric rats 7 days after 
induction of ischemia (BJ. No interference of endogenous AP was observed. lens magnification 200x (8) and 
400x (A). 
Detection of hPAP+ BMDC in renal tissue sections by (immuno)histochemical staining 
was confirmed by BMDC labeling and fluorescence-activated cell sorting (Figure 2). It 
has also been described that the expression of hPAP is stable in isolated cells in culture 
(52). 
The stable and ubiquitous expression of hPAP, its applicability in rat models and simple 
detection methods, make the ROSA26-hPAP transgene a reliable reporter for studies 







Figure 2. hPAP expression determined by FACS. 
ROSA26-hPAP transgenic bone marrow cells 
were detected by flow cytometry after isolation 
and labeling with anti-hPAP and a FITC-/abeled 
conjugate. The graph shows F/TC expression in 
Hr" bone marrow cells of a non-transgenic F344 rat 
(left), and of a ROSA26-hPAP rat (right). 
Transgenic mice ubiquitously expressing luciferase from the North-American firefly 
(Pho ti nus pyralis) have been generated, in which the firefly luciferase gene is controlled 
by promoter and enhancer elements of the human cytomegalovirus major immediate 
early gene (53). Firefly luciferase, an enzyme that causes light emission from yellow 
to green wavelengths in the presence of a substrate (luciferin), oxygen, ATP and 
magnesium (54), is the most commonly used bioluminescent reporter in biomedical 
research. The fast rate of firefly luciferase enzyme turnover in the presence of the 
substrate luciferin and its short half-life allows for real-time measurements, because 
firefly luciferase does not accumulate intracellularly to the extent of other reporters 
(55). Moreover, luciferase expression has been shown to be stable in isolated cells in 
culture (54). 
The greatest advantage of the use of the bioluminescent firefly luciferase gene as 
a reporter protein is that the internal biological light source provided by luciferase 
can penetrate relatively easy through tissues, allowing in vivo detection using in vivo 
imaging techniques. Therefore, luciferase-produced bioluminescence can be non­
invasively and repetitively measured in real-time in the same animal, thereby reducing 
the interference of animal-to-animal variation and requiring fewer animals per study 
(56). 
A short-coming of the currently available techniques is that it is not possible to 
accomplish the imaging of real-time luciferase expression within individual cells within 
living organisms (57). /n vivo imaging can provide information on the renal localization 
of luciferase, but cellular localization must be determined, similar to other reporters, 
in (post-mortem) tissue sections or cell lysates. Nevertheless, sensitive noninvasive 
imaging of firefly luciferase gene expression makes this reporter suitable for studying 
BMDC recruitment to the circulation and homing to the injured kidney in a living 
organism. 
Despite these advantages, bone marrow transplantation of ubiquitous luciferase­
expressing bone marrow to study renal infiltrating BMDC has not been described. 
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However, the use of a murine mesenchymal stem cell line transfected with a retroviral 
construct encoding firefly luciferase to study homing of these cells to the ischemic 
kidney was recently described (abstract by Kielstein J.T. et al. J. Am. Soc. Nephrol. 2007; 
17: 527A). Detection of selectively luciferase-expressing BMDC was reported in the 
kidney (35) and will be discussed in the section on transgenic reporters under control 
of tissue or cell type-specific promoters. Moreover, the recently generated firefly 
luciferaselEGFP double transgenic mouse (58) will be very useful in studies on BMDC 
fate in the renal disease. 
Transgenic reporters under the control of tissue or cell type-specific promoters 
Phenotypical changes or functional properties of renal infiltrating BMDC are mostly 
studied by combined immunohistochemistry detecting the reporter marker in 
conjunction with a cell type-specific marker. Another option is to perform bone marrow 
transplantation with transgenic bone marrow in which the reporter gene is driven by 
a cell type-specific promoter. Since differentiation of BMDC to that specific cell type 
will elicit activation of the promoter and expression of the reporter marker, this allows, 
in addition to mere localization of the BMDC, to evaluate potential differentiation 
of the BMDC to a certain cell type in a more reliable way. A problem that can be 
encountered when using these tissue or cell type-specific promoters is that activation 
of the promoter and thus expression of the reporter is not as specifically as it should 
be. However, when expression is cell-type-specific within the organ of interest, the 
reporter can be utilized. For example, in the first version of the GFP expressing 'green' 
mice, GFP was expressed in the renal podocytes, skeletal muscle, pancreas and heart 
(37). Although GFP expression was not exclusively observed in renal podocytes, these 
mice could be used to study differentiation of BMDC to podocytes (7;59). 
Epithelial-specific expression of EGFP 
Lin et al. (42) crossed two mouse strains to accomplish conditional tubular epithelial 
specific expression of EGFP to study the contribution of intra-renal and BMDC to 
post-ischemic tubular regeneration. The first mouse strain, ZIEG, is a double reporter 
mouse. The first reporter, lacZ, is linked to a ubiquitous promoter and is flanked by 
two loxP sites. The second reporter, EGFP, resides further downstream. The EGFP gene 
will only be activated in the presence of ere recombinase, resulting in recombination 
between the loxP sites and subsequent deletion of the lacZ sequence. Once activated, 
EGFP expression is irreversible and inheritable, irrespective of the continued presence 
of ere recombinase. 
The second transgenic mouse strain, crek•P, expresses ere recombinase under the 
control of the renal tubular epithelial-specific Ksp-cadherin promoter. Crosses between 
these two mouse strains result in the crek•P;ZIEG transgenic mice which specifically and 
permanently express EGFP in mature tubular epithelial cells (42). In crek•P;ZIEG bone 
marrow chimeric mice, differentiation of BMDC to tubular epithelial cells would be 
visible by EGFP expression. However, the crek•P;ZIEG transgenic mice that were used 
in this study showed a mosaic expression pattern of EGFP, due to inefficient crelloxP 
recombination and non-ubiquitous expression of the ZIEG promoter. Therefore BMDC 
fate could not be determined reliably using this reporter marker (42). 
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Fibroblast-specific expression of EGFP 
To determine the source of renal interstitial fibroblasts in  renal fibrosis, lwano et al. 
(60) used FSP1.GFP bone marrow chimeras. In  these chimeras, renal infiltrating BMDC 
express GFP under control of the FSP1 (fibroblast specific protein 1) promotor, and 
therefore, express GFP upon conversion to a fibroblast phenotype. Although lwano 
demonstrated differentiation of BMDC to FSP-1+ cells after unilateral ureter obstruction 
(UUO), the question remains if FSP-1 is specifically expressed by fibroblasts. 
The use of transgenic mice constitutively expressing a reporter molecule under the 
control of an endothelial-specific promoter for bone marrow transplantation studies 
has, to the best of our knowledge, not been described in renal disease models. 
In cardiovascular research however, the use of bone marrow chimeras in which 
J3-galactosidase expression is transcriptionally regulated by endothelial-specific 
promoters Flk-1 or Tie-2 has been proven suitable to study BMDC differentiation to an 
endothelial phenotype (61). Moreover, the use of transgenic mice in which a reporter 
gene is placed under the control of a podocyte-specific promoter, such as nephrin or 
podocin, will also be a useful tool to extend our knowledge on BMDC differentiation 
in renal injury models. 
Pro-collagen 1A2-specific expression of luciferase/�-ga/actosidase 
The use of reporters driven by cell-type specific promoters for BMDC detection can 
give information about differentiation fates of BMDC. However, another important 
question is whether BMDC are functional in their differentiated state. This question was 
addressed in a study by Roufosse (35), using the UUO model of renal fibrosis to study 
the functional contribution of BMDC to fibrosis by determination of their capacity to 
produce collagen. To this end, a transgenic mouse was generated that expressed both 
luciferase and 13-galactosidase reporter genes under the control of a promoter and 
enhancer element of the gene encoding pro-COL1A2 (coding for the a2 chain of the 
pro-collagen type 1). Roufosse demonstrated the unreliability of 13-galactosidase in 
this model (see also J3-galactosidase section). However, detection of pro-collagen 1 
could still be accomplished by luciferase. The presence of luciferase was determined 
by measurement of luminescence or luciferase protein, or by in situ hybridization for 
luciferase mRNA, the latter allowing the authors to determine the exact location of 
luciferase activity and co-expression with other markers (35). 
In the study of Roufosse, in vivo imaging techniques were not used to determine 
luciferase activity. When performed on living animals in vivo bioluminescence imaging 
would have provided information on renal luciferase activity and would have allowed 
for non-invasive tracing of luciferase activity in time in the same animal. 
Stability of transgene expression 
It may occur that a transgene is not expressed, that expression disappears in 
subsequent generations of the transgenic rodent, despite the presence of the 
transgene i n  the genome, or that expression is or becomes variable in different 
tissues. This phenomenon can be caused by gene silencing, which causes the loss 
of transcription of the particular gene (62). Gene silencing can be the result of DNA 
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methylation and/or histon deacetylation, causing alterations in chromatin structure 
by as yet unknown but cell-type restricted mechanisms. Both cause the shutting-off 
of gene transcription (63). 
Gene silencing can also take place on a post-transcriptional level (62). This occurs 
when mRNA of the transgene is degraded or blocked prior to translation e.g. by 
microRNA. Alternatively, the stability of transgenic protein may be affected, causing a 
high degradation rate, e.g. by increased ubiquitination. 
The possibility of gene silencing in transgenic bone marrow transplantation models is 
often not considered and is likely to be an underestimated problem. 
Ex vivo labeling of BMDC 
Besides the use of bone marrow transplantation to study the role of BMDC in renal 
disease models, local or systemic infusion of BMDC, or a sub-set of BMDC, has been 
used. This approach does not require total body irradiation and is more relevant in 
pre-clinical, rather than experimental, studies. However, since the native bone marrow 
is not replaced by bone marrow transplantation, the infused BMDC will compete with 
physiologically recruited BMDC, which might hamper the interpretation of BMDC 
function. 
Infusion of BMDC can be performed using the same genetically labeled reporter cells 
as used in bone marrow transplantation models, i.e. Y-chromosome, �-galactosidase, 
EGFP and hPAP. To allow detection of the infused cells in the kidney, non-genetic 
labeling methods have been applied, e.g. infusion of CFDA fluorescence labeled (64) 
or iron-dextran labeled cells (65). 
Long-lasting dyes - CFDA 
In a study by Togel (64), carboxy-fluorescein diacetate (CFDA; Vybrant cell tracer 
kit, Molecular Probes) pre-labeled mesenchymal stem cells were infused in the left 
carotid artery to study their contribution to post-ischemic renal recovery. CFDA enters 
the cell by passive diffusion and starts to fluoresce after conversion by intracellular 
esterases, and is therefore suitable for marking living cells. The label is retained 
during development, meiosis and in vivo tracing, and is inherited by daughter 
cells after division or fusion, but is not transferred to adjacent cells in a population. 
However, after each cell division the fluorescence level is two-fold reduced. The major 
drawback of this labeling method and other comparable fluorescent labels is the 
limited stability of the fluorescence. In vivo, the label could be traced up to 20 days 
after labeling (66) and is, therefore, not suitable for use in longer-term experiments. 
The emitted fluorescence of CFDA does not penetrate deep enough through tissue to 
allow for in vivo detection of the label. However, when the kidney was exposed and 
renal vasculature was visualized using rhodamine-dextran or FITC-albumin, BMDC 




Particles - lron-dextran labeled particles 
Lange et al. (65) infused mesenchymal stem cells, pre-labeled with carboxy-dextran­
coated iron oxide nanoparticles ("Resovist", Schering), into the thoracic aorta via a 
carotid artery after ischemia. These non-toxic iron-dextran particles are smaller 
than erythrocytes and are readily taken up by rat mesenchymal stem cells (65). 
An advantage of this method is the non-invasive detection of the labeled cells by 
Magnetic Resonance Imaging (MRI}, which allows for real-time imaging in the living 
animal. However, MRI is a laborious technique which requires equipment and trained 
personnel .  Besides in vivo detection with MRI, ex vivo histological identification of 
the iron-labeled cells by Prussian blue staining can be used to determine the exact 
location of the cells. It is unknown how these iron-dextran particles, likely to be 
cleared by phagocytosis, influence the inflammatory response. In the study by Lange 
(65), the particles did not elicit an immune response, were stable and detectable in 
a non-invasive way, therefore, providing an elegant method for ex vivo labeling of 
cells. 
Summary and future perspectives 
Various detection methods have been described to study the functional relevance 
of renal infiltrating BMDC. Provided that the essential prerequisites of enzymatic 
staining are met, all above mentioned reporters would seem applicable and useful 
for tracing BMDC in renal disease models. Some have, however, advantages over 
others. EGFP and luciferase both can be detected in living cells, which is an advantage 
for functional studies. The advantage of EGFP as a reporter molecule over luciferase 
is that detection of the protein can be accomplished without the introduction of a 
substrate. Luciferase needs a substrate for excitation, but it does not require external 
light excitation and, therefore, is less susceptible to background noise than EGFP. 
The background noise of EGFP, which is especially problematic in the kidney, can be 
overcome by the use of one of its spectral variants (cyan-, blue- and yellow fluorescent 
protein). These spectral variants also allow simultaneous labeling of multiple cell 
types. Both luciferase and EGFP have their advantages and disadvantages. However, a 
considerable disadvantage of EGFP is that, in contrast to firefly luciferase, it does not 
penetrate tissues enough for non-invasive in vivo detection of the signal in the living 
animal. Firefly luciferase does provide the opportunity to in vivo, real-time, repetitive 
measurements in the same animal. Where reporter molecules previously limited 
investigators to study the presence of BMDC only ex vivo, bioluminescent imaging 
(used for luciferase detection), magnetic resonance imaging (MRI) and Positron 
Emission Tomography (PET) techniques now allow for in vivo tracking of BMDC in 
living animals. Advantage of bioluminescent imaging over MRI and PET is that the 
use of light for bioluminescent imaging is safe and not subject to radioactive decay, 
as are the tracers used in PET, and does not require the introduction of particles or 
contrast fluids, as are required for MRI (56). A major short-coming of the currently 
available imaging techniques is that their resolution is not sufficient for visualization 
of individual cells or nephrons (57). Therefore, additional phenotypical analysis on 
tissue section will be necessary to study differentiation fates of BMDC. 
In conclusion, most described reporter molecules can, knowing their strong and weak 
sides, be reliably applied for detection of renal infiltrating BMDC. The application 
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determines which reporter is most suitable. Firefly luciferase would be suitable for in 
vivo detection of BMDC mobilization and homing to the damaged kidney. However, 
for phenotypical analysis of BMDC to determine their functional relevance in renal 
repair, EGFP has been described as the reporter marker with the most opportunities. 
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Abstract 
lschemia/reperfusion injury (IRI) is a major cause of acute renal failure (ARF). ARF is 
reversible, due to an innate regenerative process, which is thought to depend partly 
on bone marrow-derived progenitor cells. The significance of these cells in the repair 
process has been questioned in view of their relatively low frequency. Here, we 
hypothesize that the severity of renal damage and the post-ischemic recovery time 
are determinants of tubular bone marrow-derived cell (BMDC) engraftment. 
We used a model of unilateral renal ischemia/reperfusion in F344 rats reconstituted 
with R26-hPAP transgenic bone marrow, in which we quantified and characterized 
tubular BMDC engraftment with increasing severity of damage and in time. 
After IRI, BMDC en grafted the tubular epithelium and acquired an epithelial phenotype. 
Tubular epithelial BMDC engraftment increased with longer ischemic time, indicating 
that tubular epithelial BMDC engraftment increases with the severity of damage. 
The number of circulating progenitor cells doubled early after IRI and was followed 
by a transient increase in tubular epithelial BMDC engraftment. The latter positively 
correlated with morphological recovery of the kidney over time. 
The extent of tubular BMDC engraftment depends on the severity of renal damage 
and follows a distinct time course after IRI. Therefore, the severity of damage and time 
course need to be taken into account when interpreting data on the role of tubular 
BMDC engraftment in renal repair after IRI. 
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Introduction 
Renal ischemia/reperfusion injury (IRI) is a major cause of acute renal failure (ARF), 
a condition affecting up to 5% of long-term hospital patients (1), and, additionally, 
posing a potential post-operative problem for kidney transplant patients. Renal IRI 
is the result of oxygen deprivation and the subsequent cumulative assaults of the 
ensuing inflammatory reaction on renal vascular and epithelial tissue. 
Severe IRI is characterized by tubular epithelial cell death and loss of kidney function 
(2). Interestingly, however, renal IRI is reversible (3), indicating that innate repair 
mechanisms are activated upon renal damage. One of these mechanisms is thought 
to involve bone marrow-derived (BMD) progenitor cells, which have been shown to 
engraft affected kidneys and to adopt an epithelial phenotype (4-7), possibly replacing 
damaged tubular epithelial cells. The functional significance of bone marrow-derived 
cells (BMDC) in renal repair is so far uncertain. Whereas there is data to suggest a 
contribution to renal repair, it has been pointed out that the number of BMDC detected 
in the kidney after IRI is low and variable, typically ranging between just 2% and 8%, 
which led to questioning their functional significance (5;7). 
The determinants of the extent of BMDC engraftment have not been explored so far, 
which hampers the interpretation of previous data. Here, we hypothesize that the 
extent of BMDC engraftment is modulated by the severity of renal damage and post 
IRI recovery time. Moreover, the impact of endogenous repair, based on proliferation 
of surviving renal cells, was investigated. While the impact of these three parameters 
on renal BMDC engraftment has not yet been explored, they are likely to play a role in 
renal repair. It is known, for example, that increasing severity of IRI negatively affects 
renal recovery. Furthermore, studies concerning mobilization kinetics of endothelial 
progenitor cells (EPC) after acute myocardial infarction demonstrated a gradual 
increase in numbers of these cells in the circulation, peaking on day 7 post-infarction, 
suggesting the presence of windows of opportunity for engraftment of these cells in 
the heart (8). Finally, proliferation of resident tubular epithelial cells that survive renal 
IRI is thought to contribute to the restoration of kidney morphology and function (9-
11). 
The hypotheses were tested using a model of unilateral renal ischemia/reperfusion 
in F344 rats reconstituted with rat R26-hPAP transgenic bone marrow. The unilateral 
model, with the other kidney remaining in situ to ensure residual renal function and 
survival of the animals, allowed us to study not only mild and moderate, but also 
severe IRI. 
Materials and Methods 
Study design 
In both experiments, unilateral renal ischemia was induced in R26-hPAP to F344 BM 
chimeric rats. 
To investigate the influence of the severity of renal damage on tubular BMDC 
engraftment we modulated damage extent by varying ischemic times (20, 30, 45 and 
60 min, n=3 per group). The effect of renal damage extent on renal morphology was 
monitored after 7 days by PAS staining, the effect on renal function and tubular BMDC 
engraftment after 28 days. 
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To study the kinetics of tubular epithelial BMDC engraftment in relation to recovery 
time, we inflicted 45 min of unilateral ischemia and evaluated tubular BMDC 
engraftment after 1 (n=6), 3 (n=6), 7 (n=6), 14  (n=7), 28 (n=5), 56 (n=3) and 112 (n=3) 
days of recovery. 
Animals 
Male, 6 week-old F344 rats (Harlan Nederland, Horst, The Netherlands) were used 
as BM recipients. R26-hPAP rats (founders were a kind gift of Dr. E. Sandgren; F344 
background, 6 week-old), transgenic for human placental alkaline phosphatase (hPAP) 
(12), were used as BM donors. 
Rats were housed in a conventional environment and received standard chow and 
water ad libitum. Drinking water was supplemented with 1 mg/ml 5-bromo-2-
deoxyurdine (BrdU, Sigma, St. Louis, USA), for 3 days before termination. 
All animal procedures were approved by the local committee for care and use of 
laboratory animals and performed according to governmental and international 
guidelines on animal experimentation. 
Irradiation and bone marrow transplantation 
Non-transgenic rats received lethal total body irradiation (9 Gy, IBL 637 Cesium-137 
gamma ray source) for bone marrow ablation. Subsequently, the rats were housed in 
filter top cages. Drinking water was supplemented with neomycin (0.35% w/v) starting 
one week before i rradiation, until 2 weeks after irradiation. 
Total BM from R26-hPAP rats was isolated by flushing femurs and tibiae with sterile 
PBS. Erythrocytes were lyzed in 155 mmol/L NHp, 10mmol/L KHCO3, 0.1 mmol/L Na 
EDTA, and the BM cell suspension was filtered through a 10 µm cell strainer (Falcon, 
Becton Dickson). BM isolation was carried out on ice. 
Twenty-four hours after irradiation, rats received approximately 1x106 R26-hPAP BM 
cells intravenously and were allowed to recover for 4 weeks. Bone marrow chimerism 
in recipients was determined by enzymatic hPAP staining (see below) on bone marrow 
cytospots from recipients and was typically between 80% and 90%. 
Surgical procedure 
Reconstituted BM recipients were sedated by general isoflurane (2% Forene, Abbot 
b.v., Hoofddorp, The Netherlands), Np (50%), 02 (50%) anaesthesia. The left renal artery 
was exposed and clamped with a non-traumatic clamp to induce ischemia. The clamp 
was removed after specified periods and renal reperfusion was confirmed visually. 
SHAM-operated control rats underwent bone marrow transplantation followed by a 
midline incision. 
At specified time points after ischemia/reperfusion, rats were anaesthetized. Blood 
samples were drawn and both kidneys were perfused in situ with cold saline. Kidneys 
were isolated and divided into quarters by a longitudinal and a transversal section. 
These quarters were fixed in zinc fixative (0.1M Tris buffer, pH 7.4 with 0.5g CaCH2COO, 
5g (CH2COO)2Zn*2Hp and 5g ZnCl2 per liter; MERCK, Darmstadt, Germany), or 
snap-frozen in N2 and stored at -80
°C. Zinc-fixed tissues were processed for paraffin 
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embedding by standard procedures and used for immunohistochemistry. Snap-frozen 
tissue was used for immunofluorescence microscopy. 
Kidney function 
Plasma creatinine levels were determined using a colorimetric test (Merck MEGA· 
analyzer, Merck). 
Detection of lineage negative (Lin') cells 
Mobilization of BMD progenitor cells to the circulation was determined using total 
mononuclear cell (MNC) fractions. Since no monoclonal antibodies (moAbs) specific 
for rat progenitor cell markers are available, we assessed circulating Un· cells as 
a population enriched for potential BMD progenitor cells. Briefly, MNC fractions 
were isolated by lympholite rat density gradient centrifugation (Cederlane, Uden, 
The Netherlands). MNCs were stained with a cocktail of PE- or FITC-labeled moAbs 
against the lineage markers CD3 (T cells, Becton Dickinson, Alphen aan den Rijn, The 
Netherlands), CDl 1 b/c (myeloid and dendritic cells, BD) and anti-rat K/'A (B cells, Sigma­
Aldrich, Zwijndrecht, The Netherlands). Un· cells were detected and quantified on day 
1 (n=3), 3 (n=3), 7 (n=3) and 14 (n=3) after 45 min of ischemia using MoFlo cytometer 
(Cytomation Inc., Fort Collins, CO), and Win list 5.0 software (Verity, Topsham, ME). 
(lmmuno)histochemistry 
Enzymatic hPAP staining was used to detect renal infiltration of hPAP+ BMDC. Briefly, 
5 µm paraffin sections were dewaxed and endogenous alkaline phosphatase was 
heat-inactivated by incubation in substrate buffer (0.l M Tris-HCI, pH 9.5, 0.l M NaCl, 
5mM MgCl2) at 65
°C for 30 min (12). Subsequently, sections were incubated in fresh 
substrate buffer containing 2% (v/v) nitroblue tetrazolium/5-bromo-4-chloro-3-indolyl 
phosphate (NBT/BCIP, Roche, Woerden, The Netherlands) (Sh, room temperature 
(RT)). 
Detection of hPAP+ BMDC was confirmed by immunohistochemical staining using 
a rabbit anti-human Placental Alkaline Phosphatase monoclonal antibody (hPAP, 
Serotec, Oxford, UK) to detect bone-marrow derived cells. Briefly, 5 µm zinc-fixed 
paraffin sections were dewaxed and subjected to endogenous alkaline phosphatase 
inactivation by incubation in substrate buffer at 65°C for 30 min (12). Non-specific 
protein binding was blocked with 2% BSA for 30 min and endogenous biotin was 
blocked with biotin blocking kit (Biotin blocking system, DAKO). Rabbit anti-hPAP 
antibody was applied to the sections for 60 min, at room temperature (RT), followed by 
biotinylated goat-anti-rabbit conjugate (DAKO, Glostrup, Denmark) and streptavidin­
alkaline phosphatase (Southern Biotechnology). Color development was performed 
with fuchsin substrate-chromogen system according to manufacturer's instructions 
(DAKO). 
The epithelial phenotype of tubular engrafted BMDC, was assessed by 
immunofluorescent double-staining for hPAP (rabbit-anti-human Placental Alkaline 
Phosphatase, Serotec) in combination with, respectively, E-cadherin (clone 36, BD 
Biosciences), pan-cytokeratin (C-11, Abeam, Cambridgeshire, UK) or a cocktail of 
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the tubular epithelial-specific lectins SBA (biotinylated soybean agglutinin), OBA 
(biotinylated dolichos biflorus agglutinin) and PNA (biotinylated peanut agglutinin; 
al l  from Vector laboratories Inc., Burlingame, CA, USA). Briefly, on 5 µm cryo sections, 
endogenous biotin was blocked with biotin blocking kit (biotin blocking system) 
according to manufacturer's instructions (Dako). BMDC were detected by incubation 
with anti-hPAP moAb (l h, RT), followed by goat-anti-rabbit-FITC conjugate (Southern 
Biotechnology, Bi rmingham, USA). Tubular epithelial cells were detected in several 
ways; by incubation with a mixture of 30 µg/mL biotinylated SBA/DBA/PNA followed 
by a streptavidin-Cy3 (Zymed Laboratories Inc., San Francisco, USA) conjugate, or by 
incubation with moAbs against E-cadherin or pan-cytokeratin (l h, RT) fol lowed by 
biotinylated goat-anti-mouse (lgG2a for E-cadherin and lgGl for pan-cytokeratin) 
(Dako) and streptavidin-Cy3 conjugates (Zymed Laboratories Inc). 
To confirm that hPAP+ cells, engrafted in renal tubul i, were not engrafted BMD 
leukocytes, we performed double-staining combining hPAP with CD45 (leukocyte 
marker). Briefly, on 5 µm cryo sections, endogenous biotin was blocked and BMDC were 
detected as described above. Leukocytes were detected by incubation with mouse 
anti-rat CD45 moAb (lh, RT, OX-1, culture supernatant), followed by biotinylated goat 
anti-mouse lgG (Southern Biotechnology) and streptavidin-Cy3 conjugates (Zymed 
Laboratories Inc). 
To detect BrdU incorporation, 5 µm paraffin sections were treated with 0.7M HCI (30 
min, 37°C), followed by incubation with 0.025% (w/v) pepsin in 0.35M HCI ( 15 min, 
37°C, Roche). BrdU was detected by incubation with anti-BrdU moAb (1 h, RT, Sigma­
Aldrich), fol lowed by biotinylated goat anti-mouse lgG (Southern Biotechnology) 
and streptavidin-conjugated peroxidase (Dako). Color development was performed 
with 3-amino-9-ethylcarbazole (Sigma-Aldrich) substrate dissolved in N,N­
dimethylformamide (MERCK) and 0.SM acetate buffer, pH 4.9. 
All conjugate incubations were performed for 30 min, RT, in the dark, and were followed 
by appropriate washing steps. lmmunofluorescence sections were counterstained with 
DAPI and mounted with citifluor (Agar scientific, Stansted, UK). lmmunohistochemically 
stained sections were counterstained with Mayer's hemalum (MERCK) and mounted in 
Kaiser's glycerol (MERCK). 
Light- and fluorescence microscopy was performed using a Leica DMLB microscope 
(Leica Microsystems, Rijswijk, The Netherlands), Leica DC300F camera and Leica QWin 
2.8 software. To confirm that double positive cel ls were not the result of overlying 
cells, confocal microscopy was performed using a Leica TCS SP2 confocal microscope 
and Leica confocal 2.5 software. 
Quantification 
The severity of morphological renal damage was assessed using an arbitrary score 
based on PAS-stained kidney sections. Briefly, the extent of 4 typical !RI-associated 
damage markers, i.e. dilatation, denudation, i ntraluminal casts and cell flattening, was 
expressed in arbitrary units (a.u.) in a range of 0-3. 
Tubular engraftment of BMDC in the cortex and outer medulla was assessed by scoring 
the number of tubulus sections containing at least one hPAP+ cell. To be considered 
an epithelial cell, hPAP· cells had to be integrated in the renal tubule at the luminal 
side of the basal membrane and have epithelial size and morphology, similar to 
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that of neighboring, resident tubular cells. Kidney section area was determined by 
computerized planimetry (Leica QWin 2.8 software) and differences in kidney section 
area were corrected for by expressing the number of hPAP+ tubuli per 10 mm2• 
The percentage of the tubular engrafted BMDC which also express a tubular epithelial 
marker was determined on kidney sections after immunotluorescence staining for 
hPAP and a tubular epithelial marker. 
To determine proliferation-mediated renal repair in the cortex and outer medulla, 
we first determined the percentage of tubulus sections containing at least one BrdU+ 
cell. Subsequently, the percentage of BrdU+ nuclei per BrdU+ tubulus section was 
determined. 
Statistics 
Statistical tests were performed using GraphPad Prism 4.0 (GraphPad Software, San 
Diego California, USA) and SPSS 12.0 software (SPSS Inc., Chicago, USA). Two-tailed 
Mann-Whitney-U tests were performed to determine differences between SHAM and 
experimental groups. Spearman correlation tests were performed to determine the 
relationship between different parameters. P-values <0.05 were considered statistically 
significant. 
Results 
Morphological and functional damage extent in relation to ischemic time 
On day 7, morphological IRI was observed in the tubular epithelium in cortex and 
outer medulla, while glomeruli were morphologically normal. Increasing ischemic 
time was associated with increasing renal damage (Figure 1 B-D), as apparent from the 
presence of all classical damage markers, such as proximal epithelial cell flattening or 
loss, tubular dilatation, and the intraluminal brush border debris and protein casts (13). 
Tubular denudation was observed after 45 min of ischemia (Figure lC). Sixty min of 
ischemia resulted in extensive damage (Figure 1 D) and was not further investigated. 
The cumulative damage score, assessed on day 28 after 20, 30 and 45 min of ischemia, 
was higher in the groups with longer ischemic time, thereby validating our model 
(Figure 2A). The cumulative damage score significantly correlated with ischemic time 
(Figure 2B). Plasma creatinine levels, assessed on day 28 after 20, 30 and 45 min of 
ischemia, were slightly but significantly higher than in SHAM controls (Figure 2C). 
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Figure 1 .  Morphological kidney damage extent in relation to ischemic time. Representative morphology of 
a healthy control kidney (AJ and of kidneys subjected to 30 (BJ, 45 (CJ and 60 min of ischemia (DJ assessed on 
day 7 after /RI induction by PAS staining of paraffin sections. Arrows indicate examples of tubular membrane 
denudation. Asterisks indicate examples of intraluminal casts. Lens magnification 200x. 
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Figure 2. Morphological and functional kidney damage extent in relation to ischemic time. Severity of 
damage was determined by an arbitrary score of the presence of 4 typical /RI-associated damage markers, 
i.e. dilatation, denudation, intraluminal casts and cell flattening and expressed in arbitrary units (a.u.J in a 
range of 0-3. The severity of damage was assessed on PAS stained kidney sections of rats sacrificed on day 28 
after 20, 30 and 45 min of ischemia (AJ. Correlation between damage score and ischemic time was assessed 
by a Spearman correlation test (BJ. SHAM-operated controls = open circles, 20 min of ischemia = squares, 
30 min of ischemia = triangles, 45 min of ischemia = closed circles. Plasma creatinine levels were measured 
on day 28 after 20, 30 and 45 min ofischemia (C). Bars indicate mean + SEM of all experimental animals per 
group. Statistically significant differences compared to SHAM are indicated as * =  P<0.0S, ** = P<0.005. 
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Tubular epithelial BMDC engraftment in relation to ischemic time 
hPAP was ubiquitously expressed in renal cells of R26-hPAP transgenic rats (Figure 3A), 
and was undetectable in non-transgenic kidneys (not shown) and in post-ischemic 
kidneys of non-BM transplanted F344 rats (Figure 3B). In ischemic kidneys of R26-hPAP 
BM transplanted rats, most hPAP+ BMDC formed interstitial infiltrates (Figure 3(). On 
day 28 after IRI induction, the extent of renal BMDC infiltration was similar in kidneys 
subjected to 20 and 30 min of ischemia, but more extensive in kidneys subjected to 45 
min of ischemia (not shown). Morphological examination of the contralateral kidney 
demonstrated small interstitial infiltrates of hPAP+ BMDC (not shown). 
To determine tubular epithelial BMDC engraftment we sought for hPAP+ cells that were 
integrated in the renal tubulus, at the luminal side of the basal membrane (Figure 3D). 
hPAP expression was confirmed by immunohistochemical staining on consecutive 
slides (Figure 3E). Typically, in engrafted tubuli, we detected one hPAP+ cell per 
tubulus section and, sporadically, two or three, but never more. In SHAM-operated 
and contralateral kidneys, BMDC-engrafted tubuli were infrequent and significantly 
lower compared to ischemic kidneys (Figure 3F). After ischemia, the number of BMDC­
engrafted tubuli in cortex and outer medulla increased progressively with ischemic 
time (Figure 3F) and, moreover, correlated significantly with ischemic time (Figure 
3G). 
Epithelial phenotype of BMDC engrafted in tubuli 
The epithelial phenotype of en grafted hPAP+ cells was assessed by immunofluorescence 
double-staining combining hPAP detection with detection of the epithelial markers 
E-cadherin, pan-cytokeratin and epithelial-binding lectins (SBA, OBA and PNA). In 
accordance with the enzymatic detection of tubular engrafted BMDC, engrafted tubuli 
contained one or two hPAP+ cells. These cells also bound lectins (Figure 4A-C), or co­
expressed pan-cytokeratin (Figure 4D-F) or E-cadherin (Figure 4G-1). Independently 
of the epithelial marker used, an average of 94% of the tubular engrafted BMDC 
also expressed a tubular epithelial marker. Neither E-cadherin nor pan-cytokeratin 
expression or epithelial lectin binding was observed within hPAP+ inflammatory cell 
infiltrates, indicating the specificity of these tubular epithelial markers (not shown). 
To confirm that tubular epithelial engrafted BMDC were not incorporated leukocytes, 
we performed a double-staining combining hPAP with CD45 (leukocyte marker). Cells 
expressing CD45 were only present in interstitial infiltrates, but were not engrafted in 
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Figure 3. Tubular epithelial BMDC engraftment in relation to ischemic time. To detect hPAf>+, i.e. bone 
marrow-derived cells, enzymatic staining of hPAP was performed after heat inactivation of endogenous 
alkaline phosphatase. Ubiquitous expression of hPAP was observed in R26-hPAP transgenic rat kidney 
(A). hPAP staining was absent in post-ischemic kidneys of non-BM transplanted F344 rats (BJ. Expression 
of hPAP was observed on infiltrating BMDC in post-ischemic kidneys of rats, reconstituted with R26-hPAP 
transgenic bone marrow (CJ. Lens magnification 400x. Engroftment of hPAf>+ cells in tubuli of ischemic 
kidney was observed on day 28 after 45 min of ischemia with enzymatic hPAP staining (DJ and was 
confirmed by immunohistochemical hPAP staining on a consecutive slide (E). Note similar morphology of 
hPAf>+ cells to that of neighboring, resident tubular cells. Arrows indicate examples of tubular epithelial 
8MDC engraftment. Lens magnification 1000x. Tubular BMDC engraftment in relation to damage extent 
was determined on day 28 after /RI induction (F). Tubulus sections containing ot least one hPAf>+ cell with 
epithelial morphology were counted in the cortex and outer medulla. Scoring was performed on SHAM 
(black bars), contralateral (grey bars) and ischemic kidneys (white bars). Bars indicate mean values + SEM of 
all experimental animals per group. Statistically significant differences compared to SHAM are indicated as 
* = P<0.05, ** = P<0.005. Correlation between tubular BMDC engraftment and ischemic time was assessed 
by a Spearman correlation test (G). SHAM-operated controls = open circles, 20 min of ischemia = squares, 30 
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overlay 
Figure 4. Epithelial 
phenotype of BMOC 
engrafted in tubuli. 
Epithelial phenotype 
of BMDC engrafted 
in tubuli after /RI 
was confirmed by 
immunof/uorescence 
co-detection of hPAP 
(A,D,G) and epithelium­
binding /ectins SBA, 
OBA, PNA (cocktail) 
(BJ or the epithelium­
specific markers 
pan-cytokeratin (E) 
and E-cadherin (HJ. 
Double-positive cells 
are shown in the 
overlay pictures (C,F,I). 
To confirm that tubular 
engrafted BMDC were 
not leukocytes we used 
immunofluorescence 
co-detection of hPAP (J) 
and CD45 (K, common 
leukocyte antigen). No 
double-positive cells 
were faund engrafted in 
the tubular epithelium 
(L, overlay). Green = 
FITC, red = Cy3, blue = 
OAP/. Arrows indicate 
examples of tubular 
engrafted BMDC. Note 
identical morphology 
of positive cells in 
both channels. Lens 
magnificatian 400x. 
Tubular epithelial BrdU incorporation in relation with ischemic time 
The extent of proliferation in tubular epithelial cells in the cortex and outer medulla 
was assessed by BrdU incorporation into nuclei of tubular epithelial cells on day 28 
after IRI induction. No differences in BrdU incorporation, quantified as the percentage 
of BrdU• tubuli and as the percentage of BrdU+ nuclei per BrdLJ+ tubulus section, were 
present between SHAM, contralateral and post-ischemic kidneys. In all cases, most 
BrdU+ nuclei were found within the tubular epithelium and often appeared in pairs. 
Sporadically, proliferating cells were present in the tubulo-interstitial spaces and in 
glomeruli (not shown). 
53 
CHAPTER3 
Time course of morphological and functional kidney regeneration 
To study the time course of renal repair, the ischemic time of 45 min was selected, since 
this model yielded sufficient renal damage, especial ly in terms of tubular denudation, 
but sti l l  a l lowed for regeneration. 
On day 1, extensive epithelial  cell loss in the cortex and outer medulla was observed 
(Figure SA). By day 112, the tubular epithelium was virtually restored and ischemic 
damage markers, discussed above, were attenuated (Figure SB). Cumulative severity 
of damage score showed a g radual morphological recovery in time (Figure SC). Plasma 
creatinine levels peaked slightly, but significantly, on day 1 ,  with a gradual decrease 
towards baseline values afterwards (Figure SD). 
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Figure 5. Time course of morphological and functional kidney regeneration. Representative morphology 
of a kidney subjected to 45 min of ischemia on day 1 (AJ and 1 12 (BJ after /RI induction, was assessed by PAS 
staining of paraffin sections. Arrows indicate examples of tubular membrane denudation. Asterisks indicate 
examples of intraluminal casts. Lens magnification 200x. The severity of damage was determined by an 
arbitrary score, ranging from 0·3 arbitrary units (a.u.J, of classic damage markers present in PAS stained 
kidney sections (CJ. Plasma creatinine levels were assessed to determine kidney function (DJ. Bars indicate 
mean levels + SEM of all experimental animals per group. Statistically significant differences compared to 
SHAM are indicated as *=  P<0.05, ** = P<0.005, *** = P<0.0005. 
Time course of mobilization of BMDC 
Tubular epithelial BMDC engraftment is preceded by mobil ization of BMD progenitor 
cells to the circulation. After a reduction on day 1 after I RI, the number of circulating 
Lin· cells, a population enriched for progenitor cells (Figure 6A), increased and peaked 
on day 3, compared to controls  (Figure 6B). After day 3 the number of Lin·cells gradually 
decreased and reached control values by day 14. 
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Time course of tubular epithelial BMDC engraftment 
The majority of infiltrating BMDC formed interstitial infiltrates. The infiltrate size peaked 
by day 7 and gradually decreased after day 14. Small interstitial infiltrates persisted in 
the kidney until day 112 (not shown). 
In engrafted tubuli, typically one hPAP+ cell was present per BMDC-engrafted tubulus 
section. On days 1 and 3 after ischemia, BMDC-engrafted tubuli were infrequent and 
comparable in number to tubular BMDC engraftment in SHAM and contralateral 
kidneys (Figure 6C). On day 7 a sharp increase in the number of BMDC-engrafted tubuli 
was observed, followed by a peak on day 14, gradually decreasing by days 28 and 56, 
to return to SHAM levels on day 112 (Figure 6C). 
The epithelial phenotype of hPAP+ cells engrafted in tubuli was confirmed as above. 
lmmunotluorescence double-staining combining hPAP detection with detection 
of the epithelial markers E-cadherin, pan-cytokeratin and epithelial-binding lectins 
(SBA, OBA and PNA) was in agreement with the peak of tubular epithelial BMDC 
engraftment on day 14 and low frequency on day 56 and 112 after IRI induction. Over 
time we observed, independently of tubular epithelial marker, a slight increase in 
the percentage of tubular engrafted BMDC which also expressed a tubular epithelial 
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Figure 6. TimecourseofrecruitmentofBMDCto the circulation and the kidney. Circulating lineage-negative 
(Lin") cells (gated) were detected by flow cytometry after staining of MNC with moAbs against the lineage 
markers CD3 and CD1 1blc (both PE labeled) and anti-rat KIA (FJTC Jabeled)(A) and quantified at various 
time points after 45 min of ischemia (8). Tubular BMDC engraftment was assessed as the number of tubuli 
containing at least one hPAP' epithelial cell by enzymatic staining for the hPAP enzyme (C). hPAP' tubuli 
were scored in the cortex and outer medulla of SHAM (black bars), contralateral (grey bars) and ischemic 
(white bars) kidneys. Bars indicate mean values + SEM of all experimental animals per group. Ctr/. = control, 
S = SHAM, * = P<0.05, ** = P<0.005. 
Time course of tubular epithelial BrdU incorporation 
Most BrdLJ+ nuclei in cortex and outer medulla were found in the tubular epithelium. 
In SHAM kidneys typically one, and sporadically, two BrdU+ nuclei per tubulus section 
were observed (Figure 7A), in ischemic kidneys, frequently three or more adjacent 
BrdU+ tubular epithelial cells were detected (Figure 7B), with the highest frequency 
on day 7 after IRI. 
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The extent of BrdU incorporation was quantified as the percentage of BrdU+ tubuli 
(Figure 7() and as the percentage of BrdU+ nuclei per BrdU• tubulus section (Figure 
7D). The percentage of BrdU+ tubuli dropped significantly early after IRI to recover 
to control values from day 7 on. The percentage of BrdU+ nuclei per BrdU+ tubule 
was difficult to determine on days 1 and 3 due to extensive tubular denudation and, 
therefore, absence of nuclei. As a result, not all experimental animals from these time 
points could be included in the quantification. The percentage of BrdU+ nuclei per 
BrdU+ tubule peaked on day 7 and decreased to control values afterwards. 
SHAM 1 3 7 14 21!1 56 112 
C Postlschemlc time (days) 
j 
SHAM 1 3 7 14 21 56 112 
PosUschemlc time (days) 
Figure 7. Time course of tubular epithelial BrdU incorporation. Single BrdLJ• nuclei (brown) were typically 
present in tubu/i of SHAM kidneys (A). Multiple BrdU' nuclei were present within tubular epithelial cells in 
ischemic kidneys 7 days after /RI (8). Lens magnification 1000x. To determine the extent of proliferative 
tubular repair we first determined the percentage of BrdLJ• tubuli in cortex and outer medulla (C). Secondly, 
we determined the percentage of BrdLJ• tubular epithelial cells in 10 tubu/i in the cortex and 10 tubu/i in the 
outer medulla (D). BrdU incorporation in ischemic kidney was compared with incorporation in corresponding 
SHAM kidneys at the respective time point. Bars indicate mean values + SEM of all experimental animals per 
group. * = P<0.05, "** = P<0.0005. 
Discussion 
The current study demonstrates that the severity of renal damage is an important 
modulator of the extent of tubular epithelial BMDC engraftment after IRI in rats. 
Moreover, BMDC engraftment follows a d istinct time course, different from the time 
course of proliferation of tubular epithelial cells. 
To detect the bone marrow origin of tubular engrafted cells, we used the rat R26-hPAP 
transgene as a reporter marker. hPAP is one of the few available rat reporter markers 
and is more reliable than other commonly used reporter molecules, such as GFP and 
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�-gal. Problems with differential expression in kidney cells, as encountered with renal 
GFP expression in mice (14), or activation of endogenous protein expression at low 
pH (e.g. mammalian �-gal expression)(Duffield JS, Park K, Hsaio L, et al: Tubular cell 
replenishment is independent of bone marrow stem cells (BMSCs) in the post-ischemic 
mouse kidney (abstract) J.Am.Soc.Nephrol. 15:38A, 2004) were not encountered when 
using hPAP as a reporter marker. 
We modulated the severity of renal damage by exposing the kidneys to different 
ischemic times. Thus, as apparent from the morphological data, a gradient in the 
severity of renal damage was obtained, that ranged from relatively moderate in the 20 
min group to severe in the 45 min group. As the contra lateral kidney remained in situ, 
the acute tubular necrosis did not result in severe acute renal insufficiency, as apparent 
from the mild rise in plasma creatinine. This al lowed the animals to survive the period 
of acute tubular necrosis, and thus enabled us to study the renal recovery after severe 
IRI. Whereas the time course of plasma creatinine corresponded to the morphological 
restoration of the kidney, the contribution of the contralateral kidney to overal l  renal 
function precludes conclusions on the functional recovery of the ischemic kidney. 
The relationship between the severity of renal damage and extent of tubular BMDC 
engraftment suggests that the extent of engraftment is determined by increasing 
need for repair. The mechanism underlying the relationship between the severity of 
damage and tubular BMDC engraftment was not addressed in our study. However, 
we propose that the presence and amount of molecular repair mediators in the post­
ischemic renal niche is influenced by the severity of damage, thereby influencing the 
extent of BMDC engraftment. 
Documentation of the time course of tubular BMDC engraftment after IR I  was the 
second purpose of our study. We first studied the time course of mobil ization of 
BMD progenitor cells to the circulation. In accordance with data by Kale et al. (4), we 
observed an early increase in the number of circulating Un· cells after IR I  induction, 
indicating a relationship between renal damage and recruitment of BMD progenitor 
cells to the circulation. Numbers of circulating Lif f cell peaked on day 3 after IR I .  A lag 
between injury and maximal recruitment of progenitor cells to the circulation was also 
reported in patients with acute myocardial infarction by Shintani et al., who found a 
peak of circulating endothelial progenitor cel ls on day 7 after the ischemic event (8). 
The gradual decrease in numbers of circulating Liff cells, observed from day 7 after IRI 
induction on, would be compatible with homing of these cells to the damaged kidney. 
The appearance of BMD interstitial infiltrates in the kidney by day 7 supports this 
scenario. Moreover, the number of engrafted BMDC with epithelial phenotype a lso 
increased on day 7, demonstrating specific differentiation of some of the i nfi ltrating 
cells to tubular epithelium. A slight increase in the percentage of tubular engrafted 
BMDC co-expressing a tubular epithelial marker was observed in time, indicating that 
differentiation of these cells upon arrival is not immediate. 
The long-term fol low-up in our study, with fol low-up data up to 1 12  days after IRI, 
allowed us to investigate tubular epithelial BMDC engraftment during the complete 
time course of the tubular epithelial restoration process of the kidney after IR I .  An 
interesting finding was the decline in numbers of BMD tubular epithelial cells at 
long term fol low-up. An explanation for this phenomenon may be turn-over, during 
which tubular engrafted BMDC may be replaced by non-BMD renal cells, resulting 
in disappearance of the hPAP signal. However, since it was not technically feasible 
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to perform double staining for hPAP and BrdU, it remains unclear whether tubular 
engrafted BMDC underwent proliferation in the kidney. Furthermore, it is conceivable 
that the presence of proper growth factors and adhesion molecules in the ischemic 
niche would be responsible for creating a compatible situation for tubular epithelial 
BMDC engraftment and differentiation. Thus, inadequacy or absence of these factors 
could lead to loss of BMD tubular epithelial cells. 
Recently, it has been suggested that BMDC engraftment may be the result of a 
spontaneous cell fusion process, thereby questioning the biological relevance of stem 
cell plasticity (15;16). In our study we are not able to distinguish cell transdifferentiation 
from cell fusion and are, therefore, unable to rule out the possible contribution of cell 
fusion to tubular BMDC engraftment. Cell fusion, followed by reprogramming of the 
fusion product and silencing of the hPAP gene, could be a cause for the decline in 
tubular epithelial BMDC engraftment we observed at later post-ischemic time points. 
Our data are in agreement with previous studies reporting low numbers of tubular 
BMDC engraftment in mouse models of renal ischemia (5;7;17). Together with the 
decline in their numbers at long term follow-up, this could be taken to argue against a 
functional role of BMDC in tubular epithelial cell replacement. However, it has recently 
been shown that, when activated by pro-inflammatory cytokines in vitro, CD34+ BMD 
progenitor cells express a variety of immuno-regulatory mediators, thereby exerting a 
potential modulatory role in their environment (18). Thus, even at low numbers, BMD 
tubular epithelial cells might have functional significance during the process of renal 
repair, but further studies are needed to substantiate this issue. 
The overall low frequency of tubular BMDC engraftment in the ischemic kidney and 
the occurrence of complete tubular re-epithelialization indicate that, besides BMDC 
engraftment, another mechanism must be involved in the repopulation of the denuded 
tubular membranes. Renal repair most likely occurs as a concerted process involving 
both tubular engraftment of BMDC and the proliferative activity of surviving renal 
cells. Indeed, epithelial proliferation increased after IRI and peaked on day 7, illustrating 
proliferation-mediated tubular repair. Interestingly, the peak in epithelial proliferation 
preceded that of tubular epithelial BMDC engraftment, which peaked on day 14 post 
IRI. Thus, tubular re-epithelialization by proliferation appears to be a distinct process 
with a different time course. In fact, tubular re-epithelialization was already ongoing 
by the time of emerging tubular epithelial BMDC engraftment, possibly explaining the 
low number of engrafted BMDC. 
In conclusion, we showed that the extent of tubular epithelial BMDC engraftment 
depends on the severity of damage, and follows a distinct time course after IRI 
induction. Tubular re-epithelialization by proliferation of renal cells appeared to be a 
distinct process with a different time course, already ongoing by the time of emerging 
tubular epithelial BMDC engraftment. Thus, the severity of renal damage, the time 
course and the contribution of proliferation to renal repair, need to be taken into 
account when interpreting data on the role of tubular BMDC engraftment in renal 
repair after IRI. 
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Abstract 
Bone marrow-derived cells (BMDC) have been proposed to exert beneficial effects 
after renal ischemia/reperfusion injury (IRI) by engraftment in the tubular epithelium. 
However, BMDC can give rise to myofibroblasts, and may contribute to fibrosis. We 
investigated BMDC contribution to the renal interstitial myofibroblast population in 
relation to fibrotic changes after IRI in rats. 
We used a model of unilateral renal IRI (45 min of ischemia) in F344 rats reconstituted 
with R26-human Placental Alkaline Phosphatase (hPAP) transgenic bone marrow to 
quantify BMDC contribution to the renal interstitial myofibroblast population over 
time. 
After IRI, transient increases in collagen Ill transcription and interstitial protein 
deposition were observed, peaking on, respectively, day 7 and day 28. Interstitial 
infiltrates of BMDC and myofibroblasts reached a maximum on day 7 and gradually 
decreased afterwards. Over time, an average of 32% of all interstitial a-SMA-positive 
myofibroblasts co-expressed hPAP and were, therefore, derived from the bone marrow. 
BMD myofibroblasts produced procollagen I protein and were thus functional. The 
post-ischemic kidney environment was pro-fibrotic, as demonstrated by increased 
transcription of TGF-13, and decreased transcription of BMP-7. TGF-13 protein was 
predominantly present in interstitial myofibroblasts, but not in BMD myofibroblasts. 
In conclusion, functional BMD myofibroblasts infiltrate in the post-ischemic renal 
interstitium and are involved in ECM production. 
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Introduction 
Renal tubular ischemia/reperfusion mJury (IRI) is, if not too severe, in principle 
completely reversible (1), indicating that innate repair mechanisms are activated 
upon damage. Regeneration and remodeling of the kidney results in recovery of 
renal function and morphology by tubular epithelial cell replacement (2;3). However, 
tubulointerstitial remodeling can also, due to an uncontrolled balance between 
synthesis and degradation of extracellular matrix proteins, result in tubulointerstitial 
fibrosis (4;5), which is an important risk factor for progressive renal function loss (6). 
Previously, we and others have shown that after renal IRI low numbers of bone 
marrow-derived cells (BMDC) engraft tubuli and differentiate to tubular epithelium 
(7-10), possibly replacing damaged tubular epithelial cells. These data have been taken 
to support a therapeutic potential for bone marrow-derived (BMD) stem-/progenitor 
cells in renal tubular IRI. However, adverse effects have also been reported in models 
of lung and liver injury, where BMD stem-/progenitor cells gave rise to myofibroblasts 
and contributed to fibrosis (l 1;12). 
Renal interstitial myofibroblasts are regarded as major producers of extracellular 
matrix (ECM) proteins in fibrosis, and thus play a central role in its pathogenesis. Their 
origin remains subject of discussion. Myofibroblasts may originate from injured tubular 
epithelial cells by epithelial-to-mesenchymal transition (EMT) (13), differentiation 
of resident fibroblasts (14), or migration of perivascular smooth muscle cells (15). 
However, in mouse models of bone marrow transplantation it was shown that the 
bone marrow is a source of myofibroblasts for many tissues, including the gut, lung, 
and kidney (10;16-18). However, functionality of renal BMD myofibroblasts after IRI was 
not shown. 
Here, we investigated the contribution of BMDC to the renal interstitial myofibroblast 
population. Moreover, we studied the contribution of these cells to ECM production. 
To this end, we used a rat model of unilateral renal ischemia/reperfusion in F344 rats, 
reconstituted with R26-hPAP transgenic bone marrow. 
Methods 
Animals 
Male, 6 week-old F344 rats (Harlan, Horst, the Netherlands) and R26-hPAP rats (founders 
kind gift of Dr. E. Sandgren; F344 background), transgenic for human placental alkaline 
phosphatase (hPAP) (19) were placed under conventional housing and diet. Drinking 
water was supplemented with 1 mg/ml 5-bromo-2-deoxyurdine (BrdU, Sigma, St. 
Louis, USA), for 3 days prior termination. All animal procedures were approved by the 
local committee for care and use of laboratory animals and performed according to 
governmental and international guidelines on animal experimentation. 
Bone marrow chimeras 
In non-transgenic rats BM was ablated by whole-body irradiation (9 Gy, IBL 637 
Cesium-137) and reconstituted with total R26-hPAP BM (lxl06 R26-hPAP cells/ 
recipient, intravenously). Rats were housed in filter top cages and drinking water 
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was supplemented with neomycin (0.35% w/v) from 1 week before to 2 weeks after 
irradiation. BM chimerism was determined after termination by enzymatic hPAP 
staining (see below) on BM cytospots, and was typically between 80% and 90%. 
Surgical procedures 
Four weeks after BM transplantation, rats were sedated by general isoflurane (2% 
Forene, Abbot b.v., Hoofddorp, The Netherlands), N2O (50%), 02 (50%) anaesthesia. The 
left renal artery was clamped for 45 min to induce ischemia, followed by reperfusion. 
SHAM-operated control rats underwent the same procedure, except for clamping of 
the left renal artery. 
One (n=6), 3 (n=6), 7 (n=6), 14 (n=6), 28 (n=5), 56 (n=5) and 1 12  (n=5) days after 
ischemia/reperfusion, rats were anaesthetized and kidneys were perfused in situ. 
Kidneys were divided into quarters and fixed in Zinc fixative (0.1M Tris buffer, pH 7.4 
with 0.5g CaCH2COO, 5g (CH2COO)2Zn*2Hp and 5g ZnC12 per l iter; MERCK, Darmstadt, 
Germany), or snap-frozen in N2 and stored at -80
°C. 
Kidney function 
Plasma creatinine levels were determined using the enzymatic colorimetric assay CREA 
plus (Roche, Woerden, the Netherlands), which is a precise and specific quantification 
method for creatinine (20). 
(lmmuno)histochemistry 
lmmunohistochemistry was performed on 5 µm zinc-fixed, paraffin-embedded 
sections. Sections were dewaxed and antigen was retrieved by overnight incubation 
in 0.1 M Tris/HCI buffer at 80°C (for a-SMA and collagen Ill staining) or incubation with 
0.7M HCI at room temperature (RT) for 30 min and 0.025% (w/v) pepsin in 0.35M HCI at 
RT for 1 5  min (for BrdU staining). Endogenous AP was heat-inactivated by incubation in 
substrate buffer (0.1 M Tris/HCI, pH 9.5, 0.1 M NaCl, 5 mM MgCI) at 65°C for 30 min (19) 
{for a-SMA/hPAP staining). Endogenous peroxidase was blocked with 0.3% Hp2 for 
30 min and endogenous biotin was blocked with biotin blocking kit (DAKO, Glostrup, 
Denmark). Sections were incubated for 1 h with primary antibodies, i.e. rabbit anti-rat 
collagen Ill (Biogenesis, Poole, UK), rabbitanti-hPAP (Serotec, Oxford, UK), mouse a-SMA 
{clone 1A4, DAKO) or anti-BrdU (Sigma-Aldrich), followed by appropriate secondary 
antibodies for 30 min. Color development was performed with 3,3'-diaminobenzidine 
tetrachloride (a-SMA, collagen 11 1), fuchsin substrate-chromogen system {hPAP) 
{DAKO) or with 3-amino-9-ethylcarbazole (Sigma-Aldrich) substrate dissolved in N,N­
dimethylformamide (MERCK) and 0.5M acetate buffer, pH 4.9 (BrdU). 
For enzymatic hPAP staining endogenous AP was heat-inactivated (see above), and 
sections were incubated in fresh substrate buffer containing 2% (v/v) of the substrate 
nitroblue tetrazolium/5-bromo-4-chloro-3-indolyl phosphate (NBT/BCIP, Roche) at RT 
for 5 h. 
Sections were counterstained with Mayer's hemalum (MERCK) and mounted in Kaiser's 
glycerol gelatine (MERCK). 
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lmmunofluorescence staining for confocal microscopy was performed on 5 µm 
cryostat sections. For double staining of a-SMA and hPAP, the primary antibodies were 
incubated for 1 h followed by development of a-SMA with tyramide-TRITC (PerkinElmer 
Life Sciences, Boston, USA) via goat anti-mouse HRP (Southern Biotechnology, 
Birmingham, USA) and hPAP with FITC-labeled goat anti-rabbit conjugate (Southern 
Biotechnology). Triple staining of a-SMA and hPAP with goat anti-procollagen I (Santa 
Cruz Biotechnology, Santa Cruz, USA) or goat anti-TGF-f3 (Santa Cruz Biotechnology) 
required the use different conjugates to prevent cross reaction. After overnight 
incubation at 4°C with goat anti-TGF-f3 and l h  incubation with the other primary 
antibodies, a-SMA was developed with tyramide-TRITC (PerkinElmer Life Sciences) 
via donkey anti-mouse HRP (Southern Biotechnology), hPAP with Cy5-labeled donkey 
anti-rabbit conjugate (Jackson lmmunoResearch, Soham, UK), procollagen I with 
FITC-labeled donkey anti-goat conjugate (Jackson lmmunoResearch) and TGF-f3 was 
developed via biotinylated donkey anti-goat (Abeam, Cambridge, UK) with SA-FITC 
(DAKO). All possible cross reactions were tested and none were found. Sections were 
counterstained with 4',6-diamidino-2-phenylindole (DAPI, Sigma-Aldrich, St.Louis, 
USA) and mounted with citifluor (Agar scientific, Stansted, UK). 
Light microscopy was performed using a Leica DMLB microscope (Leica Microsystems, 
Rijswijk, the Netherlands), Leica DC300F camera and Leica QWin 2.8 software. 
Fluorescent images were obtained using a LEICA TCS SP2 3-channel confocal laser 
scanning microscope, equipped with lasers providing 488 nm, 543 nm and 633 nm 
laser lines. Tissue sections were observed using a 20x 0.70NA oil immersion objective 
lens, stack sections were chosen to obtain a z-resolution and images were obtained at 
1024 x 1024 pixel resolution. 
Quantitative RT-PCR 
Frozen kidneys were homogenized in 4M guanidinium isothyocyanate (0.7% f3-
mercaptoethanol). Total RNA was isolated by standard procedures using phenol 
and chloroform/isoamylalcohol. After DNase treatment (DNA-free Kit, Ambion) RNA 
integrity and absence of DNA contamination were confirmed by gel electrophoresis. 
Equal amounts (5 µg) of total RNA from quarters of control and experimental kidneys 
were reverse-transcribed with M-MuLV Reverse Transcriptase in the presence of 
random hexamers (First strand cDNA Synthesis Kit, Fermentas Life Sciences, Lithuania). 
Equal amounts of cDNA (30 ng) were used for all qRT-PCR reactions. To further confirm 
that RNA was free from genomic DNA, qRT-PCR was also carried out on total RNA. 
For qRT-PCR we used TaqMan "assay by demand" primer/probe sets for rat f32-
microglobulin, collagen 1 1 1 ,  TGFf3 and BMP-7 (Applied Biosystems, Foster City, CA, USA, 
www.appliedbiosystems.com). PCR was performed in triplicate in 384-well microtitre 
plates in a final volume of 10 µI, of which 5 µI TaqMan universal PCR Master Mix (Applied 
Biosystems), 0.5 µI primer/probe mix, and 4.5 µI cDNA, using an ABl7900HT System 
(Applied Biosystems). Amplifications were performed starting with a 2 min AmpErase 
UNG activation step at 50°(, followed by a 10 min Amplitaq Gold Enzyme Activation 
step at 95°(, followed by 45 cycles of denaturation at 95°C for 15 sec and combined 
primer annealing/extension at 60°( for 1 min. Cycle thresholds (CT) for the individual 
reactions were determined using ABI Prism SDS 2.0 data processing software (Applied 
Biosystems). CT values >40 were not included in calculations. CT values were normalized 
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against �2-microglobulin expression levels (21). To correct for interassay variance, Cr 
values were normalized against an external calibrator, consisting of RNA from healthy 
and ischemic rat kidneys. Differences in expression levels between experimental 
and control rats were expressed as fold variance of expression, calculated as 2·111111cr 
{21). Briefly, fold variance of 1 indicates that there are no transcriptional differences 
compared to healthy control rats, >1 is considered increased transcription and <1 is 
considered decreased transcription. 
Quantification 
Interstitial staining of collagen 1 1 1, a-SMA and hPAP was measured by a blinded observer, 
using computerized morphometry (Leica QWin 2.8 software). Stained areas of 15-25 
randomly selected fields in cortex and outer medulla were quantified as percentage 
of total measured area. The quantification was performed at a magnification of 200x 
for each rat and time point. Vascular and glomerular expression of collagen I l l  and 
vascular expression of a-SMA was excluded from measurements. 
The percentage ofhPAP'/a-SMN cells was determined by counting by two independent 
investigators, of all a-SMN, hPAP+ and double-positive cells in 30 microscope fields in 
cortex and outer medulla per section, for each rat at a magnification of 200x. 
Statistics 
Statistical tests were performed using GraphPad Prism 4.0 (GraphPad Software, San 
Diego California, USA). Differences between controls and experimental groups was 
determined with One-way ANOVA Dunnett's Multiple Comparison Test. P-values <0.05 
were considered statistically significant. 
Results 
Post-ischemic plasma creatinine levels and renal interstitial collagen Ill deposition 
Plasma creatinine levels were significantly increased until day 28 after IRI. Afterwards 
plasma creatinine gradually decreased to reach baseline values on day 56 and 112 after 
IRI (Figure 1). 
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Figure 1 .  Post-ischemic plasma creatinine levels. 
Plasma creatinine levels were assessed to determine 
kidney function. Bars indicate mean levels and SEM 
af all experimental animals per group. All SHAM 
groups showed similar results and are therefore 
shown as one group. Statistically significant 
differences compared to SHAM are indicated as * = 
P<0.05, **= P<0.005. 
RENAL BMD MYOFIBROBLASTS 
Presence of collagen Ill, which is known to be excessively produced during fibrosis, 
was determined at transcript levels and protein level. Collagen Ill mRNA transcript 
levels increased progressively, peaking on day 7 and gradually decreasing afterwards 
at later time points (Figure 2A). 
Deposition of collagen Ill on day 1 after IRI (Figure 28, E) was comparable to that 
in kidneys subjected to a SHAM procedure (Figure 28, C) and contralateral kidneys 
(Figure 28, D). Renal interstitial deposition of collagen Ill reached a maximum on day 28 
(Figure 28, F) and gradually decreased afterwards but remained elevated as compared 
to controls (day 112: Figure 28, G). 
Irradiation, required for bone marrow transplantation, did not elicit renal interstitial 
fibrosis, as determined by negligible collagen Ill deposition in contralateral kidneys 
(Figure 2D). 
Post-ischemic infiltration of renal interstitial BMDC 
Renal interstitial BMDC infiltration was readily visible by the presence of hPAP-positive 
cells. No alkaline phosphatase activity was observed in the post-ischemic kidney of a 
non-transgenic F344 rat after heat-inactivation of endogenous alkaline phosphatase 
(Figure 3A). In R26-hPAP BM-transplanted rats, small renal interstitial BMDC infiltrates 
were observed in kidneys subjected to SHAM operation (Figure 38, G), contralateral 
kidneys (Figure 3C, G) and kidneys on day 1 after IRI (Figure 3D, G). The BMDC infiltrate 
size strongly increased after day 1, reaching a maximum on day 7 after IRI (Figure 3E, 
G). The large BMDC infiltrates persisted until day 28 after IRI (Figure 3G) and gradually 
decreased afterwards, manifesting in small interstitial infiltrates on day 112 (Figure 3F, 
G). The BMDC infiltrate size in ischemic kidneys remained, however, higher than in 
contralateral kidneys. 
Presence of renal interstitial myofibroblasts 
Renal interstitial myofibroblasts were detected using a-SMA staining. Interstitial a­
SMA-positive myofibroblasts were sporadically detected in SHAM (Figure 4A, G), 
contralateral kidneys (Figure 48, G) and in kidneys isolated on day 1 after IRI (Figure 
4C, G). After day 1 we observed a strong increase in renal interstitial a-SMA-stained 
area, with a peak on day 7 (Figure 4D, G). After day 28 after IRI (Figure 4E, G) the renal 
interstitial a-SMA-stained area was gradually decreased, up to day 112 (Figure 4F, G). 
Irradiation, required for bone marrow transplantation, did not elicit renal interstitial 
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Figure 2. Post-ischemic renal interstitial collagen Ill deposition. Expression levels of collagen Ill were 
determined by quantitative RT-PCR on RNA isolated from kidneys at various time points after /RI induction (A). 
Mean M!i.CTvalues are shown in combination with SEM of all experimental animals per group. Mean l'!.l'!.CT 
values indicate gene expression CT values normalized against expression levels of an internal calibrator 
(�2-microglobulin) and mRNA expression levels of an external calibrator. Differences in expression levels 
between experimental and healthy control rats were expressed as fold variance of expression, calculated 
as 2-Mocr (21). Fold variance of 1 indicates that there are no transcriptional differences compared to healthy 
control rats, >1 is considered increased transcription and <1 is considered decreased transcription. Bars 
indicate mean levels and SEM of all experimental animals per group. Con = contralateral. All SHAM and 
contralateral groups showed similar results and are therefore shown as one group. In healthy control 
kidneys the mean l'!.l'!.CT was 2.46 ± 0.40. Post-ischemic collagen Ill protein deposition was quantified by 
computerized morphometry (BJ. Scoring was performed on SHAM (black bars), ischemic (white bars) and 
contralateral kidneys (grey bars). All SHAM groups showed similar results and are therefore shown as 
one group. Significant differences compared to SHAM animals are indicated as *= P<0.05, ** = P<0.005. 
Photomicrographs of collagen Ill staining are shown of SHAM kidney (day 1) (CJ, contralateral kidney of an 
ischemic kidney (day 1) (DJ and kidneys subjected to ischemia and isolated on day 1 (E), 28 (F) and 1 12 (G) 
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** 
Figure 3. Post-ischemic infiltration of renal interstitial BMDC. Representative pictures of BMDC infiltration, 
determined by enzymatic hPAP staining, in a post-ischemic kidney of a non-transgenic F344 rat (AJ, a 
kidney of a hPAP BM recipient subjected to SHAM operation (day 3J (BJ, a contra lateral kidney of a hPAP BM 
recipient after /RI (day 7J (CJ and post-ischemic kidneys of a hPAP BM recipient on day 1 (DJ, 7 (E), and 1 12 
(FJ after /RI. Lens magnification 200x. Post-ischemic infiltration of renal interstitial BMDC was quantified by 
computerized morphometry (GJ. Bars indicate mean levels and SEM of all experimental animals per group. 
All SHAM groups showed similar results and are therefore shown as one group. Significant differences 
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Figure 4. Post-ischemic presence of renal interstitial myofibroblasts. Presence of renal interstitial 
myofibroblasts is shown by a-SMA expression in SHAM (day 28J (AJ, contralateral (day ZBJ (BJ and post­
ischemic kidneys on day 1 (CJ, 7 (DJ, 28 (EJ and 1 12 (FJ after /RI. Arrows indicate examples of a-SMA­
positive b/oodvessels. All a-SMA-positive vascular structures were excluded from quantitative analysis. 
Lens magnification l00x. Post-ischemic presence of renal interstitial myofibroblasts was quantified by 
computerized morphometry (GJ. Bars indicate mean levels and SEM of all experimental animals per group. 
All SHAM groups showed similar results and are therefore shown as one group. Significant differences 
compared to SHAM animals are indicated as **= P<0.00S. 
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Proliferation of renal interstitial cells 
Proliferation during three days prior to termination of the rats was assessed by BrdU 
incorporation. After IRI, most BrdU-positive nuclei were present in tubular epithelial 
cells (7), and were only occasionally found in interstitial cells (Figure 5, day 14 
postischem ia). 
Bone marrow-derived myofibroblasts 
Figure S. Proliferation of renal interstitial cells. 
Proliferation was assessed by BrdU incorporation. 
BrdU-positive nuclei (black, indicated with arrows), 
here shown on day 14 after /RI, were mainly present in 
tubular epithelial cells. The insert shows the presence 
of BrdU-positive nuclei in interstitial cells. Lens 
magnification 400x. 
After renal ischemia, cells that were double-positive for hPAP (BMDC) and a-SMA 
(myofibroblasts) were observed, albeit exclusively in the interstitium. From day 7 
after IRI on, the number of renal interstitial hPAP-positive BMDC co-expressing a­
SMA significantly increased compared to contralateral kidneys (Figure 6A). Over time, 
the number of renal interstitial hPAP-positive BMDC co-expressing a-SMA remained 
relatively stable, with an average of 4% of all interstitial hPAP-positive BMDC co­
expressing a-SMA (Figure 6A). 
On day 3 after IRI, the number of renal interstitial a-SMA-positive myofibroblasts co­
expressing hPAP significantly exceeded that in contralateral kidneys (Figure 6B) and 
further increased until day 14. Over the whole observation period an average of 32% of 
all renal interstitial a-SMA-positive myofibroblasts co-expressed hPAP (Figure 6B). 
To confirm that the observed hPAP/a-SMA double-positive cells were BMDC which 
differentiated to myofibroblasts and not overlying cells, we used confocal microscopy 
of hPAP (Figure 6C) and a-SMA (Figure 6D) immunofluorescence staining. Overlap of 
signal in both channels (Figure 6E) was present in 10 out of 14 consecutive z-planes. 
To determine if BMD myofibroblasts expressed ECM proteins, we studied their ability 
to produce procollagen I. Using fluorescence staining combining a-SMA, procollagen 
I and hPAP, we confirmed procollagen I production by a-SMA-positive myofibroblasts 
(Figure 6F-I, arrowheads). In addition, all observed hPAP/a-SMA double-positive cells 
(BMD myofibroblasts) also stained positive for procollagen I (Figure 6F-I, arrows). 





Figure 6. Bone morrow-derived myofibrob/asts. Co-expression of BMDC and myofibroblast markers was 
assessed by immunohistochemical hPAP/a-SMA double staining on post-ischemic kidneys. Co-expression of 
hPAP and a-SMA was quantified in relation to the renal interstitial population of BMDC (A) and to the renal 
interstitial myofibrob/ast population (BJ. Bars indicate mean levels and SEM of all experimental animals per 
group. All SHAM groups showed similar results and are therefore shown as one group. Significant differences 
compared to SHAM kidneys is indicated as *= P<0.05 and ** = P<0.005. BMD myofibrob/asts were detected 
by immunofluorescence staining for hPAP (CJ (green) in combination with a-SMA (DJ (red) on post-ischemic 
kidney tissue (shown here: day 7 postischemia). The overlay shows FITC, TR/TC and OAP/ channels, and the 
x/z and y/z planes on the right and underneath the merged picture demonstrate true colocalization of the 
markers (E). Arrows indicate colocalization. Production of procollagen I by BMD myofibroblasts was assessed 
by immunofluorescence staining for procollagen I (F) (green) in combination with a-SMA (G) (red) and hPAP 
(HJ (white) on postischemic kidney tissue (shown here: day 7 postischemia). The overlay (I) shows FITC, 
TR/TC, Cy5 and OAP/ channels, and the x/z and y/z planes on the right and underneath the merged picture 
demonstrate true colocalization of the three markers. Arrowheads indicate an example of a procollagen­
positive myofibroblast (a-SMA/Procollagen I double-positive). Arrow indicates an example of a procollagen 
/-positive bone marrow-derived myofibroblast (a-SMA/hPAP/procollagen I triple-positive). 
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Transcript levels of fibrosis-regulating factors TGF-(3 and BMP-7 
Expression levels ofTGF-� and BMP-7 in post-ischemic kidneys were normalized against 
�2-microglobulin expression levels and expression levels of an external calibrator and 
were expressed as b.b.Cr values (Figure 7). After IRI, b.b.Cr values for TGF-� and BMP-7 
were at most time points significantly different from b.b.Cr values of healthy control 
kidneys (Figure 7). Differences in expression levels between experimental and control 
rats were expressed as fold variance of expression, calculated as 2·11MCr (21) (Figure 
7). TGF-� transcript levels doubled on day 1, peaked on day 7 (2.7 fold increase) and 
decreased gradually afterwards, to return to baseline levels on day 56 after IRI (Figure 
7A). BMP-7 transcript levels were 10 times decreased on day 1 after IRI, as compared to 
control values and remained decreased at all studied time points (Figure 7B). 
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Figure 7. Transcript levels of fibrosis-regulating factors TGF-/3 and BMP-7. Expression levels of TGF-/3 (A) 
and BMP-7 (8) were determined by quantitative RT-PCR on RNA isolated from kidneys at various time points 
after /RI induction. Mean LILICr values are shown in combination with SEM of all experimental animals 
per group. Mean LILICr values indicate gene expression Cr values normalized against expression levels of 
{32-microglobulin and mRNA expression levels of an external calibrator. Differences in expression levels 
between experimental and healthy control rats were expressed as fold variance of expression, calculated 
as 2-=e
r 
(21). Fold variance of 1 indicates that there are no transcriptional differences compared to healthy 
control rats, >1 is considered increased transcription and <1 is considered decreased transcription. Bars 
indicate mean levels and SEM of all experimental animals per group. Con = contralateral. All SHAM and 
contralateral groups showed similar results and are therefore shown as one group. In healthy controls mean 
LILICrofTGF-/3 was 0.52 ± 0.13 and of BMP-7 was -2.38 ± 0.75. 
Post-ischemic renal presence of TGF-(3 protein. 
To address TGF-� expression at protein level and determine which cells were 
responsible for the increased TGF-� mRNA expression in post-ischemic kidneys, 
we used immunotluorescence staining for TGF-� with a-SMA and hPAP. In healthy 
kidneys TGF-� protein was mainly present in proximal tubular cells, but also in arterial 
structures and sporadically in interstitial cells (not shown). After ischemic damage renal 
TGF-� protein was occasionally observed in proximal tubular epithelial cells (Figure 
8A-D). However, using triple staining of TGF-�, a-SMA and hPAP, we could identify 
myofibroblasts (TGF-� & a-SMA double positive, yellow cells) as main producers of 
TGF-� in post-ischemic kidneys (Figure 8 E-H). We did, however, not observe TGF-� 
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expression in bone marrow-derived myofibroblasts (TGF-�, a-SMA & hPAP triple 
positive). 
Discussion 
Previously, we showed the ability of BMDC to engraft renal tubuli and differentiate 
to tubular epithelial cells in a rat model of IRI (7). Our current study investigated the 
contribution of BMD myofibroblasts to the renal interstitial myofibroblast population 
and, for the first time, their functional capacity to produce ECM proteins after IRI . We 
show that the contribution of BMDC to the renal myofibroblast population amounted 
to over 30%. Moreover, BMD myofibroblasts produced procollagen I, suggesting 
an active role of these cells in the production of extracellular matrix proteins in 
post-ischemic remodeling. Resident renal myofibroblasts produced TGF-�, thereby 
possibly contributing to the environment in which BMD myofibroblasts can become 
functionally active in producing ECM proteins. 
Renal remodeling of the ECM after injury initially proceeds as a wound healing process, 
but can develop into pathologic renal interstitial fibrosis (22). In renal remodeling 
myofibroblasts, alpha-smooth muscle actin (a-SMA) expressing cells with features 
of both fibroblasts and smooth muscle cells (23), play a dual role. First, in the early 
phase after injury, myofibroblasts participate in wound healing by producing ECM 
components (e.g. collagens I and Ill, tenascin, fibronectin) (24). Second, persisting 
inflammation after renal injury can lead to persistent myofibroblast activation (25), 
and thus to excessive ECM production. In conjunction with reduced ECM degradation, 
this can result in renal interstitial fibrosis, an important risk factor for progressive 
renal damage (6). In our IRI model, collagen Ill mRNA levels and protein deposition 
increased significantly, peaking on day 7 and 28, respectively, but gradually decreased 
afterwards. Together with decreasing BMDC infiltrates and improving kidney function, 
this is likely to reflect the process of wound healing. However, at the latest time point of 
the study, i.e. day 112, renal interstitial collagen Ill deposition and BMDC infiltrates still 
were higher than in control kidneys, which possibly reflect a transition phase between 
wound healing and fibrosis. Since our model did not result in fibrosis, we determined 
if BMD myofibroblasts could contribute to ECM deposition during renal remodeling, 
rather than to fibrosis. 
While the central role of myofibroblasts in renal remodeling is established, the origin 
of these cells is still under investigation. Epithelial-to-mesenchymal transition (EMT) 
(13;26), differentiation of resident fibroblasts (14), and migration of perivascular smooth 
muscle cells (15) have been identified as intrarenal mechanisms of myofibroblast 
formation. However, findings of bone marrow-derived, a-SMA-positive cells in skin 
(17;27), lung (27), small intestine (16), colon (16), stomach (17), liver (11) and kidney 
(10;17;18) provide evidence for an additional source of myofibroblasts. 
In the current study we investigated the contribution of BMDC to the renal interstitial 
myofibroblast population and found it to amount to over 30%. This is three times as 
high as in a study in unilateral ureteral obstruction (UUO) in mice (18). This difference 
may reflect differences between our respective models. Possibly, the method of Y­
chromosomein situ hybridization used by Roufossefordetection ofBMD myofibroblasts 
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Figure 8. Post-ischemic renal presence ofTGF-(3 protein. TGF-(3 protein expression in post-ischemic kidneys 
(A-D day 3 and E-H day 7 postischemia) was determined by immunofluorescence staining combining 
TGF-(3 (A, E) (green) with a-SMA (8, F) (red) and hPAP (C, G) (white). Overlays show FITC, TR/TC, Cy5 and 
OAP/ channels and the x/z and ylz planes on the right and underneath the merged pictures demonstrate 
co/ocalization ofTGF-(3 and a-SMA (D, H). Magnification of the indicated parts are shown on the far right of 
E-H. Asterisks indicate examples ofTGF-(3+ tubular structures. Arrowheads indicate infiltrated BMDC (hPAP'). 
Arrows indicate TGF-(3' myofibroblasts (a-SMA/TGF-(3+). 
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can lead to an underestimation by division of the nucleus in sections, and loss of the Y 
chromosome for detection. 
BMDC can, in l ine with their plasticity, differentiate into different cell types, thereby 
potentially exerting different roles in renal remodeling after IRI. The regulation of 
these differentiation choices is of pathophysiological relevance. In the present study 
we observed an altered balance between bone morphogenic protein-7 (BMP-7) and 
transforming growth factor-B (TGF-B), two major regulators of renal interstitial fibrosis 
(28). While TGF-B is a well-established inducer of fibrosis by stimulating differentiation 
to and proliferation of myofibroblasts (29;30), BMP-7 directly counteracts TGF-B­
induced extracellular matrix production and promotes epithelial differentiation (31;32). 
Thus, the transcriptional increase of TGF-� and decrease of BMP-7 may provide the 
environmental clues for preferential differentiation of BMDC towards myofibroblasts 
and subsequent production of extracellular matrix proteins. In the post-ischemic 
kidney, TGF-� was observed in proximal tubular epithelial cel ls and arterial structures, 
but not in BMD myofibroblasts. Resident renal myofibroblasts appeared to be the 
major producers of TGF-�, suggesting that these cells may contribute to the post­
ischemic renal environment in which BMDC differentiate to myofibroblasts. 
A prerequisite for a role of BMD myofibroblasts in renal remodeling is the ability of 
these cells to produce and deposit ECM proteins. We addressed the functionality of 
renal interstitial BMD myofibroblasts by showing production of procollagen I after IRI. 
This finding is in agreement with data by lwano (26), in UUO-induced renal fibrosis, 
where renal BMD fibroblasts produced collagen I and HSP47, a chaperone molecule 
for collagen I production. By contrast, Roufosse (1 8), found no collagen I synthesis 
in interstitial BMDC in a mouse model of UUO-induced renal fibrosis. The reason for 
these discrepancies is unclear but might result from differences between the models. 
UUO is a relatively straightforward model of obstruction-induced fibrosis, whereas our 
ischemia/reperfusion model leads to wound healing rather than fibrosis. Alternatively, 
differences in transgenic bone marrow transplantation models (BMDC expressing GFP 
under the promoter of the FSP-1 , luciferase under the promoter of collagen I gene, 
or hPAP) or specific type of BMDC (BMD myofibroblasts, fibroblasts or all interstitial 
BMDC) may be involved. 
In addition to previous studies showing tubular BMDC engraftment and epithelial 
differentiation after IRI (7-1 0), our current study supports the contribution of BMDC 
to the renal myofibroblast population. Remarkably, the contribution of BMDC to the 
myofibroblast population largely exceeds their contribution to the tubular epithelial 
population. This is in accordance with recent studies, showing that post-ischemic 
repair of tubular epithelium occurs only marginally by differentiation of BMDC but 
mainly by proliferation of resident epithelial cells (1 0;33). 
The different BMDC phenotypes in the kidney after IRI, point towards different roles 
in the post-ischemic process, as also supported by differences in the time courses in 
which the different BMDC phenotypes are present. We previously showed that tubular 
epithelial BMDC engraftment peaked on day 14, while the peak in tubular epithelial 
proliferation was observed a week earlier (7). Our present study showed that already 
on day 3 after IRI 27% of all renal interstitial myofibroblasts was derived from the 
bone marrow. Taken together, these data suggest that post-ischemic replacement of 
damaged tubular epithelial cells was already accomplished by proliferation of resident 
epithelial cells after the first week. Therefore, the BMDC may, possibly influenced by 
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upregulation ofTGF-13 in the post-ischemic renal environment, preferably differentiated 
to myofibroblasts rather than to tubular epithelial cells. 
It is not clear what the ontogeny of BMD myofibroblasts and BMD tubular epithelial 
cells is and if they are derived from the same source. It has been proposed that 
myofibroblasts differentiate from a circulating precursor cell type, i.e. the circulating 
fibrocyte (34). The fibrocyte is a distinct mesenchymal cell type that arises in ex vivo 
cultures of peripheral blood and has the capacity to differentiate in vitro into a-SMA­
positive myofibroblasts (34;35). Although fibrocytes are recruited to the damage site 
after injury (34;35), it is improbable that they are the only source of renal interstitial 
BMD myofibroblasts, since the large numbers of BMD myofibroblasts in our study 
contrasts with the low numbers of circulating fibrocytes (0.1-0.5% of human blood 
cells) reported previously (34;35). Moreover, the sporadic presence of interstitial cell 
proliferation argues against local amplification of the myofibroblast population. An 
alternative source of renal BMD myofibroblasts may be monocytes, since these cells 
can transdifferentiate (36-38), as well as synthesize and secrete fibrosis-promoting 
growth factors and cytokines (39). 
Data on tubular engraftment of BMDC (7-10;40), as well as promising results after 
infusion of BMDC (8;41;42), have provided support for the therapeutic potential of 
BMDC in tubular epithelial recovery after ARF. However, in line with data from others 
(10;17;18), our current results show that BMDC can differentiate to renal interstitial 
myofibroblasts as well. By producing ECM proteins, these cells can have a beneficial 
role in wound healing. However, in case of persistent inflammation and a disturbed 
balance between ECM production and degradation, these cells can play an adverse 
role by promoting processes ultimately leading to fibrosis. Therefore, for therapeutic 
application of BMDC, caution is called for. 
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lschemia/reperfusion injury (IRI) is a risk factor for the development of interstitial 
fibrosis after renal transplantation. Previously we showed that after renal IRI, bone 
marrow-derived cells (BMDC} can differentiate to interstitial myofibroblasts. Here we 
hypothesized that the immunosuppressant ciclosporin (CsA), known for its pro-fibrotic 
side-effect, promotes myofibroblast differentiation of BMDC in the post-ischemic 
kidney. 
Using a model of unilateral renal IRI in rats reconstituted with R26-hPAP transgenic 
bone marrow, CsA was administered in a previously defined critical window for 
differentiation of BMDC to myofibroblasts. We evaluated fibrotic changes in the kidney 
and myofibroblast differentiation of BMDC on day 14 after CsA treatment. 
CsA treatment for 14 days led to increased TGF-� transcript levels and collagen Ill 
deposition in the post-ischemic kidney. However, neither the total number of a-SMN 
interstitial myofibroblasts, nor the bone marrow-derived fraction thereof was affected 
by CsA administration, irrespective of dosage and duration of treatment. 
In the critical post-ischemic window of BMDC differentiation to myofibroblasts, CsA did 
not promote BMDC differentiation to myofibroblasts, suggesting that, in the clinical 
setting, CsA is not involved in myofibroblastic differentiation of BMDC. 
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Introduction 
lschemia/reperfusion injury (IRI) has been identified as a risk factor for the development 
of renal interstitial fibrosis, eventually leading to progressive loss of graft function after 
renal transplantation (1). Moreover, the detrimental effects of IRI can be amplified by 
fibrotic side-effects of immunosuppressive agents, such as ciclosporin (CsA) (2-4). 
Myofibroblasts are recognized as the major producers of extracellular matrix (ECM) 
components and are, therefore, important in the development of fibrosis (5). Persisting 
inflammation and increased excretion of pro-fibrotic growth factors (e.g. TGF-13) can 
result in increased proliferation of myofibroblasts and increased ECM production. 
When the balance between production and degradation of ECM proteins is disturbed, 
ECM proteins accumulate in the renal interstitium, resulting in interstitial fibrosis (6,7). 
We recently reported that, in a rat model of IRI, bone marrow-derived cells (BMDC) 
differentiated to myofibroblasts, forming a significant proportion (up to 40%) of 
the total renal interstitial myofibroblast population (8). Moreover, bone marrow­
derived myofibroblasts produced ECM components and could, thereby, potentially 
contribute to fibrosis (8). In the current study we are the first to investigate whether 
CsA stimulates differentiation of BMDC to myofibroblasts in the kidney, due to its pro­
fibrotic potential. We used a previously established model of unilateral renal IRI in 
rats reconstituted with R26-human Placental Alkaline Phosphatase (hPAP) transgenic 
bone marrow (BM). In this model we defined an early window of opportunity for 
BMDC differentiation to myofibroblasts in the first 7-14 days after IRI (8). In this study 
we administered CsA during this window to determine the effect of CsA on BMDC 
myofibroblast differentiation. Moreover, to extend our !RI-associated findings to 
the transplantation setting, in which CsA is commonly used, we also performed 
a pilot experiment in which we studied the effect of CsA on myofibroblastic BMDC 
differentiation in syngeneic kidney transplantation, circumventing the confounding 
influence of immune rejection. 
Materials and Methods 
Animal experimentation 
Male, 6 week-old F344 rats (Harlan, Horst, the Netherlands) and R26-hPAP rats (F344 
background), transgenic for hPAP (9) were kept under conventional housing and diet. 
Non-transgenic F344 rats underwent total body irradiation (9 Gy, IBL 637 Cesium-137) 
for BM ablation and were reconstituted with total hPAP BM (lxl06 hPAP cells/recipient, 
intravenously). After irradiation, rats were housed in filter top cages and drinking 
water was supplemented with neomycin (0.35% w/v) until 2 weeks after irradiation. 
BM chimerism, determined by flow cytometric assessment of hPAP expressing BM 
cells at experimental end points, was typically 76±3%. 
Four weeks after BM transplantation, rats were subjected to unilateral renal IRI. Rats 
were sedated by general isoflurane (2% Forene, Abbot, Hoofddorp, The Netherlands), 
Np (50%), 02 (50%) anesthesia and the left renal artery was clamped for 45 min. SHAM­
operated control rats underwent the same procedure, except for clamping the artery. 
Immediately after renal IRI, rats (n=S per group) were administered CsA (Sandimmun, 
Novartis, Basel, Switzerland) in different dosages, i.e. O (saline), 2.5 or 5 mg/kg CsA 
(all as daily subcutaneous injections for 3 days after IRI) diluted in saline (Figure 1). 
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These CsA dosages are sufficient to prevent allograft rejection in experimental 
kidney transplantation (1 0). In additional experiments, treatment was extended to 10 
and 14 days (Figure 1 ), respectively. Plasma CsA levels were measured after the last 
administration and varied between 172 and 2010 µg/L, depending on the dose and 
duration of the treatment. Post-ischemic rats injected with saline served as controls. 
SHAM-operated rats received similar CsA treatment as rats subjected to IRI. Moreover, 
healthy rats (no irradiation, no BM transplantation, no IRI) were subjected to similar CsA 
treatment to determine baseline effects of CsA. For histological analyses, contra lateral 
kidneys of I RI-treated rats served as additional controls. 
lschemia/Reperfusion 
1 o 1 2 3 4 s s 1 a 9 1 0  1 1  
!Saline � �- -v 
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Figure 1 .  Study design. Schematic representation of the CsA treatment regime. CsA was administered 
in different dosages, i.e. O (saline), Z,5 or 5 mg/kg, for 3 consecutive days starting after /RI induction. This 
treatment was applied to rats subjected to renal /RI (n=S per group), SHAM·operated control rats (n=3 per 
group) and healthy control rats (n=3 per group). Treatment with 5 mg/kg CsA was also applied during 10 or 
14 consecutive days after /RI (n=S per group). 
Additionally, we performed a pilot experiment with rats receiving syngeneic kidney 
transplantations. R26-hPAP transgenic rats served as recipients and non-transgenic 
F344 rats as donors, to allow tracing of recipient-derived cells in the transplanted kidney. 
After anesthesia, the left kidneys were excised from donors, flushed with cold saline 
and transplanted orthotopically in hPAP recipient rats by end-to-end anastomosis of 
the vessels and ureters using 10-0 prolene sutures (Johnson & Johnson Intl., Brussels, 
Belgium). Cold ischemia by storage in saline on ice was approximately 30 min. Warm 
ischemia time was 25 min. In recipients, the right kidney was nephrectomized between 
day 7 and 1 0  after transplantation. The transplanted rats were divided into two groups. 
The first group (n=S) did not receive CsA treatment after transplantation. The second 
group (n=2) received 5 mg/kg CsA for the first 1 0  days after transplantation. 
All rats were terminated on day 14  after IRI. Twenty-four hour urine was collected prior 
to termination. Blood samples were taken and kidneys were perfused in situ. Animal 
procedures were approved by the local committee for care and use of laboratory 
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animals and performed according to governmental and international guidelines on 
animal experimentation. 
Kidney function 
Creatinine levels were determined in plasma and urine using the enzymatic colorimetric 
assay CREA plus (Roche, Woerden, the Netherlands) (1 1 ). Creatinine clearance (ml/min) 
was calculated by multiplying the creatinine level of a 24 h urine sample (µmol/l) by 
the volume of this 24 h urine sample (ml/min) and dividing the resulting value by the 
plasma creatinine level (µmol/l). 
Quantitative RT-PCR 
For qRT-PCR we used TaqMan "assay by demand" primer/probe sets for rat �2-
microglobulin and TGF-� (Applied Biosystems, Foster City, CA, USA, www. 
appliedbiosystems.com). RNA isolation from frozen kidneys, cDNA synthesis and qRT­
PCR were performed as previously described (8). 
Cycle thresholds (CT) for the individual reactions were determined using ABI Prism SDS 
2.2 data processing software (Applied Biosystems). Cr values >40 were not included 
in calculations. CT values were normalized against �2-microglobulin expression levels 
(1 2). To correct for interassay variance, CT values were normalized against an external 
calibrator, consisting of RNA from healthy and ischemic rat kidneys. Differences in 
expression levels between experimental and saline-treated healthy control rats were 
expressed as fold variance of expression, calculated as 2-t.11,icr (1 2). Briefly, fold variance 
of 1 indicates that there are no transcriptional differences compared to healthy 
control rats, > 1 is considered increased transcription and <1 is considered decreased 
transcription. 
Detection of circulating progenitor cells 
Since no monoclonal antibodies (moAbs) specific for rat progenitor cell markers are 
available, we assessed circulating lineage-negative (Lin-) cells as a population enriched 
for potential BMD progenitor cells. Briefly, MNC fractions were isolated from peripheral 
blood by Histopaque-1083 (Sigma-Aldrich, Zwijndrecht, the Netherlands) density 
gradient centrifugation. MNCs were stained with a cocktail of PE- or FITC-labeled 
moAbs against the lineage markers rat K/A (B cells, Sigma-Aldrich), CD3 (T cells), CD1 1b/ 
c (myeloid and dendritic cells), CD161a (NK cells) and rat erythroid cells (erythrocytes, 
all from BD). The non-labeled population (Un- cells) was gated and quantified using 
MoFlo cytometer (Cytomation Inc., Fort Collins, CO), and Winlist 5.0 software. 
Tissue collection, fixation and histological analyses 
Immediately after termination, kidneys were divided into quarters and fixed in Zinc 
fixative (0.1 M Tris buffer, pH 7.4 with 0.Sg CaCH2COO, Sg (CH2COO)2Zn*2Hp and Sg 
ZnCl2 per liter; MERCK, Darmstadt, Germany) or snap-frozen in N2 and stored at -80
°C. 
Histological analyses were performed on 5 µm zinc-fixed, paraffin-embedded sections, 
which weredewaxed before staining. Periodic acid-Schiff (PAS) staining, used to evaluate 
renal morphology, was performed routinely at the department of Pathology. hPAP was 
detected by enzymatic or immunohistochemical staining procedures. In cases where 
infiltration of BMDC needed to be quantified by computer morphometry, we used the 
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enzymatic staining, which gives a strong signal and no background, which is essential 
for correct computerized quantification of the stained area. The immunohistological 
method was used for more detailed examination of individual hPAP· cells or in cases 
when double-staining was necessary to determine the phenotype of engrafted BMDC. 
Enzymatic hPAP detection and inactivation of endogenous alkaline phosphatase (AP) 
was performed as previously described (8). lmmunostaining of hPAP was performed by 
incubation with rabbit anti-hPAP polyclonal antibody (Serotec, Oxford, UK), followed 
by incubation with biotinylated goat anti-rabbit conjugate (DAKO, Glostrup, Denmark) 
and streptavidine-alkaline phosphatase (Southern Biotechnology, Birmingham, USA). 
Myofibroblasts were detected by a-SMA staining. Briefly, sections were incubated 
with mouse a-SMA (clone 1A4, DAKO), and subsequent labeled with peroxidase­
conjugated rabbit anti-mouse antibody, followed by peroxidase-conjugated swine 
anti-rabbit antibody (both DAKO) as previously described (8). Collagen I l l  was detected 
with rabbit anti-rat collagen Ill (Biogenesis, Poole, UK) and subsequent labeling with 
peroxidase-conjugated goat anti-rabbit antibody, followed by peroxidase-conjugated 
rabbit anti-goat (both DAKO) antibody (8) .  For a-SMA/hPAP double staining, sections 
were subsequently stained with a-SMA and hPAP (see above), as previously described 
(8). Color development was performed with fuchsin substrate-chromogen system 
(hPAP) (DAKO), 3,3'-diaminobenzidine tetrachloride (a-SMA, collagen 1 1 1). Sections 
were counterstained with Mayer's hemalum (MERCK) and mounted in Kaiser's glycerol 
gelatine (MERCK). 
All immunofluorescent stainings were performed on 5 µm cryostat sections which were 
fixed in acetone. Double staining of a-SMA and hPAP was performed by incubation 
in primary antibodies, development of a-SMA with tyramide-TRITC (PerkinElmer 
Life Sciences, Boston, USA) via goat anti-mouse HRP (Southern Biotechnology) 
and development of hPAP with FITC-labeled goat anti-rabbit conjugate (Southern 
Biotechnology), as previously described (8) . Tyramide signal amplification is used to 
amplify the fluorescent signal. The epithelial phenotype of tubular engrafted BMDC 
was assessed by double-staining for hPAP in combination with the epithelial marker 
E-cadherin (clone 36) (Becton Dickinson Biosciences). Briefly, sections were incubated 
with anti-hPAP and anti-E-cadherin. hPAP was developed with goat anti-rabbit-FITC 
conjugate (Southern Biotechnology) and E-cadherin with biotinylated goat anti­
mouse (lgG2a) (DAKO) and streptavidin-Cy3 conjugate (Zymed Laboratories Inc.). To 
confirm that hPAP· cells, engrafted in renal tubuli, were not engrafted leukocytes, 
we performed double-staining combining hPAP with CD45 (leukocyte marker). hPAP 
was detected as described above and leukocytes were detected by incubation with 
mouse anti-rat CD45 monoclonal antibody (OX-1, culture supernatant), followed by 
biotinylated goat anti-mouse lgG (Southern Biotechnology) and streptavidin-Cy3 
conjugate (Zymed Laboratories Inc.). 
All antibody incubations were performed for 1 hour at room temperature. For 
negative controls, sections were processed in the absence of primary antibody. Light 
and fluorescence microscopy was performed using a Leica DMLB microscope (Leica 
Microsystems, Rijswijk, the Netherlands), Leica DC300F camera and Leica QWin 2 .8 
software. Co-localization of hPAP and a-SMA signals within cells was demonstrated 
with confocal microscopy, using a LEICA TCS SP2 3-channel confocal laser scanning 
microscope. In each section, 14 consecutive optical sections were scanned at the 
excitation wavelengths of 488 nm (FITC) and 543 nm (TRITC), thus generating a 
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sequential Z-series of 14 optical sections. Computerized stacking of these 14 optical 
sections allowed us to obtain a three-dimensional image of cells of interest. A cell was 
considered double-positive when the signals for FITC (hPAP) and TRITC (a-SMA) were 
present concomitantly throughout at least 7/14 consecutive optical sections of the Z­
series. This method al lowed us to reliably detect double-positive cells and to exclude 
the possibility that the two markers were expressed by different, neighboring cells. 
Quantification 
The severity of morphological renal damage (severity of damage) was assessed using 
an arbitrary score based on PAS-stained kidney sections (13). Briefly, the extent of 4 
typical !RI-associated damage markers, i.e. dilatation, denudation, intraluminal casts 
and cell flattening, was scored arbitrarily and expressed in arbitrary units (a.u.) in a 
range of 0-3 per damage marker. 
Interstitial staining of hPAP, a-SMA and collagen Ill was measured using computerized 
morphometry (Leica QWin 2.8 software). Stained areas of 15 randomly selected fields 
in cortex and outer medulla were quantified at a magnification of 200x and expressed 
as percentage of total measured area. Vascular and glomerular expression of collagen 
Ill and vascular expression of a-SMA was excluded from measurements. 
The percentage of hPAP+/a-SMN cells was determined by counting all a-SMN, 
hPAP+ and double-positive cells in 30 microscope fields in cortex and outer medulla 
per section, for each rat at a magnification of 400x. Because of the low number of 
a-SMN cells in kidneys of SHAM-operated rats we did not include this group in the 
quantification. 
Tubular epithelial BMDC engraftment was determined by counting the number 
of hPAP+ cells engrafted in tubular cross-sections and all tubular epithelial cells 
in a microscope field. Tubular engrafted hPAP+ cells displaying similar shape and 
morphology as adjacent cells were counted in 10 random microscope fields (400x) in 
cortex and medulla of each rat. 
Statistics 
Statistical tests were performed using GraphPad Prism 4.0 (GraphPad Software, San 
Diego California, USA). Differences between controls and experimental groups were 
determined with One-way ANOVA Dunnett's Multiple Comparison Test. P-values <0.05 
were considered statistically significant. 
Results 
Severity of renal damage 
The impact of CsA treatment (Figure 1) on renal morphology was determined by PAS­
stained kidney sections. Healthy control rats (Figure 2A) and SHAM rats, subcutaneously 
injected with saline for 3 consecutive days showed normal renal morphology, 
irrespective of CsA dosage. Compared to these control kidneys, kidneys subjected 
to 45 min of unilateral renal IRI and treatment with saline for 3 consecutive days 
following IRI (Figure 2B) showed severe damage, characterized by tubular dilatation, 
intraluminal protein casts, tubular membrane denudation and tubular cell flattening. 






e s  
� 4  
0 3 
1 ]09+ 
CsA dosage (mg/kg) '<>'l,':> " 





i c 2.o 
u ·e 
cu :J 1.5 
.!: E 





CsA dosage (mg/kg) <::, 'l,'? <, 
Treatment regime (days) 3 3 3 
P<0.001 









3 3 3 10 14  
<::, 'l,'? ., ., ., 




Figure 2. Severity of renal damage. Representative renal morphology is shown by PAS-stained sections af 
kidneys from a saline-treated rat (AJ, post-ischemic kidney after saline treatment (BJ, post-ischemic kidney 
after treatment with 5 mg/kg for 3 consecutive days (CJ and post-ischemic kidney after treatment with 5 mg/ 
kg for 14 consecutive days (D). Lens magnification 200x. Severity of damage was quantified by an arbitrary 
score of the presence of 4 typical /RI-associated damage markers, i.e. dilatation, denudation, intraluminal 
casts and cell flattening, expressed in arbitrary units (a.u.J in a range of 0-3 (EJ. Bars indicate the mean 
severity of damage per group and SEM. Creatinine clearance was assessed to determine kidney function 
(FJ. Bars indicate the mean creatinine clearance per group and SEM. s = saline, HC = Healthy Control, /RI = 
/schemia/Reperfusion Injury. 
2C) or with 5 mg/kg CsA for 10 (not shown) or 14 consecutive days after IRI (Figure 
2D), kidney morphology was comparable to ischemic kidneys from saline-treated rats, 
without signs of additional damage. 
Quantification of morphological damage confirmed absence of damage in healthy 
and SHAM-operated kidneys, irrespective of CsA treatment, and comparably severe 
damage in kidneys of saline-treated rats after IRI (Figure 2E). When administered 
for three consecutive days, CsA did not influence renal damage in healthy rats, rats 
subjected to SHAM, or IRI operation, irrespective of dose. Because we did not observe 
changes in renal damage after administration of CsA for 3 days, we extended the 
treatment duration to 10 and 14 days, which did, however, not influence the severity 
of damage (Figure 2E). 
Creatinine clearance in healthy and SHAM-operated rats was not influenced by 
administration of CsA for 3 consecutive days, irrespective of dose (Figure 2F). Compared 
88 
CSA AND BMDC DIFFERENTIATION 
to healthy controls and SHAM-operated rats, creatinine clearance was significantly 
lower in saline-treated rats subjected to IRI. However, treatment with CsA in increasing 
dosages for 3 consecutive days after IRI or treatment with 5 mg/kg CsA for 10 or 14 
consecutive days after IRI had no additional effect on creatinine clearance (Figure 2F). 
Presence of fibrosis markers 
Fibrotic changes in the kidney after CsA treatment were determined by assessing renal 
TGF-� expression levels, the presence of interstitial myofibroblasts and interstitial 
collagen Ill deposition. Differences in TGF-� expression levels between experimental 
rats and saline-treated healthy control rats were expressed as fold variance of 
expression, calculated as 2-Me.cT (12) (Figure 3A). Compared to healthy control and 
SHAM-operated rats, TGF-� transcript levels were doubled in rats subjected to IRI 
and saline treatment (Figure 3A). TGF-� transcript levels were further increased after 
treatment with 5 mg/kg CsA for 3 or 14 consecutive days after IRI, however no statistical 
significant difference was found compared to rats treated with saline after IRI (Figure 
3A). 
Interstitial myofibroblasts were detected using a-SMA immunostaining (Figure 3B-G) 
and morphometric quantification (Figure 3H). In healthy control kidneys (Figure 3B, H) 
and SHAM kidneys (Figure 3C, H) after saline treatment and in contralateral kidneys of 
rats with unilateral IRI (Figure 3D, H) interstitial a-SMA+ cells were observed sporadically, 
irrespective of CsA dosage (Figure 3H). Compared to control kidneys, a strong increase 
in a-SMA+ interstitial myofibroblasts was present in saline-treated, post-ischemic 
kidneys (Figure 3E, H). However, neither treatment with increasing dosages of CsA for 
3 consecutive days after IRI (Figure 3F, H) nor treatment for 10 or 14 consecutive days 
after IRI with 5 mg/kg CsA (Figure 3G, H) influenced numbers of a-SMA+ interstitial 
myofibroblasts. 
Collagen Ill immunostaining (Figure 3I-N) and morphometric quantification (Figure 30) 
showed that the basal presence of collagen Ill deposition in healthy control kidneys 
(Figure 31, 0) was comparable to collagen Ill deposition in SHAM kidneys (Figure 3J, 0) 
and contralateral kidneys of rats with unilateral IRI (Figure 3K, 0). Treatment with CsA 
did not influence collagen Ill deposition in healthy control kidneys, SHAM-operated 
kidneys and contra lateral kidneys ofrats with unilateral IRI, irrespective of dosage (Figure 
30). After IRI induction and saline treatment, renal interstitial collagen Ill deposition 
was significantly higher than in healthy controls (Figure 3L, 0). No differences in renal 
collagen Ill deposition were observed after administration of increasing dosages of 
CsA for 3 consecutive days after IRI (Figure 3M, 0). However, when 5 mg/kg CsA was 
administered for 14 consecutive days after IRI, collagen Ill deposition was significantly 
increased (Figure 3N, 0) compared to the saline-treated ischemic rats. 
Detection of circulating progenitor cells and renal infiltration of BMDC 
To investigate the impact of CsA on BMDC differentiation, we first assessed BMD 
progenitor (Un-) cell mobilization to the circulation. In healthy control rats, the 
percentage of circulating Lin- cells was not influenced by CsA treatment, irrespective 
of dosage (0.1±0.03% in saline-treated vs. 0.08±0.02% Un- cells in rats treated with 5 
mg/kg CsA for 3 days, p>0.05). In SHAM-operated rats, the percentage on Un· cells 
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Figure 3. Presence of fibrosis markers. Expression levels ofTGF-/3 were determined by quantitative RT-PCR on 
RNA isolated from rat kidneys (A). Differences in expression levels between experimental and healthy control 
rats were expressed as fold variance of expression, calculated as 2- cr (12J. Fold variance of 1 indicates 
that there are no transcriptional differences compared to healthy control rats, >1 is considered increased 
transcription and <1  is considered decreased transcription. Bars indicate the mean TGF-{3 expression levels 
per group and SEM. The presence of renal interstitial myofibrob/asts was detected by staining for a-SMA 
in saline-treated healthy (BJ, SHAM (CJ and contralateral (DJ kidneys. Post-ischemic presence of interstitial 
myofibroblasts is shown after treatment with saline for 3 consecutive days (EJ, S mg/kg CsA for 3 consecutive 
days (FJ or S mg/kg CsA for 14 consecutive days (GJ. The percentage of a-SMA-stained area was quantified by 
computerized morphometry (HJ. Bars indicate the mean a-SMA-stained area per group and SEM. All a-SMA­
positive vascular structures were excluded from quantitative analysis. Renal interstitial collagen Ill protein 
deposition is shown in healthy control (I), SHAM (JJ and contralateral (K) kidneys. Post-ischemic callagen Ill 
deposition is shown after treatment with saline 3 consecutive days (LJ or S mg/kg CsA for 3 consecutive days 
after /RI (MJ or treatment with S mg/kg CsA for 14 consecutive days after JR/ (NJ. The percentage of collagen 
Ill-stained area was quantified with computerized morphometry (OJ. Bars indicate the mean percentage of 
collagen I/I-stained area per group and SEM. Lens magnification 200x. s = saline, HC = Healthy Control, Con 
= Contralateral, /RI = Jschemia/Reperfusion Injury. 
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was also not influenced by treatment with increasing dosages of CsA (0.06±0.003% 
in saline-treated vs. 0.09±0.01% Un· cells in rats treated with 5 mg/kg CsA for 3 days, 
p>0.0S). At day 14 after IRI, percentages of circulating Un· cells in ischemic, healthy and 
SHAM-operated controls were comparable. Moreover, the percentage of Un· cells was 
not influenced by treatment with increasing dosages of CsA for 3 consecutive days 
after IRI, or treatment with S mg/kg CsA for 10 consecutive days after IRI (0.08±0.02% 
in saline-treated vs. 0.1±0.01% Lin- cells in rats treated with 5 mg/kg CsA for 10 days, 
p>0.0S). 
Staining by enzymatic conversion of substrate by hPAP allowed identification of renal 
infiltrating BMDC (Figure 4A-F), and subsequent morphometric quantification (Figure 
4G). Since healthy controls were not subjected to hPAP BM transplantation, BMDC could 
not be assessed in these rats. In healthy control kidneys no hPAP signal was observed 
(Figure 4A). A low number of hPAP+ BMDC was observed in the renal interstitium of 
saline-treated SHAM-operated controls (Figure 4B, G) and in contra lateral kidneys of rats 
after IRI (Figure 4C, G), which was not changed by treatment with increasing dosages 
of CsA (Figure 4G). Compared to SHAM-operated controls, induction of IRI followed by 
treatment with saline for 3 consecutive days resulted in a significantly higher number 
of renal infiltrating BMDC (Figure 40, G). Treatment with CsA in increasing dosages for 
3 consecutive days after IRI did not influence renal BMDC infiltration (Figure 4E, G). 
Moreover, treatment with 5 mg/kg CsA for 10 or 14 consecutive days after IRI had no 
additional effect on the number of renal infiltrating BMDC (Figure 4F, G). 
Bone marrow-derived myofibroblasts 
Differentiation of BMDC into renal interstitial myofibroblasts was detected by double 
staining combining hPAP with a-SMA. After renal IRI, cells co-expressing hPAP 
(BMDC, Figure SA) and a-SMA (myofibroblasts, Figure SB) were observed in the renal 
interstitium. In these cells, co-expression of hPAP (FITC) and a-SMA (TRITC) (Figure SC) 
was detected in 8/14 consecutive confocal optical sections of the Z-series, confirming 
the double-positivity of these cells and excluding the possibility that the two markers 
were expressed by different, neighboring cells. 
In ischemic kidneys of rats treated with saline for 3 consecutive days, 40.7% of all 
renal interstitial a-SMN myofibroblasts was derived from the BM, confirming our 
previous findings (8). However, neither treatment with CsA in increasing dosages for 
3 consecutive days after IRI, nor treatment with S mg/kg CsA for 10 or 14 consecutive 
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Figure 4. Renal infiltration of BMDC. BMDC infiltration, determined by enzymatic hPAP staining, is shown 
in saline-treated, non-transgenic healthy (AJ, SHAM-operated (BJ and contralatera/ kidney after /RI (CJ. Post­
ischemic renal infiltration of BMDC is shown in kidneys after treatment with saline for 3 consecutive days 
(DJ, 5 mg/kg CsA for 3 consecutive days (EJ or treatment with 5 mg/kg CsA for 14 consecutive days (FJ. Lens 
magnification 200x. The percentage of hPAP stained area was quantified by computerized morphometry (GJ. 
Bars indicate the mean percentage of hPAP stained area per group and SEM. s = saline, Con= Contra lateral, 
/RI = lschemia/Reperfusion Injury. 
Recipient-derived myofibroblasts after experimental kidney transplantation 
On day 14 after kidney transplantation (TX), without post-operative CsA treatment, an 
average of 28% of all renal interstitial myofibroblasts in the donor kidney was recipient­
derived (Figure SD). Treatment with S mg/kg CsA for 10 consecutive days after kidney 
transplantation did not affect the percentage of recipient-derived myofibroblasts 
(Figure SD). Moreover, no statistical differences in the numbers of recipient-derived 
myofibroblasts were found between the IRI and TX groups that did not receive CsA 
treatment (Figure SD). IRI rats and kidney transplant recipients treated with S mg/kg 
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CSA AND BMDC DIFFERENTIATION 
Figure S. Bone marrow-derived and recipient-derived myofibroblasts. The presence ofBMD myofibroblasts 
was determined by confocal microscopy of staining for hPAP (FITC) (A) in combination with a-SMA (TR/TC) 
(B) on post-ischemic or post-transplant kidney tissue. The overlay shows FITC, TR/TC and OAP/ channels and 
the x/z and y/z planes underneath and on the right of the merged picture demonstrate colocalization of 
the markers (C). Arrows indicate double-positive cells. Arrowheads indicate co-expression in the x/z and ylz 
planes. Co-expression of hPAP and a-SMA was quantified in relation to the renal interstitial myofibroblast 
population in /RI rats and syngeneic kidney transplant recipients (D). Bars indicate the mean percentage 
hPAP/a-SMA double-positive cells of all a-SMA+ cells per group and SEM. s = saline, /RI= /schemia/Reperfusion 
Injury, TX= Transplantation. 
Tubular epithelial engraftment of BMDC 
Besides differentiating into myofibroblasts, BMDC have also been shown to engraft 
into renal tubules and to adopt an epithelial phenotype after IRI (13-16). Therefore, we 
assessed the influence of CsA on tubular BMDC engraftment. Since healthy controls 
were not subjected to hPAP BM transplantation, BMDC could not be assessed in 
these rats. In the kidneys of SHAM-operated control rats, BMDC were present in the 
interstitium (Figure 6A), however, tubular epithelial BMDC engraftment was observed 
sporadically. Treatment with increasing dosages of CsA for 3 consecutive days after 
SHAM operation did not influence the percentage of hPAP+ tubular engrafted cells 
(Figure 6F). After induction of IRI and treatment with saline for 3 consecutive days, 
2% of all tubular epithelial cells were hPAP+ (Figure 6B, F). Epithelial phenotype of the 
engrafted BMDC was demonstrated by double-staining combining hPAP with the 
epithelial-specific marker E-cadherin (Figure 6C-E). These engrafted hPAP+ cells did not 
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express the common leukocyte antigen CD45 (not shown). Neither administration of 
CsA in increasing dosages for 3 consecutive days, nor treatment with 5 mg/kg CsA for 
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Figure 6. Tubular epithelial engraftment of BMDC. hPAP staining in SHAM (A) and saline-treated post­
ischemic kidney (BJ showed occasional tubular BMDC engraftment in the latter. Arrow indicates an example 
of tubular epithelial BMDC engraftment. lens magnification I000x. Epithelial phenotype of the engrafted 
BMDC was demonstrated by double-staining for hPAP (CJ and E-cadherin (DJ. The overlap of signal is shown 
in the overlay (E). Arrows indicate double-positive cells. Tubular epithelial BMDC engraftment was quantified 
as the percentage of hPAf>+ tubular engrafted cells (F). Bars indicate the mean percentage of hPAf>+ tubular 
engrafted cells per group and SEM. s = saline, /RI = lschemia/Reperfusion Injury. 
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Discussion 
This study is the first to investigate the effects of CsA on differentiation of BMDC to 
myofibroblasts after renal IRI. Using a previously validated experimental model of 
IRI, we found no direct adverse effects of CsA during the critical window of BMDC 
differentiation to myofibroblasts. 
OurpreviousfindingthatBMDCcontributeupto40%ofthepost-ischemicmyofibroblast 
pool raised the question whether differentiation of BMDC to myofibroblasts may 
be promoted by CsA. Based on the described window of opportunity for BMDC 
differentiation to myofibroblasts, in the current study we administered CsA for 3, 10 or 
14 consecutive days after IRI induction. 
Benefiting from a group of unmanipulated (no irradiation, BM transplantation, IRI) 
healthy rats we showed that CsA had no baseline effects on numbers and mobilization 
of Lin- progenitor cells, irrespective of dosage and course of administration. Moreover, 
in conjunction with IRI, the effect of CsA on circulating Lin- cells was not altered. 
Since CsA was administered during the first 3 days after IRI, in the time frame when 
mobilization of progenitor cells is at its strongest, this suggests that CsA has no impact 
on production of Un· cells in or mobilization of these cells from the BM. This is, to our 
knowledge, the first report on the influence of CsA on circulating progenitor cells in 
vivo. 
Our expectation that the pro-fibrotic action of CsA may promote BMDC differentiation 
to myofibroblasts was contradicted, irrespective of treatment regimen. Importantly, 
CsA was administered in the optimal window of opportunity for myofibroblastic 
differentiation of BMDC in the renal interstitium (8), supporting the concept that 
CsA does not affect differentiation of BMDC. At short term after IRI, CsA also did not 
affect numbers of endogenous myofibroblasts. Both findings are intriguing in light 
of the fact that TGF-� transcription was stimulated by long-term treatment with CsA, 
demonstrating CsA activity (17,18) and indicating that a pro-fibrotic environment was 
generated. We previously showed that TGF-� was primarily produced by resident, 
not BMD, myofibroblasts (8). In the present study, 14 day treatment with maximal 
CsA dosages resulted in increased collagen Ill deposition, which is a result of TGF­
� production. Since numbers of BMD- and endogenous myofibroblasts were not 
affected by CsA, it is conceivable that at short-term after IRI, CsA may affect function 
of myofibroblasts, only. 
During transplantation, the setting in which CsA is commonly used, solid organs 
undergo variable times of both warm and cold ischemia. After having studied the 
impact of CsA on BMDC differentiation in an established, "clean" model of warm 
ischemia, we conducted a pilot experiment using a model of syngeneic kidney 
transplantation, in which the donor kidney was subjected to cold and warm ischemia. 
This study allowed us to investigate the effects of CsA in a relevant setting, without 
the confounding influence of immune rejection. In this model too, there were no 
differences in numbers of BMD-myofibroblasts between CsA-treated and untreated 
rats, indicating that the agent did not affect differentiation of BMDC or recipient­
derived cells within this time frame. 
Previously, we showed that, besides differentiating into myofibroblasts, a small 
percentage of BMDC differentiated into tubular epithelial cells (8,13). Since CsA has 
been shown to create a renal environment in which proliferation of tubular epithelial 
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cells is inhibited (19), we asked whether differentiation of BMDC to tubular epithelial 
cells may be impaired by CsA. Similar numbers of BMD tubular epithelial cells in CsA­
and saline-treated rats demonstrated that this was not the case. The fact that tubular 
regeneration did take place in the post-ischemic kidney, even after CsA treatment, 
suggests that tubular repair was mediated by epithelial proliferation, as previously 
shown (13), and was not affected by CsA. 
We have previously reported a positive correlation between ischemic time, the extent 
of renal damage and the contribution of BMDC to tubular repair (13). As discussed 
above, we have also identified a critical time window in renal repair and remodeling, 
in which BMDC undergo differentiation fates, probably under the influence of the 
renal microenvironment. The current study is the first to investigate the effects of CsA 
on these processes, and shows that, within the crucial early time window after the 
induction of IRI or kidney transplantation, administration of experimentally relevant 
dosages of CsA did not stimulate BMDC differentiation to myofibroblasts and thus 
did not increase the already significant contribution of these cells to the interstitial 
myofibroblast pool. Based on these data it is reasonable to speculate that, in the clinical 
setting, CsA does not exert its profibrotic action by stimulation of myofibroblastic 
differentiation of BMDC. 
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Abstract 
In human renal allografts, recipient-derived cells engrafted in various kidney 
substructures, have been detected at long term after transplantation. Here we 
investigated tubular engraftment and myofibroblast differentiation of recipient­
derived cells at short-term after experimental kidney transplantation, during a 
previously described window of regeneration and possible onset of renal interstitial 
fibrosis. 
Fisher{F344,syngeneic) and Dark Agouti {DA,allogeneic) kidneys were transplanted into 
F344-hPAP transgenic recipient rats, which allowed tracing of recipient-derived cells in 
non-transgenic donor kidneys. We evaluated tubular engraftment and myofibroblast 
differentiation of recipient-derived cells on day 14 after kidney transplantation. 
Kidney transplantation resulted in tubular engraftment of recipient-derived cells. After 
allogeneic kidney transplantation, 9.7% of tubular cross-sections contained at least 
one recipient-derived cell, which represented a significant increase in comparison to 
syngeneic transplantation {4.0%, p<0.05). Moreover, recipient-derived myofibroblasts 
were present in the renal interstitium of the transplanted kidney. These cells 
contributed 39% of the total interstitial myofibroblast population in allografts, which 
was comparable to the syngeneic situation {28%, p=0.25). 
In a defined early window of regeneration and possible onset of renal interstitial fibrosis 
after kidney transplantation, rejection-associated injury, superimposed on ischemic 
damage, increases tubular engraftment of recipient-derived cells, while it does not 
affect their relative contribution to the renal interstitial myofibroblast population. 
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Introduction 
Early after kidney transplantation both non-immunologic factors, such as ischemia/ 
reperfusion injury (IRI), and immunologic factors, such as acute rejection episodes, 
cause endothelial and tubular epithelial damage in the graft. At long term, this can 
result in interstitial fibrosis, which involves infiltration of inflammatory cells, proximal 
tubular injury and -death, extracellular matrix (ECM) accumulation and the progressive 
loss of renal function. 
Recipient-derived cells, likely originating from bone marrow-derived (progenitor) 
cells, have been detected in endothelial or tubular epithelial structures of human renal 
allografts several months after transplantation (1-8). Since the extent of replacement of 
donor endothelium or epithelium correlates with the severity of graft damage (3;5), it 
was postulated that recipient-derived cells mediate graft repair by replacing damaged 
graft cells. Furthermore, in renal transplants with chronic allograft nephropathy, the 
presence of recipient-derived myofibroblasts in the tubulointerstitial compartments 
was demonstrated, indicating a possible role for these cells in renal remodeling after 
kidney transplantation (2). 
Engraftment and differentiation of recipient-derived cells in human allografts has been 
studied in chronic renal transplant injury, but not early after transplantation. Using a rat 
model of IRI we previously identified an early window of kidney regeneration, but also 
of possible onset of fibrosis, during the first two weeks after IRI. In this early window 
we observed sporadic engraftment of bone marrow-derived cells (BMDC) in tubular 
cross-sections and differentiation to epithelium, which positively correlated with the 
severity of damage (9). Moreover, we showed that BMDC contributed significantly to 
the interstitial myofibroblast population, forming up to 40% of all ECM-producing 
interstitial a-SMN myofibroblasts (10). These results suggest that the potential 
contribution of BMDC to kidney repair or the onset and progression of chronic injury 
and repair may be determined early after IRI. Since IRI forms an unavoidable damage 
event during solid organ transplantation, in the current study we hypothesized that 
after kidney transplantation engraftment of recipient cells in the graft takes place in 
this early phase, with possible consequences for graft performance. To address this 
hypothesis we performed experimental kidney transplantations with F344-R26-hPAP 
transgenic rats as recipients to investigate, for the first time, differentiation fates of 
recipient-derived cells in the non-transgenic donor kidney using experimental kidney 
transplantation. 
Materials and Methods 
Animal experimentation 
Male, 8-12 week-old R26-hPAP rats (F344 background), transgenic for human placental 
alkaline phosphatase (hPAP) (11), their non-transgenic F344 littermates and Dark 
Agouti rats (DA/OlaHsd, Harlan, Horst, the Netherlands) were kept under conventional 
housing and diet. 
R26-hPAP transgenic rats were used as recipients to allow tracing of recipient­
derived cells in the donor kidney. Non-transgenic F344 rats served as donors in 
syngeneic kidney transplantation (F344 to F344-hPAP, n=6), DA rats served as donors 
for allogeneic transplantation (DA to F344-hPAP, n=6). Briefly, rats were sedated by 
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general isoflurane (2% Forene, Abbot b.v., Hoofddorp, The Netherlands), Np (50%), 02 
(50%) anesthesia. After anesthesia, the left kidneys were excised from donors, flushed 
with cold saline and transplanted orthotopically in hPAP recipient rats by end-to-end 
anastomosis of the vessels of the donor and recipient and, subsequently, ureters of 
the donor and recipient using 10-0 prolene sutures (Johnson & Johnson Intl., Brussels, 
Belgium). Cold ischemia by storage in saline on ice was approximately 30 min. Warm 
ischemia time was 25 min. Nephrectomy of the right kidney was performed between 
day 7 and 10 after transplantation. Death of the animals early after transplantation, 
due to acute graft rejection, was prevented by treatment with 5 mg/kg ciclosporin 
(CsA, Sandimmun, Novartis, Basel, Switzerland) as daily subcutaneous injections for 
the first 10 consecutive days after allogeneic kidney transplantation (12). 
All rats (n=6 per group) were terminated on day 14 after transplantation. Twenty­
four hour urine and blood samples were collected prior to termination. Kidneys were 
perfused in situ with cold saline. Kidney size was not measured. Animal procedures 
were approved by the local committee for care and use of laboratory animals and 
performed according to governmental and international guidelines on animal 
experimentation. 
Renal function 
Total urine protein was determined using the TCA protein assay (13) and BNII equipment 
(Dade Behring, Marburg, Germany). Creatinine levels were determined in plasma 
and urine using the enzymatic colorimetric assay CREA plus (Roche, Woerden, the 
Netherlands) (14), which is a sensitive and specific quantification method for creatinine 
(15). Creatinine clearance (ml/min) was calculated by multiplying the creatinine level 
of a 24 h urine sample (µmol/L) by the volume of this 24h urine sample (ml/min) and 
dividing the resulting value by the plasma creatinine level (µmol/L). Blood and urine 
collected from healthy F344 and DA rats served as control samples. These healthy 
F344 and DA rats were at a later stage used as kidney donors for the syngeneic and 
allogeneic transplantations. 
Tissue collection, fixation and histological analyses 
Immediately after termination kidneys were divided into quarters and fixed in Zinc 
fixative (0.l M Tris buffer, pH 7.4 with 0.5g CaCH2COO, 5g (CH2COO)2Zn*2Hp and 5g 
ZnCl2 per liter; MERCK, Darmstadt, Germany) or snap-frozen in N2 and stored at -80
°C. 
Histological analyses were performed on 5 µm zinc-fixed, paraffin-embedded sections, 
which were dewaxed before staining, or on 5 µm acetone-fixed, cryostat sections. 
Periodic acid-Schiff (PAS) staining, used to evaluate renal morphology, was performed 
using an automated procedure at the department of Pathology. 
hPAP was detected by enzymatic or immunohistochemical staining procedures. 
In cases where infiltration of recipient-derived cells needed to be quantified by 
computer morphometry, we used the enzymatic staining, which gives a strong 
signal and no background, which is essential for correct computerized quantification 
of the stained area. The immunohistological method was used for more detailed 
examination of individual hPAP+ cells or in cases when double-staining was necessary 
to determine the phenotype of engrafted recipient-derived cells. Enzymatic hPAP 
detection and inactivation of endogenous alkaline phosphatase (AP) was performed 
as previously described (10). lmmunohistochemical detection of hPAP was performed 
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by incubation with rabbit anti-hPAP polyclonal antibody (Serotec, Oxford, UK), 
followed by incubation with biotinylated goat anti-rabbit conjugate (DAKO) and 
streptavidine-alkaline phosphatase (Southern Biotechnology, Birmingham, USA) (10). 
CD4+ and CDS+ T cells were detected using mouse anti-rat CD4 and CDS antibodies 
(OX-35 and OX-S, culture supernatant), followed by incubation with biotinylated goat 
anti-mouse lgG (Southern Biotechnology) and streptavidin-peroxidase conjugates 
(DAKO). Renal interstitial myofibroblasts were detected using mouse anti-a-SMA 
(clone 1A4, DAKO), and subsequent labeling with peroxidase-conjugated rabbit anti­
mouse antibody, followed by peroxidase-conjugated swine anti-rabbit antibody (both 
DAKO, Glostrup, Denmark) as previously described (10). Collagen Ill was detected 
with rabbit anti-rat collagen Ill (Biogenesis, Poole, UK) and subsequent labeling with 
peroxidase-conjugated goat anti-rabbit antibody (DAKO), followed by peroxidase­
conjugated rabbit anti-goat (DAKO) antibody (10). For a-SMA/hPAP double staining, 
sections were first stained with a-SMA and subsequently for hPAP (see above), as 
previously described (10). Color development was performed with fuchsin substrate­
chromogen system (hPAP) (DAKO), 3,3'-diaminobenzidine tetrachloride (a-SMA, 
collagen Ill) or with 3-amino-9-ethylcarbazole (Sigma-Aldrich) substrate dissolved in 
N,N-dimethylformamide (MERCK) and 0.SM acetate buffer, pH 4.9 (CD4, CDS). Sections 
were counterstained with Mayer's hemalum (MERCK) and mounted in Kaiser's glycerol 
gelatine (MERCK). 
The epithelial phenotype of tubular engrafted recipient-derived cells, was assessed 
by immunofluorescent double-staining for hPAP in combination with E-cadherin 
(clone 36) (Becton Dickinson Biosciences) or a cocktail of the tubular epithelial specific 
lectins: SBA (biotinylated soybean agglutinin), DBA (biotinylated Dolichos biflorus 
agglutinin), and PNA (biotinylated peanut agglutinin) (all from Vector Laboratories 
Inc., Burlingame, CA, USA). Briefly, on 5 µm cryosections, recipient-derived cells were 
detected by incubation with anti-hPAP, followed by goat anti-rabbit-FITC conjugate 
(Southern Biotechnology). Tubular epithelial cells were detected by incubation with a 
mixture of30 µg/mL biotinylated SBA/DBA/PNA followed by a streptavidin-Cy3 (Zymed 
Laboratories Inc., San Francisco, CA, USA) conjugate, or by incubation with monoclonal 
antibody against E-cadherin followed by biotinylated goat anti-mouse (lgG2a for E­
cadherin) (Dako) and streptavidin-Cy3 conjugates (Zymed Laboratories Inc.). To confirm 
that hPAP+cells, en grafted in renal tubuli, were notengrafted leukocytes, we performed 
double-staining combining hPAP with CD45 (leukocyte marker). hPAP was detected 
as described above and leukocytes were detected by incubation with mouse anti­
rat CD45 monoclonal antibody (OX-1, culture supernatant), followed by biotinylated 
goat anti-mouse lgG (Southern Biotechnology) and streptavidin-Cy3 conjugates 
(Zymed Laboratories Inc.). The myofibroblast phenotype of recipient-derived cells 
was assessed by immunofluorescence double-staining of a-SMA and hPAP. hPAP 
was detected as described above and a-SMA with tyramide-TRITC (PerkinElmer Life 
Sciences, Boston, USA) via goat anti-mouse HRP (Southern Biotechnology). Tyramide 
signal amplification is used to amplify the fluorescent signal. Fluorescently stained 
sections were counterstained with 4',6-diamidino-2-phenylindole (DAPI, Sigma­
Aldrich, St.Louis, USA) and mounted with citifluor (Agar scientific, Stansted, UK). 
All antibody incubations were performed for 1 hour at room temperature. For 
negative controls, sections were processed in the absence of primary antibody. Light 
and fluorescence microscopy was performed using a Leica DMLB microscope (Leica 
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Microsystems, Rijswijk, the Netherlands), Leica DC300F camera and Leica QWin 2.8 
software. Fluorescent images of hPAP/a-SMA were obtained using a LEICA TCS SP2 3-
channel confocal laser scanning microscope. Co-localization ofhPAP and a-SMA signals 
within cells in the 5 µm thin cryosections was demonstrated with confocal microscopy, 
using a LEICA TCS SP2 3-channel confocal laser scanning microscope. In each section, 
ten consecutive optical sections were scanned at the excitation wavelengths of 488 
nm (FITC) and 543 nm (TRITC), thus generating a sequential Z-series of ten optical 
sections. Computerized stacking of these ten optical sections allowed us to obtain 
a three-dimensional image of cells of interest. A cell was considered double-positive 
when the signals for FITC (hPAP) and TRITC (a-SMA) were present concomitantly 
throughout at least 7/10 consecutive optical sections of the Z-series. This method 
allowed us to reliably detect double-positive cells and to exclude the possibility that 
the two markers were expressed by different, neighboring cells. 
Quantification 
Interstitial staining of hPAP, a-SMA and collagen Ill was measured using computerized 
morphometry (Leica QWin 2.8 software). Stained areas of 15 (hPAP, collagen Ill) or 
25 (a-5MA) randomly selected fields in cortex and outer medulla were quantified 
at a magnification of 200x and expressed as percentage of total measured area. a­
SMA expression appeared to be more variable and clustered compared to hPAP and 
collagen I l l  expression, and was therefore measured in 25, instead of 15, microscope 
fields. Vascular and glomerular expression of collagen Ill and vascular expression of 
a-SMA was excluded from measurements. 
The percentage of hPAp+/a-SMN cells was determined by two independent 
investigators by counting all a-SMA+, hPAP+ and double-positive cells in 30 microscope 
fields in cortex and outer medulla per section, for each rat at a magnification of 400x. 
In syngeneic transplanted kidneys 3250 interstitial cells (650 interstitial cells/kidney 
section) and in allogeneic transplanted kidneys 4878 interstitial cells (813 interstitial 
cells/kidney section) were counted. 
Tubular epithelial engraftment of recipient-derived cells was determined by counting 
the number of tubular cross-sections containing at least one hPAP+ cell of all tubular 
cross-sections in a microscope field. In syngeneic transplanted kidneys 800 tubular 
cross sections (133 tubuli/kidney section) and in allogeneic kidneys 786 tubular cross 
sections (131 tubuli/kidney section) (n=6 rats per group) were counted. The number 
of tubular engrafted recipient-derived cells was determined by counting the number 
hPAP+ cells engrafted in tubular cross-sections of all tubular epithelial cells in a 
microscope field. In both groups a comparable number of tubular cells was counted 
(1482 tubular cells/kidney in syngeneic vs. 1577 tubular cells/kidney in allogeneic 
kidneys). Tubular engrafted hPAP+ cells had the same shape and morphology as 
adjacent cells and were counted in 10 random microscope fields (400x) in cortex and 
medulla for each rat. 
Statistics 
Statistical tests were performed using GraphPad Prism 4.0 (GraphPad Software, San 
Diego California, USA). Differences between control, syngeneic kidney transplantation 
and allogeneic kidney transplantation groups were determined with One-way ANOVA 
Bonferroni's Multiple Comparison Test. Between group (syngeneic vs. allogeneic 
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kidney transplantation) comparison was analyzed using unpaired t-tests. Spearman 
correlation test was performed to determine the relationship between 2 different 
parameters. P-values <0.05 were considered statistically significant. 
Results 
Renal morphology and function 
Normal morphology was observed in contralateral right kidneys of the F344 or DA 
donor (Figure lA), harvested during transplantation, and nephrectomized right 
kidneys of the F344-hPAP recipient (Figure 18), harvested between day 7-10  after 
transplantation. Based on visual observation, there were no differences in kidney size 
on day 14 after F344 kidney transplantation into F344-hPAP recipients, i.e. F344 to 
F344-hPAP or transplantation of DA kidneys into F344-hPAP recipients, i.e. DA to F344-
hPAP. After F344 to F344-hPAP transplantation, kidneys showed occasional tubular 
dilatation (Figure 1 C). DA to F344-hPAP kidney transplantation resulted in more severe 
renal tubular dilatation compared to F344 to F344-hPAP kidney transplantation and 
large interstitial inflammatory infiltrates (Figure 1 0). 
Renal function reflected by total urine protein, did not differ significantly between 
F344 to F344-hPAP transplanted rats and F344 healthy controls and between DA to 
F344-hPAP transplanted rats and DA healthy controls (Figure 1 E). Moreover, total urine 
protein was similar in rats subjected to F344 to F344-hPAP transplantation and DA 
to F344-hPAP transplanted rats (Figure 1 E). Creatinine clearance in rats after F344 to 
F344-hPAP kidney transplantation was lower, albeit not significantly lower, compared 
to F344 healthy controls (Figure l F). After DA to F344-hPAP kidney transplantation, 
creatinine clearance decreased significantly compared to DA healthy controls (Figure 
1 F). Moreover, creatinine clearance was similar in rats after F344 to F344-hPAP and 
after DA to F344-hPAP kidney transplantation (Figure 1 F). 
Renal infiltration of recipient-derived cells 
Staining by enzymatic conversion of substrate by hPAP was used to detect the 
presence of recipient-derived cells in the transplanted kidney. Specificity of hPAP 
staining and adequate blocking of endogenous AP was demonstrated in DA (Figure 
2A) and F344 contralateral donor kidneys, showing no expression of hPAP, and in 
nephrectomized F344-hPAP kidneys (Figure 2B), showing ubiquitous expression 
of hPAP. Transplantation of DA or F344 donor kidneys into F344-hPAP recipient rats 
enabled tracking of recipient-derived cells in the transplanted kidney by hPAP staining. 
The number of recipient-derived cells in the renal interstitium was quantified using 
computerized morphometry. After F344 to F344-hPAP kidney transplantation a low 
number of recipient-derived hPAP+ cells infiltrated the kidney, present as single cells, 
randomly scattered in the renal interstitium (Figure 2C, E). Compared to F344 to F344-
hPAP, DA to F344-hPAP transplanted kidneys were infiltrated by a significantly higher 
number of recipient-derived hPAP+ cells, located in both perivascular and peritubular 
foci (Figure 2D, E). In this latter model, these cells were mainly macrophages, CD4+ and 
cos+ T-cells, whereas after F344 to F344-hPAP transplantation less interstitial co4+ 






Figure 1. Renal morphology and function. Representative renal morphology is shown for PAS-stained 
sections of the contralateral kidney of a DA donor (A), the nephrectomized kidney of a F344-hPAP recipient 
(BJ and kidneys isolated on day 14 after F344 to F344-hPAP (CJ or DA to F344-hPAP (DJ transplantation. Lens 
magnification 200x. Renal function was determined by total urine protein (E) and creatinine clearance (F). 
Bars indicate the mean total urine protein or creatinine clearance per group and SEM. 
Tubular epithelial engraftment of recipient-derived cells 
Tubular epithelial engraftment of recipient-derived cells was detected in  F344 to 
F344-hPAP and DA to F344-hPAP kidney transplants using hPAP immunostaining. 
Occasionally hPAp+, recipient-derived, cells were detected within tubular cross­
sections (Figure 3A). Epithelial phenotype of the engrafted recipient-derived cells was 
demonstrated by immunofluorescence double-staining combining hPAP with the 
epithelial-specific marker E-cadherin (Figure 3B-D). Moreover, we showed that tubular 
engrafted recipient-derived cells bound tubular epithelial-specific lectins (Figure 
3E-G). These engrafted hPAP+ cells did not express the common leukocyte antigen 
CD45 (not shown). After DA to F344-hPAP kidney transplantation the percentage of al l  
106 
RECIPIENT-DERIVED CELL DIFFERENTIATION IN RENAL TRANSPLANTS 
E 
Figure 2. Renal infiltration of recipient-derived cells. hPAP activity is shown in contralateral non-transgenic 
DA (AJ, nephrectomized transgenic F344-hPAP (BJ and kidneys isolated on day 14 after F344 to F344-hPAP (CJ 
or DA to F344-hPAP (DJ kidney transplantation. Lens magnification 200x. The percentage of hPAP-stained 
area was quantified by computerized morphometry (EJ. Bars indicate the mean percentage of hPAP-stained 
area per group and SEM. 
renal tubular cross-sections containing at least one hPAP+ cell (9.7%) was significantly 
increased compared to engraftment after F344 to F344-hPAP kidney transplants 
(4.0%) (Figure 3H). The percentage of recipient-derived tubular cells after DA to F344-
hPAP transplantation (0.9%) was increased, albeit not significantly, as compared to the 
percentage after F344 to F344-hPAP transplantation (0.5%, P=0.0931) (Figure 31). The 
extent of recipient-derived cell engraftment did not correlate with the intensity of 
hPAP+ cell infiltration (not shown). 
Renal interstitial myofibroblasts and collagen Ill deposition 
In contralateral F344 (Figure 4A, E) and nephrectomized F344-hPAP (Figure 4B, E) 
kidneys, a-SMA+ myofibroblasts were sporadically present. F344 to F344-hPAP kidney 
transplantation elicited compared to contralateral and nephrectomized kidneys, a 
significant increase in the number of renal interstitial myofibroblasts (Figure 4C, E). A 
significant increase in renal interstitial myofibroblasts was also observed after DA to 
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Figure 3. Tubular epithelial engraftment of recipient-derived cells. hPAP staining was occasionally observed 
in tubular engrafted cells (A) in kidneys after F344 to F344-hPAP (shown here) and DA ta F344-hPAP kidney 
transplantation. Arrow indicates an example of tubular epithelial recipient-derived cell engraftment. Lens 
magnification 1000x. Epithelial phenotype of the engrafted recipient-derived cells was demonstrated by 
double-staining for hPAP (BJ and E-cadherin (CJ. The overlap of signal is shown in the overlay (DJ. Moreover, 
tubular engrafted recipient-derived cells (E) expressed tubular epithelial-specific lectins (F). The overlap of 
signal is shown in the overlay (G). Arrows indicate double-positive cells. Tubular epithelial engraftment of 
recipient-derived cells was quantified as the percentage of hPAf>+ tubuli (HJ and os the percentage of hPAf>+ 
tubular engrafted cells (I). Bars indicate the mean percentage of hPAp+ tubuli or of hPAf>+ tubular engrafted 
cells per group and SEM. 
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F344-hPAP kidneys (Figure 4D, E). Moreover, the presence of renal interstitial 
myofibroblasts in the graft was significantly higher after DA to F344-hPAP, compared 
to F344 to F344-hPAP kidney transplantation (Figure 4E). 
Renal interstitial collagen Ill deposition was similar in the renal interstitium of 
contralateral F344 kidneys (Figure 4F, J) and nephrectomized F344-hPAP kidneys 
(Figure 4G, J). After F344 to F344-hPAP kidney transplantation, renal interstitial 
collagen Ill deposition was not increased compared to the control kidneys (Figure 4H, 
J). DA to F344-hPAP kidney transplantation resulted in a significant increase in renal 
interstitial collagen Ill deposition compared to contralateral DA kidneys and F344-
hPAP nephrectomized kidneys (Figure 41, J). Moreover, collagen Ill deposition after 
DA to F344-hPAP kidney transplantation was significantly increased compared to 
deposition in F344 to F344-hPAP kidney transplants (Figure 4J). 
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Figure 4. Renal interstitial myofibroblasts and collagen Ill deposition. The presence of renal myofibroblasts 
was detected by staining for a-SMA on a contra lateral F344 kidney (A), a nephrectomized F344-hPAP kidney 
(8) and kidneys isolated on day 14 after F344 to F344-hPAP (C} or DA to F344-hPAP (D} kidney transplantation. 
Lens magnificatian 200x. The percentage of a-SMA-stained area was quantified by computerized 
morphometry (E). Bars indicate the mean percentage of a-SMA-stained area per group and SEM. All a­
SMA-positive vascular structures were excluded from quantitative analysis. Renal interstitial collagen Ill 
protein deposition is shawn in a contralateral F344 kidney (F), a nephrectomized F344-hPAP kidney (G) 
and kidneys isolated on day 14 after F344 to F344-hPAP (H) or DA to F344-hPAP (I) kidney transplantation. 
Lens magnification 200x. The percentage of collagen I/I-stained area was quantified with computerized 
morphometry (J). Bars indicate the mean percentage of collagen I/I-stained area per group and SEM. Con = 




To determine the presence of myofibroblasts originating from extra-renal, i.e. recipient­
derived, sources after F344 to F344-hPAP and DA to F344-hPAP kidney transplantation, 
we used double staining with hPAP, to detect recipient-derived cells (Figure SA), and 
a-SMA, to detect myofibroblasts (Figure 58). After both F344 to F344-hPAP and DA to 
F344-hPAP kidney transplantation, double-positive, recipient-derived myofibroblasts 
were observed in the renal interstitium (Figure SC). In these cells, co-expression of 
the reporter marker hPAP (FITC) and the myofibroblast marker a-SMA (TRITC) was 
detected in 8/10 consecutive confocal optical sections of the Z-series, confirming the 
double-positivity of these cells and excluding the possibility that the two markers 
were expressed by different, neighboring cel ls .  We expressed the percentage of 
recipient-derived myofibroblasts in relation to al l  renal infi ltrated recipient-derived 
cel ls  (Figure SD) and in relation to al l  renal myofibroblasts (Figure SE). Of al l  interstitial 
recipient-derived cells, an average of 1 .9% after F344 to F344-hPAP transplantation 
and 2.6% after DA to F344-hPAP transplantation expressed the myofibroblast marker 
a-SMA (P=0.1 77S) (Figure SD). The recipient-derived myofibroblasts constituted up 
to 28% after F344 to F344-hPAP transplantation and 39% after DA to F344-hPAP 
transplantation of al l  renal interstitial myofibroblasts (P=0.2468) (Figure SE). The 
presence of recipient-derived myofibroblasts in kidneys after F344 to F344-hPAP and 
DA to F344-hPAP transplantation were not significantly different (Figure SD, E). 
Discussion 
In this study we investigated for the first time tubular engraftment and myofibroblast 
differentiation of recipient-derived cells in an early window of renal repair and possible 
onset of fibrosis in a rat model of kidney transplantation. Kidney transplantation 
resulted in engraftment of recipient-derived cells in the tubular epithelium by day 14 
after transplantation. Moreover, recipient-derived myofibroblasts were present in the 
renal interstitium after transplantation at this time point. 
Engraftment and differentiation of recipient-derived cells in human allografts has 
been studied at long term, but not at short term after transplantation. Yet, using a 
model of warm IRI, which forms an unavoidable damage hit during transplantation, we 
previously identified an early window of repa ir and remodeling, which may determine 
organ performance. In  this model, BMDC sporadically engrafted tubuli (9), while they 
contributed substantially to the interstitial myofibroblast pool (1 0). Based on these 
findings we asked whether, early after transplantation, recipient-derived cells may 
contribute to tubular epithel ial regeneration by tubular engraftment or to the early 
onset of fibrosis by differentiation to myofibroblasts, in this early time window. 
Tubular engraftment of recipient-derived cel ls was present after both syngeneic and 
al logeneic transplantation. The low percentage of engrafted tubular cross-sections 
and engrafted cells observed in this study after syngeneic and al logeneic kidney 
transplantation was comparable to the sporadic tubular engraftment of BMDC we 
previously observed after IRI (9). However, in this study, an increased number of tubuliar 
cross-sections was engrafted by at least one recipient-derived cell after a l logeneic 
transplantation, as compared to syngeneic transplantation. This phenomenon was 
accompanied by an increased, albeit not significantly, percentage of recipient-derived 
tubular cel ls. In the l ight of our previous results, demonstrating that the severity of 
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Figure S. Recipient-derived myofibroblasts. The presence of recipient-derived myofibrob/asts was 
determined by confocal microscopy of staining for hPAP (FITC) (A) in combination with a-SMA (TR/TC) (BJ 
on kidney tissue, isolated on day 14 after transplantation. The overlay shows FITC, TR/TC and OAP/ channels 
and the x/z and y/z planes underneath and on the right of the merged picture demonstrate co/ocalization 
of the markers (CJ. Arrow indicates a group of double-positive cells. Open arrowhead indicates hPAP single­
positive cell. Asterisk indicates a-SMA single-positive cell. Arrowheads indicote co-expression in the x/z and 
y/z planes. Ca-expression of hPAP and a-SMA was quantified in relation to all renal infiltrated recipient­
derived cells (DJ and in relation to the renal interstitial myofibroblast population (E). Bars indicate the mean 
percentage hPAP/a-SMA double-positive cells of all hPAP' cells or of all a-SMN cells per group and SEM. 
ischemic damage was associated with an increased number of BMDC-engrafted 
tubuli (9), it is conceivable that increased tubular damage after allogeneic kidney 
transplantation accounts for increased tubular engraftment of recipient-derived cells. 
This concept is in accordance with clinical studies in which the severity of graft damage 
was shown to correlate with the extent of engraftment of recipient-derived cells in 
damaged structures (3;5). However, we never observed more than one or occasionally 
two engrafted recipient-derived cells per tubular cross-section, indicating that the 
'per-tubule' amount of damage was similar in both groups. Moreover, the damage 
inflicted by the combination of ischemia and allogeneic transplantation was possibly 
amplified by administration of ciclosporin in the allogeneic transplanted rats. 
In mouse models of bone marrow transplantation it was shown that BMDC were able to 
differentiate to myofibroblasts in many tissues, including the gut, lung, and kidney (16-
20). Our previous data showed that after an acute ischemic insult, BMDC infiltrated the 
kidney and, by differentiation to procollagen I-producing myofibroblasts, contributed 
significantly to the interstitial myofibroblast population (10). Based on these findings, 
we here asked whether, early after kidney transplantation, recipient-derived cells 
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derived myofibroblasts were present in the transplanted kidney, constituting up to 
40% of all renal interstitial myofibroblasts in both settings. However, after allogeneic 
transplantation the absolute number of total infiltrating recipient cells is higher than in 
syngeneic transplanted kidneys. Since this total population of recipient-derived cells 
comprises myofibroblast progenitors, it is reasonable to conclude that the absolute 
number of recipient-derived myofibroblasts in the allogeneic transplantation setting 
is also higher. Regardless of absolute numbers of recipient-derived myofibroblast 
precursors in the two transplantation settings, the fact that their relative contribution 
to the interstitial myofibroblast population is similar suggests that the mechanism 
driving the differentiation of recipient-derived cells towards myofibroblasts must 
be shared by both settings. Obviously, the quantitative outcome of recipient cell 
differentiation by this mechanism is higher in the allogeneic transplantation situation, 
due to increased input of recipient-derived cells in the transplanted kidney. What the 
impact of this increased population of myofibroblast progenitor cells will be on long­
term graft function is not known. 
The current study is the first to describe the differentiation fate of recipient-derived 
cells in the transplanted rat kidney. Using a rat model of kidney transplantation we 
were able to investigate the short term effects of ischemia-associated (syngeneic) and 
allogeneic transplantation-associated injury on tubular engraftment and myofi broblast 
differentiation of recipient-derived cells, in a previously described early window of 
regeneration and possible onset of renal interstitial fibrosis. Our results indicated that 
allogeneic transplantation-associated injury, superimposed on ischemic damage, 
increases tubular engraftment of recipient-derived cells, while it does not affect their 
relative contribution to the renal interstitial myofibroblast population. 
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Vascular damage in transplanted kidneys may be repaired by engraftment of 
host endothelial progenitor cells (EPC). However, it is unknown in how far the 
mobilization and angiogenic function of EPC in kidney transplant recipients early after 
transplantation (TX) may be affected by previous chronic kidney disease (CKO) and 
immune suppression. To address this issue we conducted a cross-sectional study in 
37 consecutive kidney transplant recipients included ± 14 days after TX, of which 17 
patients underwent acute rejection (TX-RX) ± 7 days after TX and 20 patients were 
complication-free (TX-CF). Twenty-two patients with stage 4 CKO and 22 healthy 
individuals were included as controls. Circulating CO34-expressing EPC and co­
expressing homing receptors VEGFR-2, CXCR4, EPO-R and c-Met were quantified by 
flow cytometry. The in vitro endothelial differentiation capacity of MNC was assessed 
and transcripts of the E(P}C molecules VE-cadherin, CO31, COlOS, VEGFR-2, VEGF­
A, eNOS and vWF were identified by RT-PCR. We found decreased numbers and 
partially impaired function of human EPC at short term after kidney transplantation, 
and showed that these phenomena are associated with impaired renal function and 
immune suppression. These findings raise the question whether EPC are able to play a 
functional role in early vascular repair in kidney grafts. 
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Introduction 
During the peri-transplantation (TX)- and early post-TX period, the kidney (similar 
to other transplanted solid organs) undergoes a variable amount of damage under 
the cumulative pressure of insults such as ischemia, inflammation, immune rejection 
and exposure to immunosuppressive therapy (1ST). This damage is reflected by 
morphological and functional alterations in the graft and sets the scene for the 
progression of chronic graft failure (1). 
In response to acute damage the kidney calls upon a number of innate repair 
mechanisms, among which proliferation and migration of renal endothelial and 
epithelial cells, which repopulate denuded areas of these respective tissues (2-
4), and extracellular matrix deposition by renal myofibroblasts, which provides 
structural integrity to the organ (5;6). Moreover, host-derived endothelial, epithelial 
and myofibroblast cells can be detected in kidney grafts at long time periods after 
transplantation (7-14), raising the possibility that extra-renal cells may also participate 
in graft repair. Although the origin of these host-derived cells is under debate, the 
prevailing scenario states that they are derived from bone marrow stem/progenitor 
cells. This scenario is corroborated by recent studies that show engraftment of bone 
marrow-derived cells in various kidney substructures after acute ischemic renal 
damage (15-18). Importantly, these studies identify an early window of renal bone 
marrow-derived cell engraftment after acute damage, in which repair is proposed to 
take place. This early window has received little attention in the setting of clinical and 
experimental transplantation, where graft repair has been typically studied at long­
term follow-up. 
In solid organ transplants the primary target of damage is the vasculature, since the 
endothelium is the first tissue to undergo ischemia, while also forming the interface 
between the donor organ and the immune system of the host. Indeed, we have 
shown that graft-derived, circulating endothelial cells, a hallmark of endothelial 
anoikis, reflect vascular injury in transplanted kidneys (19). Studies in patients with an 
acute cardiovascular ischemic insult, such as myocardial infarction, have reported a 
wave of increased mobilization of endothelial progenitor cells (EPC) to the circulation 
during the first week following the vascular insult (20). These cells can incorporate into 
regenerating blood vessels and are therefore thought to participate in vascular repair 
(21-23). 
While the phenomenon of EPC mobilization early after graft damage has not been 
studied in kidneytransplant recipients, it is conceivable that, by extrapolation offindings 
in patients with cardiovascular ischemia, temporary graft ischemia (or acute rejection 
episodes) should elicit a similar effect. So far, the only indication for mobilization of 
host-derived EPC is the detection of host-derived endothelial cells in donor vasculature 
at long term after TX (7;10;13;14). However, a complicating factor in the interpretation of 
engraftment data in kidney transplant recipients is the finding that a history of chronic 
kidney disease (CKD), resulting in uremia and long-term exposure to toxic products, is 
associated with decreased numbers and impaired angiogenic function of EPC (24-30). 
Thus, it is conceivable that mobilization and angiogenic function in kidney transplant 
recipients early after TX may be, to an unknown extent, affected by previous CKD. 
In the current study we aimed at filling this information gap by investigating numbers 
and in vitro angiogenic function of EPC in kidney transplant recipients at short-term 
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follow-up. To assess the impact of post-TX complications, such as acute rejection, on 
EPC, patients were stratified by the presence or absence of acute rejection. Moreover, 
to estimate the impact of a previous history of chronic kidney disease on EPC, patients 
with stage 4 CKD were included as a control group. To our knowledge, this is the first 
study documenting EPC numbers and function in kidney transplant recipients in 
relation to these relevant parameters at short term after TX. 
Materials and Methods 
Study Groups 
In a cross-sectional, prospective study, 17 consecutive renal transplant recipients 
undergoing biopsy-proven acute graft rejection (TX-AR) were included at 10.5±1.5 days 
after biopsy, corresponding to 17±2 days after TX (Table 1). All TX-AR patients received 
a standard immunosuppressive (i.s.) regimen consisting of ciclosporin (CsA; Neoral•, 
Novartis) (or tacrolimus; Prograf•, Astellas), methylprednisolone and mycophenolate 
mofetil (MMF; Cellcept", Roche) (or mycophenolic acid (MPA); Myfortic•, Novartis) 
supplemented with additional anti-rejection medication consisting of anti-thymocyte 
globulin, methylprednisolone, or combinations thereof. 
Twenty consecutive complication-free renal transplant recipients (TX-CF) (i.e. patients 
without acute rejection, acute tubulus necrosis or opportunistic infections in the period 
between transplantation surgery and inclusion) were included at 13±1 days after TX 
(Table 1). These patients received a standard i.s. regimen (see above). Eleven of these 
patients were studied again at 146±16 days after TX, after tapering of i.s. medication 
and/or improvement of kidney function. 
Twenty-two consecutive patients with stage 4 chronic renal failure (CKD; mean 
duration of stage 4 chronic renal failure 57±4 months months, range 9-168 months) 
were included as controls. These patients had a mean creatinine clearance of 18.1±1.3 
ml/min (range 15-29 ml/min) for at least 4 months and thus were uremic. In all study 
groups, exclusion criteria were the presence of diabetes mellitus, vasculitides or other 
chronic inflammatory diseases, neoplasms, cardiovascular events and transplantations 
less than one year prior to kidney TX. Previous medications were continued. 
Twenty-two healthy controls (HC; 15 male, 7 female, age 42±3 years) were also 
included. 
The study protocol was approved by the Institutional Review Board of the University 
Medical Centre Groningen and was consistent with the principles outlined in the 
Declaration of Helsinki. Informed consent was obtained. 
Flow Cytometry 
Mononuclear cells (MNC) were isolated from 10 ml of heparinized peripheral blood 
by lymphoprep density gradient centrifugation (Axis-Shield, Oslo, Norway). Cell 
counts were performed using Coulter Counter (Beckman Coulter, Mijdrecht, The 
Netherlands). 
CD34-expressing circulating EPC (cEPC) were quantified byflowcytometry(FACScalibur, 
Becton Dickinson, Sharon, MA), using PERCP-labelled mouse anti-human CD34 
monoclonal antibody (moAb) (Becton Dickinson). To assess the expression of homing 
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Table 1 .  Clinical data of kidney transplantation patients 
No. Clln. Gender Age Donor Isch. t. (min.) l.s. C.c. iltrx-1nctuslon AtrRX�ncluslon lndlc. !m/f) (ys.) c/w (mUmln.) !ds.) !ds.) 
TX-AR m 57 LUR 1 96/50 MMF, CsA, P 36 7 7 
2 TX-AR m 56 LUR 211/52 MPA, CsA, P 31 7 6 
3 TX-AR m 55 NHB 1000/62 MPA, CsA, P dialysis 40 2 1  
4 TX-AR m 42 HB 1 230/35 MPA, CsA, P dialysis 16  14 
5 TX-AR m 45 HB 1467/32 MPA, CsA, P 1 9  1 9  1 
6 TX-AR m 52 HB 802/49 MMF, CsA, P 21 1 6  7 
7 TX-AR 34 HB 30/997 MPA, CsA, P 16  24 1 2  
8 TX-AR m 1 8  HB 1 1 1/29 MMF, CsA, P dialysis 14  6 
9 TX-AR m 57 NHB 780/40 MMF, CsA, P 32 64 30 
10 TX-AR 27 LR 1 37/43 MPA, CsA, P dialysis 21 1 8  
1 1  TX-AR m 60 NHB 1012/59 MPA, CsA, P dialysis 1 5  5 
1 2  TX-AR m 48 LUR 1 20/40 MPA, CsA, P 55 14 8 
1 3  TX-AR m 37 LR 1 82/51 MPA, CsA, P 81 1 0  8 
14 TX-AR 32 HB 796/41 MPA. Tac, P 32 29 7 
15  TX-AR 68 LUR 1 50/48 MMF, CsA, P dialysis 21 1 3  
16 TX-AR 28 NHB u.k MMF, CsA, P 1 8  25 9 
1 7  TX-AR m 41 LR 1 20/30 MPA. CsA, P dialysis 9 7 
1 8  TX-CF 44 LR 1 70/45 MMF, CsA, P 72 8 
19 TX-CF m 70 HB 1 060/40 MMF, CsA, P 63 1 6  
1 9/1 TX-CF 55 126 
20 TX-CF m 39 LR 1 1 7/41 MMF, CsA, P 47 1 6  
20/1 TX-CF 47 1 1 3  
21 TX-CF m 65 HB 1 1 21/50 MMF, CsA, P 57 16 
21/1 TX-CF 61 1 05 
22 TX-CF m 41 LR 94/35 MMF, CsA, P 71 1 6  
22/1 TX-CF 58 105 
23 TX-CF 48 HB 1440/50 MMF, Tac., P 45 16 
23/1 TX-CF 49 89 
24 TX-CF 24 LR 144/38 MMF, CsA, P 66 8 
25 TX-CF m 67 HB 1 590/30 MMF, CsA, P 49 9 
25/1 TX-CF 65 212 
26 TX-CF m 57 LR 1 76/34 MMF, CsA, P 69 1 0  
26/1 TX-CF 64 203 
27 TX-CF 37 HB 1440/42 MMF, CsA, P 38 1 2  
27/1 TX-CF 56 77 
28 TX-CF m 56 HB 900/34 MMF, CsA, P 76 1 3  
28/1 TX-CF 93 213 
29 TX-CF m 73 HB 1 182/55 MMF, CsA, P 46 14 
29/1 TX-CF 62 201 
30 TX-CF m 65 HB U.k. MMF, CsA, P 28 1 5  
31 TX-CF 46 NHB 801/96 MMF, CsA, P 31 1 3  
31/1 TX-CF 46 1 58 
32 TX-CF 41 HB 28/1084 MMF, CsA. P 43 18 
33 TX-CF m 58 LUR 41/149 MMF, CsA, P 61 14 
34 TX-CF 58 LUR 49 MPA, CsA, P 60 14 
35 TX-CF m 27 LUR 48 MPA, CsA, P 56 14 
36 TX-CF 58 HB 29 MPA, CsA, P 65 13  
37 TX-CF 47 LUR 120 u.k. 77 49 
Abbreviations: II= late re-inclusion (of some TX-CF patients); m: male; f= female; ys.=years; WR= living 
unrelated; LR= living related; NHB= non-heartbeating; HB= heartbeating; isch. t= ischemic time; clw= 
cold/warm (ischemia); u.k= unknown; i . s .= immune suppression; C.c= creatinine clearance (shown at 
inclusion); TX=transplantation; RX=rejection; ds= days; MMF= mycophenolate mofetil; CsA= ciclosporin; 




receptors on CD34+ cEPC, double staining for CD34, as described, and VEGFR-2 (mouse 
anti-human VEGFR-2-biotin, Sigma-Aldrich, St. Louis, USA), CXCR4, (mouse anti-human 
CXCR4-APC), EPO-R (mouse anti-human EPO-R-PE) or c-Met (mouse anti-human c­
Met-biotin; all from R&D Systems, Minneapolis, USA) was performed. As a secondary 
conjugate we used streptavidin-FITC (DAKO, Glostrup, Denmark). All incubations were 
performed for 30 min on ice in the dark and were followed by appropriate washing 
steps. FACS data were analysed using Winlist 5.0 software (Verity, Topsham, ME). 
Cell culture 
1x106 MNC were plated in 24-wells tissue culture plates (Corning Inc., NY, USA ) coated 
with 1% v/v gelatine and 5µg/ml fibronectin (Peprotech, NJ, USA), in RPMI medium 
containing 20% FCS, 5 µg/ml ECGF, 1 ng/ml VEGF and 10 ng/ml bFGF. Cells were 
cultured in a humidified incubator at 5% CO2, 37
°C for 6 days, when colony forming 
units (CFU) were counted. Microscopy was performed using a Leica DMLB microscope, 
Leica DC300F camera and Leica Qwin 2.8 software (Leica Microsystems, Rijswijk, The 
Netherlands). Colony size was determined by computer-assisted planimetry, using 
lmageJ software. 
lmmunofluorescent stainings 
Cultured cells were harvested 6 days after plating, cytospun and double-stained 
with mouse anti-human CD31 (DAKO) and rabbit anti-eNOS (BD), to assess their 
endothelial phenotype. DAPI (Sigma-Aldrich) was used as a nuclear dye. Secondary 
antibodies were donkey anti-mouse-RedX or donkey anti-rabbit-Cy5 (both from 
Jackson lmmunoResearch, Cambridgeshire, UK). Microscopy equipment was used as 
described. 
RT-PCR 
Total RNA was isolated from day 6 cell cultures using the Absolutely RNA Microprep Kit 
(Stratagene, TX, USA). RNA purity and concentration were measured using Nanodrop 
equipment (NanoDrop Technologies, NC, USA). After DNase treatment (Absolutely 
RNA Microprep Kit), copy DNA was synthesized (Kit 1612, Fermentas Vilnius, Lithuania). 
RT-PCR was performed on a PTC-200 PCR machine (MJ Research Inc, MA, USA), in a final 
volume of 25 µI, containing 23 µI PCR Master Mix, 1 µI primers for a-SMA and the EC 
markers VE-cadherin, CD31 (PECAM), CD105 (endoglin), VEGFR-2 (FLK-1), VEGF-A, eNOS, 
vWF and the housekeeping gene beta-2 microglobulin, and 5 ng cDNA. Amplification 
conditions were 92 °c for 3 min (denaturation), followed by 35 cycles of 94°C for 45 s 
(denaturation), 57°C for 45 s (annealing) and 72°C for 1 min (elongation), followed by 
72 °C for 3 min. PCR products were visualized on 1% agarose gels by electrophoresis. 
Statistics 
All statistical analyses were performed using GraphPad Prism 4.0 (GraphPad Software, 
San Diego California, USA) and SPSS 12.0 software (SPSS Inc., Chicago, USA). One-way 
ANOVA tests were performed to determine differences between experimental groups. 
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Differences between paired samples were determined using the Wilcoxon matched 
pairs test. Pearson or Spearman correlation tests were performed to determine the 
relationship between different parameters. P-values <0.05 were considered statistically 
significant. Values exceeding the mean ± 2x5D were excluded from analyses. 
Results 
Numbers of co34+ cEPC 
Numbers of cEPC were assessed in all groups using flow cytometric analysis of CD34 
expression, an accepted marker for cEPC. CD34+ cells were detected within the 
mononuclear cell gate and typically featured a low side-scatter (not shown). 
Healthy controls had an average of 1370 co34+ cEPC/ml blood (range 800-2360 
cells/ml) (Figure l A). In the TX-AR group, numbers of co34+ cEPC were app. 4 times 
lower (mean 350 cells/ml, range 48-1080; P<0.001) than in healthy controls (Figure 
l A). Numbers of CD34+ cEPC in TX-AR patients correlated with white blood cell (WBC) 
numbers (P=0.007; r=0.7). 
To test whether the drastic decrease in cEPC numbers in TX-AR patients was attributable 
to additional immunosuppressive medication (high-dose methylprednisolone, 
anti-thymocyte globulin), we included a group of TX patients who did not undergo 
complications after kidney TX (complication-free, TX-CF) and therefore received 
a standard immunosuppressive regime (CsA, methylprednisolone, MMF or MPA), 
only. While numbers of cEPC in TX-CF patients were app. 2.5x higher than in TX-AR 
patients (mean 830 cells/ml blood, range 63-3102, n.s), they were significantly lower 
than in healthy controls {1.5 times, P<0.01) {Figure lA). cEPC numbers in TX-CF patients 
correlated inversely with cold ischemia time (P=0.001; r=-0.68) and positively with 
warm ischemia time (P=0.0001; r=0.7). Moreover, there was an inverse correlation 
between cEPC numbers and methylprednisolone dosage (P=0.03; r=-0.44). 
Beside the impact of immune suppression on cEPC numbers in TX patients, a history 
of chronic renal fai lure has been reported to negatively affect cEPC numbers (24-30). 
Therefore we included a group of patients with stage 4 renal failure (CKD). Numbers 
of CD34+ cEPC in this group were significantly lower than in healthy controls (mean 
955 cells/ml blood, range 48-1080) (Figure lA), but significantly higher than in TX-AR 
patients (2.7 times; Figure l A). In CKD patients there was a weak inverse correlation 
between cEPC numbers and serum urea (P=0.04; r=-0.3), but not serum creatinine, 
creatinine clearance or proteinuria. Moreover, cEPC numbers correlated positively 
with serum CRP levels (P=0.02; r=0.7) and WBC counts (P=0.02; r=0.4). 
To further distinguish between the relative impact of renal function and 
immunosuppressive medication on cEPC numbers, we followed TX-CF patients 
longitudinally. Numbers of CD34+ cEPC were reassessed at a mean 146±16 days after TX, 
if patients had not developed complications (TX-related or other) in the intermittent 
period and if immune suppression was tapered. Eleven of 18 TX-CF patients fulfilled 
these criteria. In these patients CsA was significantly tapered in comparison to the 
first inclusion point from a mean 306 mg/day to a mean 233 mg/day {Figure 1B). 
Prednisolone was significantly tapered from 18 mg/day to a mean 10 mg/day (Figure 
lC). MMF was not tapered. Creatinine clearance improved in 6 of 11 patients but was 
not significantly higher at long-term follow-up at a group level (Figure 1 D). Numbers 
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of co34+ cEPC were significantly higher at long-term fol low-up (mean 1350 cells/ml 
blood, range 240-3219) than at first inclusion (mean 570 cel ls/ml blood, range 63-1490) 
(Figure l E). cEPC numbers correlated inversely with 24 hour proteinuria (P=0.03; r=-
0.54) and serum CRP levels (P=0.01; r=-0.9). 
No correlations with relevant parameters (age, gender, duration of disease, weight, 
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Figure 1:  Numbers of CD34• cEPC. cEPC were detected in the MNC cell subset by flow cytometric analysis of 
CD34 expression (A}. Patients 72, 14 (TX-AR) and 36, 37 (TX-CF) were excluded from the analysis since they 
were statistical outliers. Tapering of CsA (BJ and prednisolone (CJ, as well as changes in creatinine clearance 
(D) and numbers of CD34• cEPC at long-term follow-up (E) is shown for a subgroup of TX-CF patients 
followed longitudinally. Dots indicate individual patients, horizontal lines indicate the mean. Abbreviations: 
HC: healthy controls, CKD: chronic kidney disease; TX-CF: complication-free transplantation patients; TX-AR: 
transplantation patients with acute rejection. 
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Expression of homing receptors on co34+ cEPC 
Since numbers of co34+ cEPC were significantly lower in TX patients, we asked whether 
the mobilization of these cells to the circulation was impaired. It has been previously 
shown that growth factors such as stromal-derived factor-1 (SOF-1), erythropoietin 
(EPO), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) 
can recruit bone marrow-derived cEPC to the circulation (23;31-34). Therefore, we 
assessed the relative frequency of co34+ cEPC expressing the corresponding growth 
factor receptors as a measure of the capacity of these cells to be recruited to the 
circulation. 
In healthy controls, a fraction of co34+ cells (mean 4.3% of all co34+ cells, range 1,4-
8,6%) expressed CXCR4, the receptor for SOF-1 (Figure 2A). In TX-AR patients, who had 
the lowest number of co34+ cells, the percentage of CXCR4+ cells thereof was similar 
to that in healthy controls (mean 4.0% of co34+ cells, range 0.5-9.3%) (Figure 2A). The 
percentage of CO34+/CXCR4+ cells in TX-CF was slightly, albeit not significantly higher 
than in healthy controls (mean 6.4%, range 0-43.1%) (Figure 2A). In CKO patients the 
percentage of CXCR4+ cells within the CO34+ cell subset was similar to that in healthy 
controls (mean 2.3%, range 0.6-4.7%). 
Assessment of the relative frequency of EPO-R expressing cells within the co34+ cell 
subset again revealed no significant differences between the groups (Figure 2B) .  The 
mean percentage of EPO-R+ cells was similar in all groups (85.8% in healthy controls, 
78.6% in TX-AR, 80.9% in TX-CF and 80.9% in CKO), with minimum values ranging from 
34.73% (CKO) to 79.2% (healthy controls) and maximum values ranging from 90.0% 
(TX-AR) to 96.5% (TX-CF) (Figure 2B). 
More pronounced, albeit not consistently significant differences were present in 
percentages of co34+ cells expressing VEGFR-2, the receptor for VEGF-A (Figure 2C). 
While the frequency of CO34+/VEGFR-2+ cells was comparable in TX-AR patients (mean 
12.4%, range 1.6-24.3%) and healthy controls (mean 8.7%, range 4.1-16.2%), the latter 
was significantly higher than in TX-CF patients (mean 4%, range 1.3-10.7%; P<0.01) and 
CKO patients (mean 5.4%, range 0.3-10.2%; P<0.05) (Figure 2C). 
Finally, we assessed the percentage of co34+ cells expressing the HGF receptor c­
Met. The mean percentage of c-Mer+ cells was similar in healthy controls (mean 4.0%, 
range 2.7-6.0%), CKO patients (mean 3.1%, range 1.1-6.2%) and TX-CF patients (mean 
4.6%, range 0.9-9.1%) (Figure 20). The percentage of co34+ cells expressing c-Met was 
significantly higher in TX-AR patients (mean 10.7%, range 1.6-19.2%) than in healthy 
controls (P<0.01), CKO patients (P<0.001) and TX-CF patients (P<0.01) (Figure 2D). 
In vitro formation of endothelial outgrowth cells 
An alternative to phenotypic detection of EPC is their functional characterization as 
mononuclear cells that can differentiate to endothelial outgrowth cells (EOC) under 
angiogenic conditions in vitro (35;36). 
When cultured under angiogenic conditions for 6 days, MNC from healthy controls 
developed colonies, as described previously (21). The mean number of colonies in 
healthy controls (35 colonies/cm2, range 1.5-61) did not differ significantly from that 
in TX-AR patients (mean 36 colonies/cm2, range 0-83.7) or CKD patients (mean 40.5 
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Figure 2: Expression of homing receptors on CD34· cEPC. The percentage of CD34' cEPC expressing the 
homing receptors CXCR4 (A), EPO-R (B), VEGFR-2 (C) and c-Met (DJ was determined by dual stainings, 
followed by flow cytometric analysis. Statistical outliers were excluded from graphs (CXCR4: TX-AR # 14, 
TX-CF #19; EPO-R: TX-AR # 2, 4; VEGFR-2: TX-CF #20; c-MET: TX-CF #20). Dots indicate individual patients, 
horizontal lines indicate the mean. 
CF patients the number of colonies was app. 3.5 times lower than in healthy controls 
(mean 10.7 colonies/cm2, range 0-32.5), differences with healthy controls or other 
groups were not statistically significant (Figure 3A). 
While the number of colonies did not differ significantly between groups, the 
morphology and size of colonies clearly indicated lower in vitro differentiation capacity 
of MNC from TX- and CKD patients. MNC from healthy controls formed CFU consisting 
of spindle-shaped cells (Figure 3B). In CKD patients colonies were smaller in size than 
in healthy controls, albeit not significantly (Figure 3C,F). Moreover, the typical spindle 
shape of cells constituting colonies from healthy MNC (Figure 3B) was reduced in CKD 
colonies (Figure 3C). In TX-CF patients colony size was significantly smaller than in 
healthy controls (mean 0.01mm2, range 0.001 -0.03; P<0.05) (Figure 3D,F) and spindle 
shape of constituting cells was virtually absent (Figure 3D). Similarly, colony size in 
cultures from TX-AR MNC were significantly smaller than in healthy controls (mean 
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0.01 mm2, range 0.004-0.02; P<0.05) (Figure 3E,F) and spindle-shaped cells were absent 
(Figure 3E). There was no statistical correlation between the number or size of CFU and 






















Figure 3: In vitro formation of endothelial outgrowth cells. Total MNC were cultured under angiogenic 
conditions for 7 days, when CFU were quantified (AJ. CFU from healthy individuals (BJ, CKD patients (CJ, TX-CF 
patients (DJ and TX-AR patients (E) differed in morphology and size. CFU size was determined by computer­
assisted planimetry (F). Means (bars) and SEM are shown. N=6 individuals/group. Lens magnifications 
100x. 
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Endothelial characteristics of EOC 
EOC from healthy controls were large, flat cells that co-expressed CD31 on the cell 
membrane and eNOS in intracytoplasmic vesicles (Figure 4B). While EOC from CKD 
patients were comparable in shape and expression of CD31 and eNOS to healthy 
EOC (Figure 4C), cells from TX patients retained the morphology of healthy EOC but 
displayed lower expression of CD31 and eNOS. Moreover, CD31 was no longer confined 
to the cell membrane but was also detectable in the cytoplasm (not shown). Due to 
this phenotypic variation of EOC between groups we used morphology as a criterion 
for quantification. Based on this criterion, numbers of EOC were present at similar 
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Figure 4: Endothelial characteristics ofEOC. After 7 days of culture under angiogenic conditions, MNC were 
isolated, cytospun and stained for CD31 (red) and eNOS (green). (A) HUVEC control. (BJ MNC from HC. (C) 
MNC from CKD patients. Lens magnification 400x. Cells expressing CD31 (white bars), eNOS (gray bars) and 
CD37/eNOS-double positive cells (black bars) were quantified (D). Means (bars) and SEM are shown. Due to 
poor culture behavior, cells from only 7/5 TX-AR patients could be obtained for staining. 
Since, especially in patients, the number of cultured cells and thus cytospot material 
for immunophenotyping was limited, we extended our endothelial marker analysis 
by RT-PCR (Table 2). VEGF transcripts were detected in cultured cells from all healthy 
controls and CKD patients and in most TX-CF and TX-AR patients. Transcripts for the 
VEGFR-2 were detected with variable frequency in all groups, confirming previous 
reports of the instability of this transcript (37). Transcripts of vWF were present in all 
cultures derived from healthy controls and in all but one cultures from CKD patients, 
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but only in approximately half of the cultures from TX-CF and TX-AR patients. VE­
cadherin was expressed at variable frequency in all groups, while CD105 (endoglin) 
transcripts were present in all cultures from healthy controls and CKD patients, and 
in all but one cultures from TX-CF and TX-AR patients. Transcripts for a-SMA were 
detected in all subjects, irrespective of group (Table 2). 
Table 2: Endothelial transcripts in EOC. 
HC CKD TX-CF TX-AR 
�2M 5/5 6/6 4/4 5/5 
aSMA 5/5 6/6 4/4 5/5 
VE-cadherin 2/5 3/6 1 /4 1 /5 
CD31 (PECAM) 5/5 5/6 4/4 5/5 
CD105 (Endoglin) 5/5 6/6 3/4 4/5 
VEGFR-2 (FLK-1 ) 1/5 5/6 0/4 1 /5 
VEGF-A 5/5 6/6 3/4 4/5 
eNOS 3/5 5/6 1 /4 4/5 
vWF 5/5 4/6 2/4 3/5 
Numbers denote in how many patients out of the total group o transcript was detected by PCR. 
Discussion 
In the current study, we show decreased numbers and partially impaired function of 
human EPC at short term after kidney transplantation, and show that these phenomena 
are associated with impaired renal function and immune suppression. 
Based on their vascular engraftment, EPC have been proposed to contribute to blood 
vessel repair (21-23). Although this contribution is difficult to demonstrate formally, 
especially in human individuals, EPC are attributed therapeutic value. In conditions 
associated with acute ischemia (e.g. acute myocardial infarction), EPC are transiently 
mobilized to the circulation, suggesting that they may be recruited to the site of 
vascular injury (20). In patients with chronic cardiovascular or renal disease, however, 
the number and angiogenic capacity of circulating EPC (cEPC) is low (24-30), suggesting 
that the contribution of these cells to vascular repair may be impaired. 
Shortly after transplantation, the donor kidney undergoes vascular damage due 
to ischemia, immune rejection and immunosuppressive therapy. In this early time 
window after transplantation, rapid and adequate repair of graft vasculature, e.g. by 
recipient EPC, is important, since the initial amount of graft damage has been shown 
to determine long-term graft survival (1). However, kidney recipients typically present 
with a history of CKD and thus with an impaired EPC compartment (38). Therefore, 
an assessment of the functional fitness of this compartment during the peri­
transplantation period is important and should provide a reflection of the cumulative 
127 
CHAPTER7 
impact of previous chronic kidney disease, acute ischemia, and immune suppression 
on EPC quality. Since information on EPC numbers and function in kidney recipients 
at short-term after transplantation is lacking, the aim of the current study was to study 
these parameters. 
NumbersofEPC, defined asCD34-expressing cells, decreased gradually and significantly 
with increasing complications (acute rejection and increased immunosuppressive 
therapy). This decrease appeared to be multifactorial, and probably had its origins 
in CKD, as suggested by significantly decreased EPC numbers in CKD patients. In 
these patients, chronic exposure to toxic wastes, particularly to urea, may affect EPC 
generation or survival, as suggested by the negative correlation between EPC numbers 
and serum urea. Moreover, the positive correlation between EPC numbers, WBC and 
CRP suggests an influence of chronic inflammation on EPC. 
In complication-free (TX-CF) kidney recipients, EPC numbers were significantly lower 
than in healthy individuals, but not lower than in CKD patients. Compared to the latter 
group, TX-CF patients had undergone dialysis prior to transplantation, a procedure 
that has been associated with fluctuations in numbers of cEPC (24). While dialysis also 
induces a state of chronic inflammation (39), which, in its turn, may affect EPC, we found 
no correlations between EPC numbers and inflammatory markers in TX-CF patients, 
similar to those found in the CKD group. However, it is conceivable that other factors 
mask the effect of inflammation on EPC in this patient group. Exposure of the graft 
to acute ischemia may, for instance, lead to increased EPC mobilization, in analogy 
to acute myocardial ischemia (20). Indeed, EPC numbers in TX-CF patients correlated 
positively with warm ischemia time, but not with cold ischemia time, suggesting that 
during reperfusion the graft may start to produce EPC-recruiting chemoattractants 
that lead to the increased recruitment of EPC. 
The group of TX-CF patients allowed us to study possible associations between 
immunosuppressive treatment and EPC numbers. These patients received a standard 
immunosuppressive regimen consisting of methylprednisolone, ciclosporin (CsA) and 
mycophenolate mofetil. While a previous report described the inhibitory effect of 
CsA on the angiogenic potential of EPC in vitro (38), the current patient study could 
not reveal an association between CsA and EPC numbers. However, EPC numbers 
did correlate inversely with methylprednisolone dosage. Interestingly, EPC numbers 
in TX-CF patients at long-term follow-up, when CsA and methylprednisolone were 
significantly tapered, increased significantly compared to first inclusion at short 
term after transplantation. Thus, long-term follow-up of TX-CF patients allows us to 
speculate on the relative impact of ischemia, immunosuppressive therapy, and kidney 
function on EPC numbers. Since in these patients the period elapsed between the 
episode of acute ischemia and second inclusion is considerable, and since kidney 
function was not yet significantly improved at the time point of second inclusion, 
immunosuppression by methylprednisolone and, possibly, by CsA, is delineated as 
the most probable cause of decreased EPC numbers. Whether these agents affect the 
generation or survival of EPC remains to be determined. 
In kidney recipients undergoing acute rejection (TX-AR), a dramatic drop in EPC 
numbers compared to healthy individuals and CKD patients pointed to an altered 
EPC compartment in the period shortly following transplantation. The effect of 
immune suppression on EPC was further corroborated by the fact that the dose of 
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methylprednisolone, which we have proposed to affect EPC numbers, was raised to 
1000 mg/day. 
While we discussed the possible impact of various factors on EPC numbers, the question 
remains, which EPC functions are impaired. In the present study, the amount of blood 
available for experimentation and the number of co34+ cells therein were limited and 
did not allow in vitro function tests. Therefore, we selected the expression of homing 
receptors on EPC as a reflection of the homing capacity of these cells, arguing that 
altered expression patterns may explain the reduced numbers of these cells. Several 
growth factors have been shown to stimulate recruitment, long- or short-distance 
migration, and homing of EPC after organ damage, by binding to their receptors 
on EPC. Among these, SDF-1 and its receptor CXCR4 and EPO/EPO-R elicit increased 
mobilization of EPC to the circulation when administered systemically (31;33;34). In 
our study, the percentage of CD34+ cells expressing these receptors was similar in 
all groups, indicating that the low number of EPC in CKD- and TX patients was not 
due to alteration in mobilization capacity in response to SDF-1 and EPO. Surprisingly, 
the percentage of co34+ cells expressing VEGFR-2 and c-Met, the respective ligands 
for vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), 
was significantly higher in TX-AR patients than in the other groups, despite the fact 
that these patients had the lowest numbers of cEPC. Among other functions, VEGF 
mediates release of EPC from the bone marrow (23) and long-distance recruitment to 
the damaged tissue, while HGF, mediates short-distance migration in the tissue (40). The 
increased percentage of EPC expressing VEGFR-2 and c-Met indicates that recruitment 
of EPC from the blood into the graft is not a probable reason for the decreased EPC 
numbers in TX-AR patients. To reconcile decrease numbers of cEPC with increased 
percentages of VEGFR-2- and c-Met-expressing EPC in this patient group, we propose 
that, upon cumulative injury by ischemia and acute rejection, the graft releases VEGF 
and HGF, thus mobilizing increased numbers of EPC. However, immune suppression, 
superimposed on the previous history of CKD and chronic uremia in the recipient, lead 
to impaired production of EPC and thus to altogether decreased numbers of cEPC. 
Interestingly, in TX-AR patients we found a positive correlation between EPC numbers 
and WBC counts. Despite expression of VEGFR-2 and HGF, this finding suggests that 
EPC may not be specifically mobilized and recruited upon graft injury, but may rather 
accompany the inflammatory immune reaction triggered by graft damage and 
immune incompatibility, as a bystander effect. 
Since the number of co34+ cells was too low to allow isolation and in vitro function 
analysis of these cells, we employed a frequently used alternative strategy to identify 
cells with angiogenic capacity, i.e. with EPC-like characteristics. According to this 
strategy, mononuclear cells are cultured under angiogenic conditions, giving rise to 
colony-forming units (CFU) consisting of cells with spindle-shaped, endothelial-like 
morphology and expressing endothelial markers (21). This strategy has been formerly 
used to detect EPC in patients with renal conditions (24-30;38;41 -43). Of note, while 
this strategy allows greater flexibility regarding in vitro experimentation, in the current 
study limitations in numbers of patients fulfilling our inclusion criteria, in blood volume 
available for experimentation and in numbers of MNC (due to immune suppression), 
still imposed boundaries on our assays. 
NostatisticaldifferencesinCFUnumberswerefoundbetweengroups,andnocorrelation 
was present between CFU number and the number of CD34+ cells, suggesting that the 
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MNC fraction harbors progenitors of endothelial-like cells that, unlike CD34+ cells, are 
not affected by the factors discussed above. However, the decreased size and altered 
morphology of CFU from transplantation patients suggests that the adhesive property 
of colony-forming cells is impaired in these patients, possibly affecting their engrafting 
capacity in vivo. Interestingly, after 7 days of culture under angiogenic conditions, 
comparable numbers of cells expressing the endothelial markers CD31 and eNOS were 
isolated in al l groups, indicating that the capacity to differentiate towards endothelial 
cells was unaffected in transplantation- and CKD patients. Thus, the mononuclear cells 
fraction harbors a subset of endothelial progenitor cells that, unlike the CD34+ cell 
subset, appears to be numerically unaffected in transplantation patients and, besides 
decreased adhesive capacity, displays normal differentiation towards endothelial 
cells. This subset may consist of monocytes, which have been previously described to 
display EPC characteristics (44-46). 
To our knowledge, this is the first study that investigates numbers and function of EPC 
in kidney recipients at short term after transplantation. Previous studies have assessed 
EPC numbers and function in these patients at several months after transplantation, 
reporting near normal EPC behavior (38;42). Our work complements these studies by 
showing that early after transplantation, EPC bear the burden of the effects of previous 
chronic kidney disease, and a high dosage of immunosuppression. We propose that 
the normal numbers of EPC reported in other studies is due to removal of the chronic 
uremic environment and tapering of immune suppression. In addition, various studies 
have reported the presence of endothelial microchimerism in renal allograft biopsies 
at long term after transplantation (7-14), suggesting that recipient (progenitor) cells 
participate in vascular repair. Since two definitions of EPC are currently used, i.e. CD34+ 
cells and MNC with angiogenic properties, and since in the present study we show 
decreased numbers in the former subset and partially impaired adhesiveness in the 
latter, a chal lenging goal for future research will be to determine which recipient cell 
subset is able to engraft and survive in the donor vasculature at long term. 
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In this thesis we have investigated the differentiation capacity of bone marrow-derived 
cells (BMDC) in different models of acute renal injury. Our data showed that, in contrast 
to what was previously thought, BMDC contribute only marginally to tubular epithelial 
repopulation. Moreover, we showed that BMDC contributed significantly to the renal 
interstitial myofibroblast population. In this chapter we will discuss the dual role of 
BMDC in renal repair and place it in the context of the current understanding of the 
BMDC. Therefore, the following questions will be addressed; 
1. Are BMDC mobilized to the circulation upon kidney injury? 
2. Do BMDC home to the injured kidney? 
3. Do BMDC differentiate to kidney specific cell types in vivo? 
4. Which cells from the heterogeneous BMDC population differentiate to kidney 
specific cell types? 
Mobilization of BMDC to the circulation upon kidney injury 
For a possible role of BMDC in renal repair by differentiation to renal specific cell types, 
mobilization of BMDC to the circulation and homing to the injured organ is crucial. We 
showed an increased number of bone marrow-derived (BMD) progenitor cells, defined 
as lineage negative (Lin·) cells, in the circulation on day 3 after renal ischemia/reperfusion 
injury (IRI) (Chapters 3 & 5) (1). In mice, mobilization of Lin·, Sca-1+ progenitor cells was 
reported at 24 hours after IRI in a study by Kale et al. (2). The exact composition of the 
mobilized population of potential progenitor cells in our study and that of Kale needs 
to be determined. Moreover, the mechanism behind mobilization of BMDC needs to 
be unraveled. Mobilization is possibly mediated by cytokines that are secreted in large 
amounts in the inflamed kidney. Several cytokines have been identified that stimulate 
the mobilization of BMD stem cells, i.e. granulocyte-colony stimulating factor (G-CSF) 
(3;4), stem cell factor (SCF) (3;5), and granulocyte-macrophage-colony stimulating 
factor (GM-CSF) (6). Mobilization by G-CSF, the most potent and non-toxic mobilizing 
agent, was reported to attenuate acute renal failure (7-9) but was also associated with 
co-mobilization of excessive amounts of granulocytes, resulting in severe worsening of 
acute renal failure (10). BMDC are released from the bone marrow and mobilized to the 
circulation by release of proteases and the reduced expression of adhesion molecules 
on BMDC, e.g. very late antigen-1 (VLA-1) and vascular adhesion molecule-1 (VCAM-1) 
(11). However, these mobilization mechanisms will not result in specific mobilization 
of BMD progenitor cells, but inflammatory cells will be mobilized simultaneously. 
Identification of mobilization mechanisms for specific BMDC subpopulations will allow 
mobilization of BMDC that can differentiate to tubular epithelial cells without the co­
mobilization of inflammatory cells. This approach can be used as a novel therapeutic 
strategy for renal repair. 
Homing of BMDC to the injured kidney 
Upon ischemic injury, co34+ progenitor cells were reported to home to the kidney due 
to decreased expression of stromal cell-derived factor-1 (SDF-1) in the bone marrow and 
increased SDF-1 in the kidney (12). SDF-1 was also shown to have adverse effects, i.e. 
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inducing leukocytosis (13) and attracting BMD fibroblasts (14). These findings indicate 
that SDF-1 does not mediate homing of only CD34+ progenitor cells, but also of other 
cell types. In our studies, large inflammatory infiltrates were accompanied by BMDC 
that differentiated towards tubular cells or myofibroblasts. The described mechanisms 
of mobilization and homing mechanisms for inflammatory cells are also responsible for 
mobilization and homing of BMD progenitor cells. We speculate that BMD progenitor 
cells are not specifically recruited and homed to the kidney, but accompany the wave 
of inflammatory cells that enter the circulation upon renal injury. 
Differentiation of BMDC in the injured kidney 
Differentiation towards tubular epithelium 
Following renal IRI, BMDC engrafted tubuli and expressed tubular epithelial markers 
(1;2;15-19) (Figure 1). Denudation and disruption of the tubular basement membrane 
after renal injury might have provided optimal conditions for BMDC to enter the 
tubule and fill the denuded areas. This was supported by our finding that the extent 
of tubular BMDC engraftment positively correlated with the severity of post-ischemic 
renal damage (1). The possibility of migration of cells from the tubular interstitium to 
the tubular lumen and differentiation was already shown in the opposite direction in 
a process called epithelial-to-mesenchymal transition (EMT). During EMT, tubular cells 
respond to injury by loosing their epithelial characteristics, detach from the tubular 
basal membrane and migrate through the disrupted tubular basal membrane to the 
renal interstitium where they differentiate to myofibroblasts (20;21). 
Interestingly, tubular BMDC engraftment appeared to be a transient process (Chapter 
3) (1). BMD tubular epithelial cells were possibly cleared by apoptosis during normal 
epithelial turn-over. In contrast to this finding in rats, tubular engrafted recipient­
derived cells were observed in human kidney transplants months after transplantation 
(19;22;23). The discrepancy between rodent and human models is unclear but can 
be due to differences in the type of renal injury, the rate of epithelial turn-over or 
detection techniques. 
Our data and those of others indicated that tubular engraftment of BMDC occurred 
only occasionally, with the number of BMDC-engrafted tubuli ranging between 2 o/o 
and 8 o/o (1;16;19). Although tubular BMDC engraftment was observed only occasional, 
BMDC might mediate tubular repopulation from within the tubule by secreting 
growth factors. However, their contribution to repair seems small since, by the time 
of emerging tubular BMDC engraftment, replacement of damaged tubular cells by 
proliferation of surviving tubular epithelial cells was already ongoing (Chapter 3) (1). 
Several factors have been identified that can promote tubular epithelial regeneration 
in animal models, such as vascular endothelial growth factor (VEGF), hepatocyte 
growth factor (HGF), insulin-like growth factor-1 (IGF-1), epidermal growth factor 
(EGF) and fibroblast growth factor (FGF) (24). Possibly, these factors promote 
epithelial regeneration by increasing BMDC recruitment and homing after injury. This 
assumption is supported by the finding that HGF is upregulated in serum of healthy 
humans after G-CSF stem cell mobilization (25). Moreover, VEGF was shown to be 
involved in recruitment of endothelial progenitor cells (EPC) (26). Although we did not 
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measure their presence, the increased presence of these growth factors might have 
caused increased recruitment, homing and tubular engraftment of recipient-derived 
cells, which we observed after allogeneic kidney transplantation (Chapter 6). T cells 
that infiltrated the allograft might have stimulated tubular engraftment of recipient­
derived cells by producing these promoting factors. For example, T cells were shown 
to produce EGF and FGF and to deliver VEGF to sites of inflammation (27;28). However, 
increased tubular engraftment by recipient-derived cells might also be explained by 
the severity of tubular injury after kidney transplantation. This assumption is supported 
by our previous study in the model of IRI (Chapter 3) (1) and by several clinical studies in 
which the severity of graft damage was associated with increased tubular engraftment 
of recipient-derived cells (29;30). 
BMDC were, upon tubular engraftment, shown to express proximal tubular epithelial­
specific proteins, such as cytokeratin (1;15;1 9), megalin (2), FxlA  (1 6) or to bind tubular 
epithelial-specific lectins (1 ;17-1 9). This specific protein expression or lectin-binding 
suggested that BMDC differentiated to tubular epithelial cells. Moreover, expression 
of adhesion molecules, e.g. e-cadherin (1), and transporter-proteins, e.g. sodium/ 
phosphate transporter type 2 (Na/Pi-2) ( 16) by BMD tubular epithelial cells indicated 
that BMD tubular epithelial cells display similar functional properties as resident 
tubular epithelial cells. Based on these findings BMDC seem capable of mediating 
renal repair by replacement of tubular cells. Nevertheless, the low numbers and late 
onset of tubular engraftment of BMDC make the relevance of BMDC in renal repair 
doubtful. 
Differentiation towards myofibroblasts 
Since BMDC were reported to differentiate towards myofibroblasts in many tissues 
(17;21;31 -34), the awareness arose that BMDC, by production of ECM, could possibly 
contribute to the onset of interstitial fibrosis (Figure 1). In Chapter 4 we showed that 
BMD myofibroblasts constituted an average 32% of all interstitial myofibroblasts in 
the post-ischemic kidney (35). Differentiation of BMDC to myofibroblasts preceded 
tubular engraftment of BMDC and the contribution of BMDC to the myofibroblast 
population largely exceeded the contribution of BMDC to the tubular epithelial 
population. Possibly, different BMDC subsets are responsible for differentiation towards 
myofibroblasts and tubular epithelium and the subset responsible for myofibroblast 
differentiation exceeds that responsible for epithelial differentiation in number. The 
observed renal downregulation of the anti-fibrotic bone morphogenetic protein-7 
(BMP-7) and upregulation of the pro-fibrotic transforming growth factor-� (TGF-�) (35) 
could have provided the optimal conditions for this BMDC subset to differentiate to 
myofibroblasts. 
Other pro-fibrotic factors in the renal environment might promote BMD differentiation 
to myofibroblasts. In Chapter 5 we studied myofibroblast differentiation of BMDC 
after administration of the immunosuppressive agent ciclosporin (CsA), which is 
known for its pro-fibrotic side-effects (36-38). In this study, the profibrotic potential 
of CsA was shown by increased renal TGF-� expression and interstitial collagen Ill 
deposition. However, administration of CsA did not stimulate BMDC differentiation to 
myofibroblasts in the post-ischemic rat kidney. It is therefore likely that cells other than 
BMD myofibroblasts were stimulated by CsA to produce TGF-� and ECM. In Chapter 6 
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Figure 1. The role of bone marrow·derived cells in renal repair. Upon infiltration in the injured kidney, BMDC 
can engraft in and differentiate to tubular epithelial, endothelial and glomerular cells. Moreover, BMDC can 
infiltrate the interstitium and adopt a myofibroblast phenotype. Tubular epithelial replacement by BMDC 
can lead to restoration of the tubular epithelium. BMDC myofibroblasts can contribute to tubular repair by 
wound healing or they can mediate renal scarring by causing the onset of interstitial fibrosis. 
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we showed that recipient-derived cell differentiation towards myofibroblast was not 
promoted after allogeneic kidney transplantation. These allogeneic transplanted rat 
kidneys were histologically characterized by marked renal infiltration of T cells, which 
are known to influence the renal environment by secreting soluble factors. Since we 
did not observe differences in the relative contribution of recipient-derived cells to the 
myofibroblast population after syn- or allogeneic kidney transplantation, it is not likely 
that T cell activity and their production of soluble factors influence recipient-derived 
cell differentiation to myofibroblasts. 
Our studies showed that the relative contribution of BMDC or recipient-derived 
cells to the total renal interstitial myofibroblast population was equal in different 
injury models with different severity of renal damage (Chapters 4, 5, 6). The fact 
that their relative contribution to the interstitial myofibroblast population is similar 
in settings with different severity of renal injury, caused by IRI, CsA administration, 
kidney transplantation or allograft rejection, suggests that the mechanism driving 
the differentiation of BMDC or recipient-derived cells towards myofibroblasts must 
be shared by these settings. Nevertheless, BMDC or recipient-derived cells contribute 
significantly to the interstitial myofibroblast population and might harm renal structure 
by excessive production of ECM. 
The observed expression of a-SMA by renal interstitial BMDC (Chapter 4), indicated that 
these BMDC obtained the contractile properties that are unique for myofibroblasts 
and vascular smooth muscle cells. We showed that these a-SMN BMDC produced 
procollagen I in the post-ischemic kidney, suggesting that BMDC differentiated to 
myofibroblasts and play an active role in the production of ECM in post-ischemic 
remodeling (Chapter 4) (35). Since in our model of renal IRI is not a model for 
progressive fibrosis and collagen Ill deposition was cleared in time, we could not 
study BMD myofibroblasts in fibrosis. However, Li et al. (39) recently confirmed that 
BMD myofibroblasts contribute to the development of interstitial fibrosis. This study 
showed that blockade of the p38 mitogen-activated protein kinase and TGF-(31/ 
Smad signaling pathways, that control the pro-fibrotic action of TGF-13, resulted in a 
decreased number of BMD myofibroblasts and the attenuation of fibrosis in mice with 
adriamycine-induced renal fibrosis. The study by Li et al. (39) indicates that control of 
BMDC myofibroblast differentiation, necessary to prevent possible adverse effect of 
BMDC in therapeutic application, is a feasible option. However, not only the number 
of BMD myofibroblasts, but that of the resident renal interstitial myofibroblasts was 
decreased in this study. Since myofibroblasts are essential for wound healing, therapy 
should be aimed at specific blockade of BMDC differentiation to myofibroblasts. 
BMDC populations in the injured kidney 
The major question remains which cells of the heterogeneous BMDC population are 
able to differentiate to renal specific cell types in vivo. 
In human renal allografts, recipient-derived cells were shown to engraft renal structures 
and differentiate to renal endothelial and epithelial cells, suggesting that recipient­
derived cells mediated repair by replacing damaged graft cells (19;22;23;29;30;40;41). 
The recipient-derived cells, described in these studies, were assumed to represent 
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BMDC but can actually be any cell type that was not present in the donor kidney 
before transplantation. 
To investigate if cells from the bone marrow contribute to renal repair, we and others 
performed bone marrow transplantation in mice or rats to create bone marrow 
chimeric animals. Since we transplanted whole bone marrow and did not have the 
tools to distinguish between different BMDC subpopulations, we do not know exactly 
which cell s  of the heterogeneous BMDC population are able to differentiate to renal 
cell types in vivo. The majority of the BMDC population that infiltrates the kidney upon 
injury consists of inflammatory cells, probably accompanied by small subsets of stem­
and/or progenitor cells. Several bone marrow stem- and progenitor cells have been 
identified that possess the capacity to differentiate to renal specific cell types in vivo. 
The bone marrow contains two stem cell populations, i.e. mesenchymal stem cells 
(MSC) and the hematopoietic stem cells (HSC), which were reported to contribute to 
renal repair after acute renal failure. Intravenous infusion of MSC resulted, in contrast to 
infusion with whole bone marrow (17) and fibroblasts, in functional improvement after 
glycerol-, cisplatin-, and ischemia/reperfusion-induced acute renal failure (15;1 8;42-
44). Several studies showed that MSC had the potential to engraft and differentiate to 
tubular epithelial cells, which correlated with functional improvement of the kidney 
(15;18). Other studies postulated that not engraftment but paracrine actions of MSC, 
i .e. secretion of renoprotective factors such as VEGF, HGF and IGF-1, were responsible 
for the observed improvement of renal function (43;44). Functional improvement by 
paracrine actions of MSC seem feasible mechanisms, since it was also demonstrated 
in other injury models, such as the hindlimb ischemia model (45;46). Based on these 
findings, MSC might provide an attractive candidate for therapeutic application after 
acute renal injury. However, caution is warranted since MSC resemble myofibroblasts 
in their origin and phenotypical characteristics, suggesting that MSC can easily 
differentiate towards myofibroblasts. MSC may thereby exert pro-fibrotic rather 
than regenerative actions, which obviously entails risks. Moreover, the resemblance 
between MSC and myofibroblasts indicates that the BMDC population, which we 
showed to differentiate towards myofibroblasts, was derived from MSC. 
HSC have also been shown to contribute to post-ischemic tubular regeneration by 
homing to the injured kidney, engrafting tubular structures and differentiating 
towards tubular cells in mice (16). These data indicate that HSC might have been part 
of the BMDC population that differentiated to tubular epithelial cells in our studies. 
Circulating endothelial progenitor cells (cEPC) are also part of the BMDC population. 
EPC are BMDC that are functionally and phenotypically distinct from mature 
endothelial cells and can differentiate into endothelial cells in vitro (47-52). Since in 
humans the number of cEPC has been shown to correlate with endothelial function 
and cardiovascular risk (53), the general hypothesis is that a reduction of cEPC results 
in endothelial dysfunction. We showed in Chapter 7 that the number of cEPC was 
decreased in patients with chronic kidney disease. The number of cEPC was further 
decreased in short term kidney transplant recipients without complications or 
undergoing acute rejection. Similar data were obtained in other studies, showing 
reduced numbers of cEPC in patients with different stages of renal failure (54-63). 
Possibly, long-term exposure of cEPC to uremic toxins during renal failure results in 
reduced numbers of cEPC. The influence of uremic toxins on cEPC is supported by 
the fact that improvement of renal function and clearance of uremic toxins after 
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long-term follow-up in kidney transplant recipients was paralleled by an increase 
in the number of cEPC (Chapter 7). Moreover, other follow-up studies showed that 
replacement therapy, i.e. dialysis or kidney transplantation, was associated with a 
normalization of cEPC numbers (55;57;58;61). Since the kidneys of these patients have 
not been investigated, no causal relationship between reduced cEPC numbers and 
renal endothelial dysfunction was shown in these studies. Examination of the kidneys 
of these patients would reveal if the reduction in cEPC after injury reflects increased 
infiltration of cEPC in the kidney, where EPC can contribute to vascular repair. This is 
however unlikely, since the reduction of cEPC numbers was not associated with an 
improvement of renal function. 
BMDC differentiation into tubular epithelium or myofibroblasts, which we showed 
in our studies, possibly represents differentiation of cells from the above mentioned 
BMDC subpopulations. Identification of the contributors to the BMDC population is 
necessary to select candidates for therapeutic application in renal repair. 
Concluding Remarks 
In this thesis we showed that BMDC have the plasticity to differentiate towards tubular 
epithelium and myofibroblasts (Figure 1). This finding suggests that BMDC might 
play a dual role in renal repair. BMDC were occasionally shown to engraft the tubular 
epithelium and differentiate towards tubular epithelial cells (Chapters 3, 5, 6), but were 
largely exceeded by BMDC that infiltrated the renal interstitium and differentiated 
towards myofibroblasts (Chapters 4, 5, 6). By producing ECM BMD myofibroblasts 
can participate in wound healing, and possibly in the onset of interstitial fibrosis. 
Identification of the mechanisms that specifically control differentiation of BMDC 
to myofibroblasts, in order to control and direct this differentiation process, will 
be important objectives in future studies. Therefore, we propose that, until these 
mechanisms are identified, the possible therapeutic use of BMDC in patients with 
renal failure should be approached cautiously. 
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NEDERLANDSE SAMENVATTING VOOR NIET-INGEWIJDEN 
Nierfalen 
Bij nierfalen zijn de nieren niet in staat om afvalstoffen en overtollig vocht uit het lichaam 
te verwijderen. In zulke gevallen kan door middel van dialyse of niertransplantatie de 
nierfunctie vervangen warden. Momenteel zijn er echter geen therapieen beschikbaar 
die de schade aan de nier zelf kunnen herstellen. Het onderzoek beschreven in dit 
proefschrift richt zich op de mogelijkheid om herstel van beschadigde nieren te 
bewerkstelligen. 
De nier kan beschouwd warden als een afvalverwerkingsbedrijf in het lichaam. Dankzij 
de ongeveer 1 miljoen filtratie-eenheden, de nefronen, waaruit de nier bestaat, plassen 
wij dagelijks zo'n 1000-2500 ml urine met daarin diverse afvalstoffen uit. Elk nefron is 
opgebouwd uit een kluwen van haarvaatjes, de glomerulus, met daarop aansluitend 
een buisvormig systeem, de tubulus, die uitmondt in de verzamelbuis. De verzamelbuis 
staat in verbinding met de urineleider en de blaas (Figuur 1). In de glomerulus vindt 
de filtratie van het bloed plaats. Afvalstoffen en overtollig vocht warden uit het 
bloed gefilterd en via de tubulus verder vervoerd richting urineleider. Alvorens het 
daar aankomt warden er door de cellen van de tubulus, de tubulaire epitheelcellen, 
grate hoeveelheden water en stoffen die voor het lichaam behouden moeten blijven, 
opgenomen en teruggetransporteerd naar de bloedbaan. Het resterende filtraat zal 
als urine via de blaas het lichaam verlaten. Dit filtratiesysteem functioneert dusdanig 
dat grate moleculen, zoals eiwitten, niet in de urine terechtkomen. Wanneer schade 
aan de nier optreedt kan er "lekkage" van eiwitten naar de urine optreden, waardoor 
kostbare stoffen voor het lichaam verloren gaan. Lekkage van eiwitten kan bovendien 
de afvoerbuisjes beschadigen, waardoor nierfunctieverlies optreedt en het lichaam 
vergiftigd wordt met afvalstoffen. 
Proximale tubulus Distale tubulus 
,.,�\..� "-··"· I 
Lis van Henle 
I 
Verzamelbu,s 
Positie in het lichaam Dwarsdoorsnede Nefron 
Figuur 1 .  De nier 
Fibrose 
Een van de mogelijke oorzaken van nierfalen is fibrose. Men spreekt van nierfibrose 
wanneer er overmatige hoeveelheden bindweefsel warden gevormd in de nier, 
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waardoor de nier zijn functie niet meer goed kan uitoefenen. Myofibroblasten zijn 
cellen die bindweefsel-eiwitten produceren en daardoor betrokken zijn bij het 
ontstaan van fibrose. Myofibroblasten hebben echter normal iter een nuttige rol, 
omdat bindweefselformatie ook onmisbaar is voor wondheling. 
lnterne herstelmechanismen van de nier 
De nier is in staat om, tot op zekere hoogte, te herstel len na schade. Dit is mogelijk door 
twee mechanismen. Ten eerste kunnen cellen van de tubulus die de schade hebben 
overleefd zich vermeerderen en vervolgens verplaatsen naar plaatsen waar cellen door 
schade verdwenen zijn om daar deze "gaten" op te vullen. In de tweede plaats maakt 
de nier extra bindweefsel aan na schade. Dit proces wordt wondheling genoemd en 
zorgt ervoor dat de structuur  van de nier behouden blijft. Als er te veel bindweefsel 
wordt gevormd, treedt fibrose op (zie hierboven). Normaal gesproken functioneren 
deze interne herstelmechanismen dusdanig dat de nier na veel vormen van schade 
volledig zal herstellen. Bij zeer ernstige schade kan echter het herstelmechanisme 
van de nier te kort schieten, waardoor nierschade, en verlies van nierfunctie resteert. 
B ij een zeer slechte nierfunctie is kunstnierbehandeling (dialyse) noodzakelijk is om 
te overleven. Nadeel daarvan is  dat weliswaar de n ierfunctie wordt overgenomen 
door de kunstnier, maar dat de eigen n ierschade niet hersteld wordt. Gelukkig is vaak 
transplantatie mogelijk, waardoor de patient weer nierfunctie heeft. Zowel bij dialyse 
als bij transplantatie kunnen echter compl icaties optreden, en de sterfte is dan oak 
hoger dan in  de gezonde populatie. Voor transplantatie bestaat bovendien een lange 
wachtlijst door het tekort aan donor-organen. 
Therapie die herstel van ernstige nierschade kan bewerkstel l igen zou daarom een 
g rote vooruitgang zijn, en in ons onderzoek willen wij een bijdrage leveren aan het 
ontwikkelen daarvan. 
Mogelijke ro/ van beenmergafkomstige eel/en in nierherstel na schade 
In  dit proefschrift onderzoeken we de mogelijke rol van cellen uit het beenmerg in  het 
herstel van de nier na n ierschade. Het beenmerg is de sponsachtig rode substantie 
die zich bevindt in het binnenste van batten; in deze substantie bevinden zich de 
zogenaamde stamcellen. Ditzijn cellen waaruitzich al lerlei verschil lende soorten cellen 
kunnen ontwikkelen. Naast het vormen van botweefsel is het vormen van bloedcellen 
een belangrijke functie van het beenmerg. Witte bloedlichaampjes (leukocyten), rode 
bloedlichaampjes (erythrocyten) en bloedplaatjes (thrombocyten), warden gemaakt 
uit de bloedvormende, hematopoietische, stamcel len die zich in het beenmerg 
bevinden. Botweefsel wordt gevormd uit een andere type stamcellen dat zich oak i n  
het beenmerg bevindt, namelijk de mesenchymale stamcellen. Hematopoietische en 
mesenchymale stamcellen kunnen niet a Ileen bloed-cellen en botcellen vormen, maar 
ze kunnen zich oak specialiseren (= differentieren) tot weefsel-specifieke cellen, zoals 
n iercellen. Men neemt aan dat stamcellen in het beenmerg na schade van een orgaan 
een signaal krijgen waardoor ze losgemaakt warden uit het beenmerg en zich, via de 
bloedbaan verplaatsen, naar de plaats van de schade. In het geval van nierschade is 
de hypothese (veronderstel l ing) dat beenmergafkomstige cellen zich, na aankomst 
in de nier, onder invloed van het omringende nierweefsel, kunnen specialiseren tot 
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niercellen om daarmee de beschadigde niercellen te vervangen en de schade te 
herstellen. Deze hypothese hebben wij proefondervindelijk onderzocht. 
Proefdiermodellen 
Deze hypothese hebben we onderzocht in proefdiermodellen. In de eerste plaats 
moesten we daartoe een model opzetten waarin het mogelijk was om aan cellen in 
de nier te kunnen zien dat ze oorspronkelijk uit het beenmerg afkomstig waren. Om 
dit te bewerkstelligen werd het beenmerg van ratten voorzien van een makkelijke 
herkenbaar label, door eerst het eigen beenmerg te verwijderen door bestraling en 
vervolgenseen beenmergtransplantatietedoen metgelabeld beenmerg (Figuur2). Het 
gelabelde beenmerg was afkomstig uit transgene ratten. Het kenmerk van transgene 
ratten is dat in al hun lichaamscellen een bepaald, normaal niet-voorkomend, eiwit 
tot expressie komt. Wij hebben gebruik gemaakt van het beenmerg van transgene 
ratten waarin het eiwit hPAP (humaan Placentaal Alkalische Phosphatase) in alle 
lichaamscellen tot expressie komt. Door dit hPAP beenmerg te transplanteren naar 
niet-transgene ratten konden we het hPAP eiwit gebruiken om beenmergafkomstige 
cellen in de nier te detecteren met simpele histologische technieken. 
Vervolgens hadden we een model nodig dat nierschade in de mens simuleert. In 
hoofdstuk 3 t/m 5 beschrijven we processen die optreden na ischemie/reperfusie schade. 
Deze schade is het gevolg van een tijdelijke onderbreking van de doorbloeding van 
de nier (ischemie) en het daarop volgende herstel van de bloedstroom (reperfusie). 
Deze vorm van schade vindt bijvoorbeeld plaats tijdens niertransplantatie wanneer 
de nier van het ene lichaam naar het andere wordt verplaatst. We hebben ischemie/ 
reperfusie schade in ratten gernduceerd door de nierarterie gedurende 45 minuten 
af te klemmen, gevolgd door herstel van de bloedstroom (Figuur 2). In hoofdstuk 6 
hebben we niertransplantaties in ratten uitgevoerd. Aan de hand van dit model 
konden we de schade na het onderbreken van de bloedstroom onderzoeken, maar 
oak wat er gebeurt wanneer een nier uit een donor met een andere genetische 
achtergrond dan de ontvanger (=allogene transplantatie) wordt getransplanteerd en 
er een immunologische reactie optreedt die tot afstoting kan leiden. 
Het uitgevoerde onderzoek -per hoofdstuk 
Hoofdstuk 1 geeft een overzicht van de vragen die we in dit proefschrift willen 
beantwoorden. Dit wordt gedaan aan de hand van een beschrijving van de 
biologische processen die optreden bij acuut en chronisch nierfalen, de interne herstel 
mechanismen van de nier en de mogelijke rol van beenmergafkomstige cellen in het 
herstel na nierschade. 
Voor een goede interpretatie van de rol van beenmergafkomstge cellen in nierherstel 
is het cruciaal om deze cellen in het lichaam te kunnen detecteren. Zoals gezegd 
hebben we gebruik gemaakt van een diermodel voor beenmergtransplantatie om 
de beenmergafkomstige cellen te kunnen detecteren in de nier. In de literatuur 
warden echter vele verschillende detectiesystemen om beenmergafkomstige cellen 
mee te traceren beschreven. Daarom geven we in hoofdstuk 2 een overzicht van deze 
verschillende detectiesystemen en hun voor- en nadelen bij het gebruik in modellen 









Figuur 2. Schematische weergave van de gebruikte proefdiermodellen. Door middel van bestraling 
wordt het beenmerg van een rat vernietigd. Vervolgens wordt een beenmerg transplantatie uitgevoerd 
waarmee het vernietigde beenmerg wordt vervangen door transgeen hPAP beenmerg. De rotten herstellen 
gedurende 30 dagen voor volledige reconstitutie van het beenmerg. Na de herste/periode wordt nierschade 
aangebracht door afklemming van de nierarterie gedurende 45 minuten (=ischemie). Vervolgens kunnen 
de transgene hPAP beenmerg afkomstige eel/en in de nier gedetecteerd warden met simpe/e histologische 
technieken. 
De capaciteit van beenmergafkomstige cellen om na nierschade te differentieren tot 
niercellen hebben we onderzocht in hoofdstuk 3. Hiervoor hebben we in ratten met 
hPAP• beenmerg nierschade aangebracht door hun nierarterie gedurende 45 minuten 
af te klemmen. Op verschillende tijdstippen na de schade-inductie hebben we de nier 
onderzocht op de aanwezigheid van beenmergafkomstige (hPAP+) cellen. In de nier 
vonden we beenmergafkomstige cellen die ingebouwd waren in de tubulus. Met 
verdere analyses konden we vaststellen dat deze cellen oak daadwerkeli jk niercellen 
waren geworden. Bovendien vonden we dat er meer beenmergafkomstige cellen 
ingebouwd werden in de nier tubulus naar mate de nierschade erger was. Een zeer 
onverwachte bevinding was dat op lange termijn de ingebouwde cellen oak weer 
verdwenen. Onze resultaten suggereren dat de beenmergafkomstige cellen de 
beschadigde niercellen kunnen vervangen maar dat ze, wanneer de schade herstelt 
is, weer verdwijnen. Het inbouwen van beenmergafkomstige cellen in de tubulus 
gebeurde echter slechts op kleine schaal, en kon daarom onmogelijk verantwoordelijk 
zijn voor het herstel van de nier dat we in de loop der tijd observeerden. Aangezien het 
bekend is dat de nier zichzelf tot op zekere hoogte kan herstellen, onderzochten we of 
cellen uit de nier zelf verantwoordelijk waren voor het geobserveerde herstel proces. 
Het bleek dat het merendeel van de beschadigde niercellen inderdaad vervangen 
werd door vermeerdering van niet-beschadigde niercellen. 
In de tubulus van beschadigde nieren werden dus slechts sporadisch 
beenmergafkomstige cellen werden ingebouwd. In de ruimte tussen de nefronen, de 
interstitiele ruimte, werd daarentegen een grate hoeveelheid beenmergafkomstige 
cellen aangetroffen. Voor het merendeel waren dit ontstekingscellen, die 
aangemaakt warden in het beenmerg en na orgaanschade vanuit het beenmerg 
naar de plaats van schade bewegen om daar lichaamsvreemde en dode cellen op 
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te ruimen en de wondheling te bevorderen. In hoofdstuk 4 hebben we onderzocht 
of de beenmergafkomstige cellen in de interstitiele ruimte van de beschadigde 
nier in staat zijn om differentieren tot myofibroblasten. Zoals eerder genoemd zijn 
myofibroblasten in staat om bindweefsel eiwitten te produceren en zijn ze kart na 
het moment van beschadiging op de plaats van de schade aanwezig om een bijdrage 
leveren aan wondheling. In het geval van overtollige productie van bindweefsel 
kunnen myofibroblasten bijdragen aan het ontstaan van fibrotische nierschade. 
Uit ans onderzoek bleek dat beenmergafkomstige cellen inderdaad in staat waren 
om te differentieren tot myofibroblasten en dat ruim 30% van alle myofibroblasten 
in de nier van afkomstig was uit het beenmerg. Additionele analyses wezen uit dat 
myofibroblasten die ontstaan waren uit beenmergafkomstige cellen bindweefsel 
konden produceren en dus functioneel waren. In ons nierschade model toonden 
we daarmee indirect aan dat beenmergafkomstige cellen een bijdrage leveren aan 
wondheling. Omdat in ans model geen nier ti brose optrad, konden we geen uitspraak 
doen over een eventuele bijdrage van beenmergafkomstige cellen aan fibrose, maar 
andere onderzoekers hebben inmiddels een bijdrage van de beenmerafkomstige 
cellen aan nierfibrose kunnen bevestigen. 
Om afstoting van de getransplantateerde nier te voorkomen, warden de ontvangers 
van een donor nier behandeld met immunosuppressieve medicatie. Een veel gebruikt 
immuunosuppressief medicijn is ciclosporine (CsA). Een bijwerking van CsA is echterdat 
CsA het ontstaan van nier fib rose stimuleert. Om te onderzoeken of die pro-fibrotische 
bijwerking komt doordat CsA de differentiatie van beenmergafkomstige cellen tot 
myofibroblasten stimuleert, hebben we ratten behandeld met CsA. In hoofdstuk 5 
beschreven we dat CsA behandeling inderdaad leidt tot een verhoogde afzetting van 
bindweefsel in de interstitiele ruimte, maar de differentiatie van beenmergafkomstige 
cellen naar myofibroblasten werd niet gestimuleerd. CsA ge'induceerde fibrose, zoals 
die vaak optreedt in CsA behandelde niertransplantatie patienten, wordt dus niet 
veroorzaakt door beenmergafkomstige cellen. 
In alle tot nu toe beschreven experimenten hebben we beenmergafkomstige cellen 
bestudeerd na ischemische nierschade, d.w.z. na schade die veroorzaakt wordt door 
het tijdelijk onderbreken van de bloedtoevoer naar de nier. Deze schade treedt op 
tijdens niertransplantatie, wanneer het donor orgaan van de donor naar de ontvanger 
wordt verplaatst en daarmee de bloedtoevoer tijdelijk onderbroken wordt. Echter, 
een getransplanteerde nier wordt oak aan andere schade prikkels blootgesteld. Zo 
warden immunologische afstotingsreacties in gang gezet door het immuun systeem 
van de ontvanger als gevolg van de aanwezigheid van het lichaamsvreemde donor 
orgaan. Vandaar dat we de differentiatie mogelijkheden van beenmergafkomstige 
cellen wilden onderzoeken in een model waarin oak een reactie van het immuun 
systeem optreedt, omdat dat meer overeenkomst vertoont met de situatie bij de 
nierpatient. Om dit te bewerkstelligen hebben we niertransplantaties uitgevoerd in 
ratten. In dit model hebben we geen gebruik gemaakt van beenmerg transplantatie 
om beenmergafkomstige cellen te kunnen detecteren. In plaats daarvan hebben 
we een nier uit een gewone rat getransplanteerd naar een transgene ontvanger 
rat. Zoals eerder beschreven, brengen alle lichaamscellen van de transgene rat een 
eiwit, in ons geval hPAP, tot expressie. Door met histologische technieken hPAP in de 
getransplanteerde nier aan te tonen, kunnen we cellen detecteren die van buiten de 
nier afkomstig zijn. We spreken in dit geval dus niet van beenmergafkomstige cellen 
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maar we noemen de cel len die van buitenaf de nier infiltreren ontvangerafkomstige 
cell en. In hoofdstuk 6 hebben we het inbouwen van ontvangerafkomstige cellen in de 
nier tubul us en differentiatie tot myofibroblasten bestudeerd na niertransplantatie in 
ratten. We hebben de processen na 2 vormen van transplantatie bestudeerd, namelijk 
syngene (donor en ontvanger zijn genetisch identiek) en allogene (donor en ontvanger 
zijn genetisch verschi l lend) niertransplantatie. Het in bouwen van ontvangerafkomstige 
cellen in de nier tubulus werd gevonden in de syngene getransplanteerde nier, 14 
dagen na transplantatie. Na allogene niertransplantatie vonden we dat een groter 
aantal tubuli ontvangerafkomstige cellen bevatten. Aangezien de nier na allogene 
transplantatie ernstiger beschadigd is, geeft dit aan dat, vergelijkbaar met onze 
bevindingen in hoofdstuk 3, het aantal ingebouwde ontvangerafkomstige cellen 
toeneemt met toenemende mate van schade. Eveneens vergelijkbaar met onze 
voorgaande bevindingen was het lage aantal ingebouwde ontvangerafkomstige 
cellen. Een grater deel van de ontvangerafkomstige cellen bleek te differentieren 
tot myofibroblasten. Na allogene transplantatie was het aantal myofibroblasten in 
de nier verhoogd in vergelijking met de situatie na syngene transplantatie. Echter, 
percentueel was er geen verschil in de bijdrage van ontvangerafkomstige cellen 
aan de totale myofibroblast eel populatie. Deze resultaten suggereren dat allogene 
niertransplantatie, in vergelijking met syngene niertransplantatie, tot gevolg heeft dat 
ontvangerafkomstige cellen in grotere aantallen inbouwen in de nier tubulus, terwijl 
er geen verschi l  is in de relatieve bijdrage van ontvangerafkomstige cellen aan de 
myofibroblast eel populatie in de nier. 
Alie bovenstaande experimenten zouden moeil ijk, danwel onmogelijk, uit te voeren 
zijn in mensen. In hoofdstuk 7 hebben we met de beperkte mogelijkheden die we voor 
handen hadden, getracht de rol van de beenmergafkomstige cellen te onderzoeken 
in de humane situatie. Hierbij hebben we de aanwezigheid van beenmergafkomstige 
cellen onderzocht in het bloed van patienten met nierfalen  die nog geen dialyse 
behandeling nodig hadden en in het bloed van patienten die recentelijk een 
niertransplantatie hebben ondergaan. We hebben ans hierbij gericht op een specifiek 
type beenmergafkomstig eel, de endotheel voorloper eel (endothelial progenitor 
cell, EPC). EPC kunnen inbouwen in beschadigde bloedvaten en daarmee zijn deze 
beenmergafkomstige cel len mogelijk betrokken bij het herstel van bloedvaten na 
schade. Gedacht wordt dat een verminderde hoeveelheid EPC in het bloed duidt op 
een verminderde capaciteit tot bloedvat herstel en daarmee een verhoogde kans op 
slechtfunctionerende bloedvaten. Uitons onderzoek bleekdat patienten met nierfalen 
een verlaagd aantal EPC in hun bloed hadden in vergelijking met gezonde mensen. 
Doordat de nieren van deze patienten niet goed functioneren, blijven afvalstoffen 
(uremische toxines) achter in het lichaam. Mogelijk warden de cel len in het bloed 
blootgesteld aan deze toxines waardoor ze afnemen in aantal. Het aantal EPC was 
nog verder verlaagd in het bloed van patienten die recentelijk een niertransplantatie 
hadden ondergaan. Deze patienten hebben vaak een voorgeschiedenis van langdurig 
nierfalen, wat mogel ijk verklaart waarom hun aantallen EPC nag verder verlaagd zijn. 
Wanneer we het bloed van deze ontvangers van een niertransplantatie op een later 
tijdstip, en met een verbeterde nierfunctie nogmaals onderzochten, bleek dat het 
aantal EPC was verbeterd ten opzichte van de eerste meting. Deze resultaten suggeren 
dat niertransplantatie, met een verbetering in nierfunctie tot gevolg, kan leiden tot 
normalisatie van het aantal EPC in het bloed. 
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In hoofdstuk 8 warden de resultaten van dit proefschrift geplaatst in het kader van 
het huidige internationale onderzoek naar beenmergafkomstige cellen in nierherstel. 
Verder wordt in dit hoofdstuk bediscussieerd waar het toekomstige onderzoek zich op 
zou moeten richten. 
Conclusies 
In dit proefschrift hebben we aangetoond dat beenmergafkomstige cellen de 
mogelijkheid hebben om te differentieren tot andere celtypen, te weten nier 
tubulus cellen en myofibroblasten. Onze bevindingen suggereren dat de rol van 
beenmergafkomstige cellen in nierherstel twee-ledig is. Enerzijds hebben we 
aangetoond dat beenmergafkomstige cellen soms inbouwen in de nier tubulus 
en differentieren tot tubulus eel (hoofdstukken 3, 5, 6). Anderzijds, en in veel 
grotere aantallen troffen we beenmergafkomstige cellen in de interstitiele ruimte 
aan die differentieerden naar myofibroblasten (hoofdstukken 4, 5, 6). Door de 
productie van bindweefsel eiwitten kunnen myofibroblasten, die ontstaan zijn uit 
beenmergafkomstige cellen, bijdragen aan wondheling maar mogelijk oak aan het 
ontstaan van nier fibrose. 
Gebaseerd op bovenstaande bevindingen lijktdetoepassing van beenmergafkomstige 
cellen om nierherstel te bewerkstelligen in patienten met nierfalen niet geheel 
zonder gevaar. Zo zou het inbrengen van grate hoeveelheden beenmergafkomstige 
cellen in nierpatienten kunnen leiden tot nierfibrose. Daarom zijn wij van mening 
dat het gebruik van beenmergafkomstige cellen voor therapeutische doeleinden 
niet zonder het nodige vervolgonderzoek kan plaatsvinden. De mechanismen die 
verantwoordelijk zijn voor de differentiatie van beenmergafkomstige cellen tot 
myofibroblasten zullen moeten warden ge'identificeerd om controle en sturing van 
deze differentiatie stap te kunnen bewerkstelligen. Tot deze mechanismen ontrafeld 
zijn, is de therapeutische toepassing van beenmergafkomstige cellen in patienten 
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!oYt/t.,. f/1, c:u. h/�"°9 .-bv t.a1 &Yi,,/� loa� {ij2A,, r,?f4l., -kt dz/{_,, 
/ot', �,t/(i�/t, Alt/_ Mine/. 6«tcl/J� 11.at � r cfo.,..Jcu 1.1124 ?­
I.Jd/Cvt11, tlf1 v'74b lcllA1cr W 1.1a-; v:tr at ? � fJttlJ-CAutn11.­
flv'e/ /l14.'CU- 1-WC,:21i/u.,t,c1"0rl.1'711.,, .£.tt; � &1t"aar�. 
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Et'A.,, kzli;#.(/Jciv dZlf'ltJrt� leMv 
�cyaj l!f�I& �r �� � /Jc/a � � �/W cl}� 
� - {/vi,;, r a �Jlt . � , � � ?i fou'? � 
,iv �t'A-4, �- ,4/rtr-t ud� kduU na1 _I 
tfatr ilf,/� i'Al/v .,tbv ,;d/flU, /ffla,cd/jdd j;_,t �;,- vY.,;y7 _, t:/1.,, kur 
/»a )tt(t (7)nr dv-t- : 
f:;17v IP6)C 
�f ;ra:tdv-v ,4d/lt,(/v r ,,,oi, T � aL/ar�; tJtlU" �Iv aJIC. 
� at 6?1/J.t, rt-avmt/u,m,v �.,-{, t-l ?c/1.,, /2'.J�u bor �"' v.dv.._1 
/lutt.Jtt tJt. 4/tt:l../:/>t- at/(!/Jfd4 hlf/Jftbu tJ./Jf,,ftt //tzt4 [flt, t/t, tl7t4 atY/c, 
t-j kJ /1)/i, tk.t fat /1t«r /ud �'c{_ P[/C/ aY� �f 1/�' . 
,k/j 1JJtti etkW ";� _I //tar'7t� 1/t:j',::t jctk 3/1- .&/v 
�a/,id( . kfadr. 
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